Methods of treating hemophilia A
By developing the chimeric protein Enochronin alpha, the problem of frequent injection of coagulation factor VIII replacement therapy in patients with severe hemophilia A is solved, and the prevention and control of bleeding for a longer period of time has been achieved and the quality of life has been improved.
Patent Information
- Application Number
- CN202380025281.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-02-06
- Filing Date
- 2023-03-07
- Publication Date
- 2024-11-19
AI Technical Summary
The existing alternative coagulation factor VIII therapy is burdened by frequent intravenous injections for patients with severe hemophilia A, and the current FVIII activity level is not sufficient to effectively prevent all bleeding attacks, leading to serious complications such as joint bleeding.
Developed a chimeric protein, Efanosoctocogα, which is independent of vasophilia factor (VWF), prolongs the half-life of coagulation factor VIII and reduces the frequency of bleeding episodes through dosing intervals, including FVIII The polypeptide and VWF fragments are linked by disulfide bonds to form the FVIII-ELNN-Fc/D'D3-ELNN-Fc heterodimer for the prevention and treatment of hemophilia A.
Inocoagulin alpha significantly reduces the frequency of bleeding attacks and joint bleeding, improves the patient's quality of life, prolongs the half-life of coagulation factor VIII, reduces the frequency of treatment, and improves compliance and quality of life.
Smart Images

Figure BDA0005024887360000391 
Figure BDA0005024887360000461 
Figure BDA0005024887360000462
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application Nos. 63 / 317,957, filed March 8, 2022; 63 / 318,361, filed March 9, 2022; 63 / 335,970, filed April 28, 2022; 63 / 359,704, filed July 8, 2022; 63 / 369,893, filed July 29, 2022; and 63 / 371,327, filed August 12, 2022. 7; 63 / 380,857 filed October 25, 2022; 63 / 383,764 filed November 15, 2022; 63 / 480,328 filed January 18, 2023; 63 / 481,418 filed January 25, 2023; and 63 / 483,391 filed February 6, 2023; these provisional applications are hereby incorporated by reference in their entirety for all purposes. References to electronically submitted sequence listings
[0002] The contents of the electronically submitted sequence listing in the XML file (name: 739510_SA9-487-11_ST26.txt; size: 55,589 bytes; creation date: February 6, 2023) are incorporated herein by reference in their entirety. Background Art
[0003] Hemophilia A is an X-linked bleeding disorder that occurs primarily in males and is characterized by a deficiency of functional coagulation factor VIII (FVIII). The global prevalence of hemophilia A is estimated to be 1 in 10,000, with a global incidence of approximately 1 in 5,000 male newborns. The severity of the disease is characterized by endogenous levels of FVIII measured in plasma. Severe hemophilia A (<1% endogenous FVIII activity level; or <1 IU / dL) accounts for approximately 30% to 50% of all hemophilia A cases (Aznar et al. Haemophilia 2009;15(3):665-75).
[0004] Individuals with severe hemophilia experience frequent episodes of bleeding into major joints, soft tissues, and muscles, either spontaneously or after minor trauma. The disease can be severely life-threatening. Recurrent bleeding can lead to debilitating long-term complications, including hemophilic arthropathy caused by intraarticular bleeding (Roosendall and Lafeber. Semin Thromb Hemost. 2003;29(1):37-42). Another serious complication is inflammation of the target joint due to previous bleeding. Intracranial hemorrhage can lead to disability and death and is the leading cause of hemorrhagic death in individuals with hemophilia (Witmer et al. Br J Haematol. 2011.152(2):211-6). Significant impacts on physical and psychosocial health and quality of life, as well as a heavy economic burden, have been reported in patients with severe hemophilia (Lee et al. J Korean Med Sci. 2016;31(1):33-8).
[0005] The current recommended standard of care includes regular administration (routine prophylaxis) of FVIII to minimize the number of bleeding episodes. Routine prophylaxis is associated with improved long-term outcomes, but is a demanding treatment regimen due to the need for frequent intravenous (IV) administration. See Manco-Johnson et al., N Engl J Med. [New England Journal of Medicine] 357(6):535-44(2007). Extended half-life FVIII products reduce the frequency of FVIII administration for prophylaxis; however, all of these interact with von Willebrand factor (VWF) and have comparable circulating half-lives, which is consistent with the upper limit of the half-life of rFVIII variants due to the half-life of endogenous VWF. For example, see Pipe et al., Blood. [Blood] 128(16):2007-16(2016). The prophylactic dose of these FVIII products is once every 3 to 5 days.
[0006] In addition to the patient burden caused by frequent administration, it is also recognized that the currently accepted trough levels of FVIII activity (1% to 3%) are insufficient to protect patients from all bleeding and the resulting morbidity associated with such bleeding episodes. Joint bleeds still occur at these levels, predisposing patients to long-term morbidity (Soucie et al. Blood Adv. 2018; V. 2: 2136-2144; Manco-Johnson et al. Blood. 2017; 2368-2374. The ability to increase patient protection by achieving higher sustained levels of factor activity remains a pressing need for patients and follows recommendations from the World Federation of Hemophilia (Skinner MW. Haemophilia 2012; 18(Suppl 4): 1-12).
[0007] There remains a need for improved coagulation factor replacement products with extended half-lives for the treatment of hemophilia patients. The next generation of extended half-life FVIII products that prevent and control bleeding episodes for longer periods of time, thereby resulting in less frequent dosing, may address the challenge of complying with demanding prophylaxis regimens, which in turn may improve the quality of life of hemophilia patients. Summary of the Invention
[0008] Efanesoctocog alpha (also known as "BIVV001," "efanesoctocogum alpha," "efa," and "rFVIIIFc-VWF-XTEN") is the first recombinant FVIII (rFVIII) engineered to be independent of VWF, thereby extending its half-life and the ability to prevent and control bleeding episodes for a longer period of time. This reduces the burden of frequent intravenous (IV) administration for individuals with hemophilia A, thereby improving compliance and outcomes, including quality of life.
[0009] Treating hemophilia A with enogram alfa has the potential to enable patients to achieve and maintain higher levels of factor activity with less frequent dosing than currently available therapies.
[0010] Certain aspects of the present disclosure relate to a method of treating hemophilia in a human subject in need thereof, the method comprising administering to the subject a plurality of doses of a chimeric protein comprising (i) a factor VIII (FVIII) protein and (ii) a von Willebrand factor (VWF) fragment comprising the D' domain of VWF and the D3 domain of VWF, at a dosing interval, wherein at least one of the plurality of doses is, for example, about 45 IU / kg to about 70 IU / kg, and the dosing interval is at least about every 7 days. In some embodiments, the hemophilia is severe hemophilia A. In some embodiments, at least one of the plurality of doses is about 50 IU / kg. In some embodiments, each of the plurality of doses is about 50 IU / kg.
[0011] In some embodiments, treatment of hemophilia A comprises controlling or reducing the incidence or frequency of bleeding episodes, such as treated bleeding episodes (e.g., treated bleeding episodes that are spontaneous bleeding episodes or traumatic bleeding episodes) and untreated bleeding episodes other than normal bleeding episodes, in a human subject in need thereof. In some embodiments, treatment of hemophilia A comprises preventing or treating bleeding episodes, such as treated bleeding episodes (e.g., treated bleeding episodes that are spontaneous bleeding episodes or traumatic bleeding episodes) and untreated bleeding episodes other than normal bleeding episodes, in a human subject in need thereof.
[0012] In some embodiments, the dosing frequency is at least once a week. In some embodiments, the dosing frequency is once a week.
[0013] In some embodiments, the chimeric protein is administered as a prophylactic treatment.
[0014] In some embodiments, the chimeric protein is administered as an on-demand treatment.
[0015] Certain aspects of the present disclosure relate to a method of achieving an annualized bleeding rate (ABR) of 2 or less, the method comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0016] Certain aspects of the present disclosure relate to a method of reducing the annualized bleeding rate (ABR) compared to treatment with a factor VIII (FVIII) replacement protein that is capable of binding to endogenous von Willebrand factor (VWF), the method comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a VWF fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0017] Certain aspects of the present disclosure relate to a method of reducing the annualized bleeding rate (ABR) compared to prophylactic treatment with a complex, the method comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide sequence, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond, and wherein the complex comprises a FVIII protein and a wild-type VWF protein, or a portion thereof, wherein the FVIII protein and the VWF protein, or a portion thereof, are not covalently attached, directly or indirectly, to each other.
[0018] Certain aspects of the present disclosure relate to a method of reducing the annualized bleeding rate (ABR) compared to prophylactic treatment with emicizumab, the method comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide sequence, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0019] Certain aspects of the present disclosure relate to a method of reducing the amount of analgesics required to reduce or manage pain associated with hemophilia A, the method comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0020] Certain aspects of the present disclosure relate to a method of maintaining a FVIII activity level of at least 2%, the method comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide sequence, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0021] Certain aspects of the present disclosure relate to a method of reducing the risk of a bleeding episode requiring supplemental, on-demand administration of a FVIII replacement protein more than once during prophylactic treatment of hemophilia A, wherein the prophylactic treatment of hemophilia A comprises administering to a human subject in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0022] Certain aspects of the present disclosure relate to methods of resolving a withdrawal bleeding episode, the methods comprising administering to a human subject in need thereof a single, on-demand dose of a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0023] Certain aspects of the present disclosure relate to a method of prophylactically treating hemophilia A comprising administering to a subject in need thereof a therapeutically effective amount of a chimeric protein, wherein a total of less than 3500 IU / kg / year, less than 3400 IU / kg / year, less than 3300 IU / kg / year, less than 3200 IU / kg / year, less than 3100 IU / kg / year, less than 3000 IU / kg / year, less than 2900 IU / kg / year, less than 2800 IU / kg / year, less than 2700 IU / kg / year, or about 2600 IU / kg / year is administered to the subject. The invention provides a chimeric protein of the present invention, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond.
[0024] Certain aspects of the present disclosure relate to methods for prophylactically treating hemophilia A, the methods comprising administering to a human subject in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond, wherein the subject is not receiving any on-demand treatment for hemophilia A prior to engaging in strenuous activity.
[0025] Certain aspects of the present disclosure relate to methods of improving quality of life by prophylactically treating hemophilia A, the methods comprising administering to a human subject in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0026] Certain aspects of the present disclosure relate to a method of improving one or more joint outcomes, the method comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0027] Certain aspects of the present disclosure relate to a method for treating minor, moderate, or major bleeding on demand, the method comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0028] Certain aspects of the present disclosure relate to a method for perioperative management of bleeding, the method comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0029] Certain aspects of the present disclosure relate to a method of achieving an ABR of 2 or less, the method comprising administering 50 IU / kg of enogram alfa once weekly to a human subject with hemophilia A in need thereof.
[0030] Certain aspects of the present disclosure relate to a method of reducing the ABR compared to treatment with a FVIII replacement protein capable of being bound by endogenous VWF, the method comprising administering 50 IU / kg of enogram alfa once weekly to a human subject with hemophilia A in need thereof.
[0031] Certain aspects of the present disclosure relate to a method of reducing an ABR compared to prophylactic treatment with a complex, the method comprising: administering a therapeutically effective amount of 50 IU / kg of enogram alfa to a human subject with hemophilia A in need thereof once weekly, wherein the complex comprises a FVIII protein and a wild-type VWF protein, or a portion thereof, wherein the FVIII protein and the VWF protein, or a portion thereof, are not covalently attached, directly or indirectly, to each other.
[0032] Certain aspects of the present disclosure relate to a method of reducing the ABR compared to prophylactic treatment with emicizumab, the method comprising administering 50 IU / kg of enogram alfa once weekly to a human subject with hemophilia A in need thereof.
[0033] Certain aspects of the present disclosure relate to a method of reducing the amount of analgesics required to reduce or manage pain associated with hemophilia A, the method comprising administering 50 IU / kg of enogram alfa once weekly to a human subject with hemophilia A in need thereof.
[0034] Certain aspects of the present disclosure relate to a method of maintaining a FVIII activity level of at least 2%, the method comprising administering 50 IU / kg of Aynog alfa once weekly to a human subject with hemophilia A in need thereof.
[0035] Certain aspects of the present disclosure relate to a method of reducing the risk of a bleeding episode requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the prophylactic treatment of hemophilia A comprises administering 50 IU / kg of enogram alfa once weekly to a human subject in need thereof.
[0036] Certain aspects of the present disclosure relate to a method of resolving a withdrawal bleeding episode comprising administering a single on-demand dose of 50 IU / kg of enogram alfa to a human subject in need thereof.
[0037] Certain aspects of the present disclosure relate to a method of prophylactically treating hemophilia A, the method comprising administering a therapeutically effective amount of eloquent alfa to a subject in need thereof, wherein a total of less than 3500 IU / kg / year, less than 3400 IU / kg / year, less than 3300 IU / kg / year, less than 3200 IU / kg / year, less than 3100 IU / kg / year, less than 3000 IU / kg / year, less than 2900 IU / kg / year, less than 2800 IU / kg / year, less than 2700 IU / kg / year, or about 2600 IU / kg / year of eloquent alfa is administered to the subject.
[0038] Certain aspects of the present disclosure relate to a method of prophylactically treating hemophilia A, comprising administering 50 IU / kg of enogram alfa to a human subject in need thereof once weekly, wherein the subject is not taking any on-demand treatment for hemophilia A prior to engaging in strenuous activity.
[0039] Certain aspects of the present disclosure relate to a method of improving quality of life with prophylactic treatment of hemophilia A, the method comprising administering 50 IU / kg of enogram alfa once weekly to a human subject in need thereof.
[0040] Certain aspects of the present disclosure relate to a method of improving one or more joint outcomes, comprising administering 50 IU / kg of enogram alfa once weekly to a human subject with hemophilia A in need thereof.
[0041] Certain aspects of the present disclosure relate to a method of treating minor, moderate, or major bleeding on demand, comprising administering 50 IU / kg of enogram alfa to a human subject with hemophilia A in need thereof.
[0042] Certain aspects of the present disclosure relate to a method for perioperative management of bleeding comprising administering 50 IU / kg of enogram alfa to a human subject with hemophilia A in need thereof.
[0043] Certain aspects of the present disclosure relate to a kit comprising a drug label and a chimeric protein, wherein the drug label comprises recommendations or instructions for practicing the methods disclosed herein, and wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond.
[0044] Certain aspects of the present disclosure relate to kits comprising a drug label and a chimeric protein, wherein the drug label comprises information sufficient to enable a human subject, a caregiver, or a healthcare practitioner to perform the methods disclosed herein, and wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0045] Certain aspects of the present disclosure relate to a chimeric protein for achieving an annualized bleeding rate (ABR) of 2 or less, wherein a therapeutically effective amount of the chimeric protein is administered to a human subject with hemophilia A, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond.
[0046] Certain aspects of the present disclosure relate to a chimeric protein for reducing the annualized bleeding rate (ABR) compared to treatment with a factor VIII (FVIII) replacement protein capable of being bound by endogenous VWF, wherein a therapeutically effective amount of the chimeric protein is administered to a human subject with hemophilia A, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond.
[0047] Certain aspects of the present disclosure relate to a chimeric protein for reducing the annualized bleeding rate (ABR) compared to prophylactic treatment with a complex, wherein a therapeutically effective amount of the chimeric protein is administered to a human subject with hemophilia A, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, and wherein the complex comprises a FVIII protein and a wild-type VWF protein, or a portion thereof, wherein the FVIII protein and the VWF protein, or a portion thereof, are not covalently attached, directly or indirectly, to each other.
[0048] Certain aspects of the present disclosure relate to a chimeric protein for reducing the annualized bleeding rate (ABR) compared to prophylactic treatment with emicizumab, wherein a therapeutically effective amount of the chimeric protein is administered to a human subject with hemophilia A, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0049] Certain aspects of the present disclosure relate to a chimeric protein for reducing the amount of analgesics required to reduce or manage pain associated with hemophilia A, comprising administering a therapeutically effective amount of a chimeric protein to a human subject with hemophilia A in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0050] Certain aspects of the present disclosure relate to a chimeric protein for maintaining a FVIII activity level of at least 2%, wherein a therapeutically effective amount of the chimeric protein is administered to a human subject with hemophilia A, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond.
[0051] Certain aspects of the present disclosure relate to a chimeric protein for reducing the risk of a bleeding episode requiring supplemental, on-demand administration of a FVIII replacement protein more than once during prophylactic treatment of hemophilia A, wherein the prophylactic treatment of hemophilia A comprises administering to a human subject in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0052] Certain aspects of the present disclosure relate to a chimeric protein for use in resolving a bleeding episode, comprising administering to a human subject in need thereof a single, on-demand dose of a therapeutically effective amount of the chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0053] Certain aspects of the present disclosure relate to a chimeric protein for use in prophylactic treatment of hemophilia A, comprising administering to a human subject in need thereof a therapeutically effective amount of the chimeric protein, wherein a total of less than 3500 IU / kg / year, less than 3400 IU / kg / year, less than 3300 IU / kg / year, less than 3200 IU / kg / year, less than 3100 IU / kg / year, less than 3000 IU / kg / year, less than 2900 IU / kg / year, less than 2800 IU / kg / year, less than 2700 IU / kg / year, or about 2600 IU / kg / year of the chimeric protein is administered to the subject, wherein the chimeric protein comprises a first polypeptide and a second polypeptide. A polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond, and wherein the chimeric protein is administered at a dose of 45 IU / kg to 70 IU / kg of the chimeric protein at a dosing interval of about 6 days to about 14 days.
[0054] Certain aspects of the present disclosure relate to a chimeric protein for use in reducing the need for on-demand administration before strenuous activity in the prophylactic treatment of hemophilia A, wherein a therapeutically effective amount of the chimeric protein is administered to a human subject with hemophilia A, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0055] Certain aspects of the present disclosure relate to a chimeric protein for improving quality of life by prophylactically treating hemophilia A, wherein a therapeutically effective amount of the chimeric protein is administered to a human subject, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0056] Certain aspects of the present disclosure relate to a chimeric protein for improving one or more joint outcomes, wherein a therapeutically effective amount of the chimeric protein is administered to a human subject with hemophilia A, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0057] Certain aspects of the present disclosure relate to a chimeric protein for the on-demand treatment of minor, moderate, or major bleeding, wherein a therapeutically effective amount of the chimeric protein is administered to a human subject with hemophilia A, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond.
[0058] Certain aspects of the present disclosure relate to a chimeric protein for the perioperative management of bleeding, comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of the chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond. BRIEF DESCRIPTION OF THE DRAWINGS
[0059] Figure 1 FIG2 is a non-limiting schematic diagram of an exemplary FVIII-ELNN-Fc / D'D3-ELNN-Fc heterodimer. Abbreviations: FVIII: Factor VIII; VWF: von Willebrand Factor; A1, A2, A3, C1, C2: domains of FVIII; D'D3: domain of VWF; Fc: Fc region of an immunoglobulin constant region.
[0060] Figure 2 is a schematic representation of the design of the Phase 3 clinical study disclosed in Example 1.
[0061] Figure 3 is a graphical representation showing that weekly prophylaxis with Aynol alpha provided highly effective prevention of bleeding in the Phase 3 study described in Example 1. ABR is used to treat bleeding episodes.
[0062] Figure 4is a graphical representation showing that Aynol alpha prophylaxis provided superior bleeding protection compared to pre-study prophylaxis (242HA201 / OBS16221) (n=78) in the Phase 3 study described in Example 1. ABR is used to treat bleeding episodes.
[0063] Figure 5 is a graphical representation of the distribution of annualized bleeding rate (ABR) and annualized joint bleed rate (AjBR) for study subjects in Group A of Example 1. ABR and AjBR are used to treat bleeding episodes.
[0064] Figure 6 is a graphical representation of the bleeding event rate for each study week in Group A. This analysis includes treated bleeds in Group A with no missing bleeding dates (n=79) up to Week 52. Bleeding episodes were plotted to each week based on the event date and time. The bleeding episode rate was calculated as the number of bleeds per participant per week. A linear regression model was used to determine the slope and 95% confidence interval (CI) for the slope.
[0065] Figure 7 A to Figure 7 B is the group A in the treatment of spontaneous bleeding episodes ( Figure 7 A) and traumatic hemorrhagic episodes ( Figure 7 B) Graphical representation of the time since the last prophylactic dose. For traumatic bleeding episodes, one traumatic bleeding episode (not shown) occurred 13 days after the last prophylactic dose and one traumatic bleeding episode (not shown) occurred during the screening period and therefore had not received a prophylactic dose previously.
[0066] Figure 8 A to Figure 8 B is the weekly injection frequency for subjects receiving standard of care FVIII prophylaxis (pre-study) or enoxaprogestin alfa prophylaxis (on-study) ( Figure 8 A) and weekly FVIII consumption ( Figure 8 B) Graphical representation of within-participant comparisons.
[0067] Figure 9 is a graphical representation of the mean observed ABR demonstrating that enogram alfa prophylaxis reduced bleeding events following switching from enogram alfa as-needed treatment in Arm B of the Phase 3 study described in Example 1. The ABR is used to treat bleeding episodes.
[0068] Figure 10 A graphical representation of the results of measurements of physical well-being according to the Haem-A-QoL score, pain assessment according to PROMIS 3a Q1, and joint health according to the Hemophilia Joint Health Score (HJHS). Prophylactic treatment with Anocog alfa showed significant improvements in physical well-being, pain, and joint health.
[0069] Figure 11 This figure shows the mean LS change from baseline to week 52 in the Haem-A-QoL domain and total scores in Group A. Nominal p-values are given except for the physical health domain score. **p ≤ 0.0001, *p < 0.05. For physical health, the prespecified endpoint was included in the multivariate analysis; all other domains were analyzed post hoc. Lower scores indicate better HRQoL. Abbreviations: CI, confidence interval; Haem-A-QoL: Adult Hemophilia Quality of Life Questionnaire; HRQoL: health-related quality of life; LS: least squares method.
[0070] Figure 12 This figure represents the mean changes from baseline to week 52 in the Haem-A-QoL domain and total scores observed in Group B. Lower scores indicate better health-related quality of life. All domains and the total score are exploratory endpoints. Abbreviations: Haem-A-QoL: Adult Hemophilia Quality of Life Questionnaire; HRQoL: Health-Related Quality of Life; SD: Standard Deviation.
[0071] Figure 13 The figure is a graphical representation of the proportion of patients in Group A who experienced improvement, no change, or worsening from baseline to week 52 in the EuroQol 5-Dimension 5-Level (EQ-5D-5L) dimensions. Each dimension was rated by the patient as one of five levels of perceived problem: 1 = "no problem," 2 = "slight problem," 3 = "moderate problem," 4 = "severe problem," and 5 = "extreme problem or unable to." For each EQ-5D-5L dimension, a patient was considered improved if at least one category improved and worsened if at least one category worsened.
[0072] Figure 14 is a visual representation of the endpoints achieved in the Phase 3 study outlined in Example 1.
[0073] Figure 15 is a line graph showing mean Factor VIII (FVIII) activity levels (IU / dL, %) over 14 days following administration of Anogram alfa at Week 1 (circled line) or Week 26 (triangular line). Once-weekly Anogram alfa provided mean Factor VIII activity levels >40% for 4 days and >10% on Day 7.
[0074] Figure 16 This figure shows a visual representation of the timeline of perioperative management for each major surgery in the study. Abbreviation: TKP, total knee prosthesis. Only factor activity measurements from the central laboratory are shown. On the day of surgery, surgery was followed by factor activity measurements and enoxacin alfa administration in all cases. Footnotes: (a) Orthopedic surgery. (b) Same patient undergoing two surgeries.
[0075] Figure 17is a schematic representation of the design of the Phase 1 study disclosed in Example 2. Samples for FVIII inhibitor testing were obtained before administration of each rFVIII product and 14 and 28 days after administration of Aynol alfa.
[0076] Figure 18 is shown in Example 2, where a single dose of octocognin alpha at 50 IU / kg is administered. (circles), Luligin alfa administered as a single dose at 50 IU / kg Line graph of mean (±SD) plasma FVIII activity levels (IU / dl, %) after administration of (squares), or a single dose of 50 IU / kg of Aynog alfa (triangles).
[0077] Figure 19 Included is a graphical representation showing that Aynol alpha provides high, sustained FVIII levels throughout the weekly dosing interval, as evaluated in the study of Example 1.
[0078] Figure 20 is a graph showing the cumulative distribution function of the change from baseline in the Haem-A-QoL physical health score at week 52 in group A
[0079] Figure 21 is a graph showing the cumulative distribution function of the change from baseline in pain at Week 52 for Group A for the PROMIS Pain Intensity 3a Item 1 (at its most severe) score.
[0080] Figure 22 is a graph showing the transition analysis for the first item 3a (pain at its worst) of PROMIS pain intensity for Group A. Only patients who provided a score at each visit were considered in this graph.
[0081] Figure 23 Figure 1 is a graph showing analgesic use at baseline and week 52 in the Example 1 study. Depicted are the number of days (n=159) on which hemophilia-related analgesics were taken within 2 weeks of the visit. Percentages are based on the number of participants included in the safety analysis. Assessments during major surgery were excluded. If more than one analgesic was reported, the maximum number of days on which hemophilia-related analgesics were taken was calculated.
[0082] Figure 24A To C. Figure 24AFigures and additional disclosures showing that enocoag alfa prophylaxis in the study of Example 1 provided highly effective protection against bleeding that was superior to previous FVIII therapy. ABR, annualized bleeding rate; CI, confidence interval; FVIII, factor VIII; IQR, interquartile range. Footnotes: (a) The CI for the mean ABR was estimated using a negative binomial model with the total number of treated bleeding episodes during the efficacy period as the response variable and the log-transformed duration of the efficacy period (in years) as the offset variable. (b) Estimated using a negative binomial regression model with treatment (enocoag alfa prophylaxis versus pre-study FVIII prophylaxis) as a covariate. (c) P values are associated with the null hypothesis that the ratio of enocoag alfa prophylaxis / pre-study prophylaxis is equal to 1. Abbreviations: ABR, annualized bleeding rate; CI, confidence interval; FVIII, factor VIII; IQR, interquartile range. Figure 24B -C is a graph showing the lower bleeding rates observed after switching to Anocog alfa prophylaxis in both study arms of the Example 1 study. ABR, annualized bleeding rate; SD, standard deviation. Footnotes: (a) Based on treated bleeds. (b) The mean (SD) estimated number of bleeds in the first 12 months of the study was 3.2 (5.4). (c) The mean (SD) estimated number of bleeds in the first 12 months of the study was 35.7 (22.2).
[0083] Figure 25 is a line graph showing mean Factor VIII (FVIII) activity levels (IU / dL) over 14 days (168 hours) following administration of Aynol alpha in all participants <12 years of age.
[0084] Figure 26 This figure shows the change in the Hemophilia Joint Health Score (HJHS) total score from baseline to Week 52 among participants in Group A (weekly prophylaxis) of a Phase 3, open-label, multicenter study, separated by age. LS means (95% CI) and P values were estimated using a repeated-measures mixed-effects model with visit as a fixed effect and baseline HJHS as a covariate. Only patients with HJHS measurements at both time points were included.
[0085] FIG27 is a diagram showing the results of a Phase 3 open-label multicenter study separated by HJHS domain ( Figure 27A ) and Group B ( Figure 27B) from baseline to Week 52. HJHS assessments within 2 weeks after joint or muscle bleeds were excluded. Joint scores after joint surgery were replaced using the last observation carried forward method. Assessments during other major surgeries were excluded. HJHS domains were assessed using the following score ranges: swelling (0-3); duration of swelling (0 or 1); muscle atrophy (0-2); crepitus with movement (0-2); loss of flexion (0-3); loss of extension (0-3); joint pain (0-2); and strength (0-4). Domain scores were calculated if all 6 joints for each domain were present.
[0086] Figure 28 is a graph showing the estimated mean annualized bleeding rate (ABR) for all participants (n=74) in the completed study disclosed in Example 3. The data shown apply to all participants (overall) and each specified age group. ABR, annualized bleeding rate; CI, confidence interval.
[0087] Figure 29 is a graphical representation of the distribution of the annualized bleeding rate (ABR), annualized joint bleed rate (AjBR), and annualized spontaneous bleeding rate (AsBR) for all study participants (n=74) in the completed study disclosed in Example 3.
[0088] Figure 30 Is a line graph showing the mean Factor VIII (FVIII) activity levels (IU / dL, %) over 7 days after the first dose of Aynol alpha for participants less than 6 years of age (circle line) or 6 to 12 years of age (triangle line). The data shown are from the PK analysis set, n=19 (<6 years of age) and 18 (6-<12 years of age). DETAILED DESCRIPTION
[0089] The present disclosure relates to methods for treating hemophilia A. In some embodiments, these methods comprise the use of a chimeric protein, such as enogram alfa, comprising two polypeptides, i.e., a first polypeptide comprising a FVIII polypeptide comprising an insertion of a first ELNN polypeptide sequence fused to a first Fc region, and a second polypeptide comprising a VWF fragment (e.g., a VWF fragment comprising a mutation as disclosed herein) fused to a second Ig constant region via a second ELNN polypeptide sequence, wherein the first ELNN polypeptide sequence contains about 280 to 300 amino acids (e.g., about 288 amino acids) and the second ELNN polypeptide sequence contains about 140 to 150 amino acids (e.g., about 144 amino acids), and the first and second Ig constant regions are covalently linked together by a disulfide bond.
[0090] In some embodiments, the present disclosure relates to methods for treating hemophilia A using a chimeric protein comprising (i) a factor VIII (FVIII) polypeptide and (ii) a von Willebrand Factor (VWF) fragment comprising the D' domain and the D3 domain of VWF (e.g., the D'D3 region can be mutated to replace cysteines involved in dimerization). Also disclosed are pharmaceutical compositions comprising the chimeric protein. Also disclosed are uses of the chimeric protein or pharmaceutical composition disclosed herein for treating hemophilia A.
[0091] In some embodiments, the chimeric protein is anolectin alfa. I. Definition
[0092] It should be noted that the term "a" or "an" entity refers to one or more of that entity; for example, "a nucleotide sequence" is understood to mean one or more nucleotide sequences. Thus, the terms "a / an," "one or more," and "at least one" are used interchangeably herein.
[0093] Furthermore, “and / or” where used herein should be taken as a specific disclosure of each of the two specified features or components with or without the other. Thus, the term “and / or” as used herein in phrases such as “A and / or B” is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Likewise, the term “and / or” as used in phrases such as “A, B, and / or C” is intended to cover each of the following: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0094] The term "about" is used herein to mean approximately, roughly, roughly, or around. When the term "about" is used in conjunction with a numerical range, it defines the range by extending the boundaries above and below the numerical values set forth. Generally speaking, the term "about" can define a numerical value to be above and below a specified value with a variation of, for example, 10% or more (higher or lower). In some embodiments, the term represents a deviation from a specified numerical value of ±10%, ±5%, ±4%, ±3%, ±2%, ±1%, ±0.9%, ±0.8%, ±0.7%, ±0.6%, ±0.5%, ±0.4%, ±0.3%, ±0.2%, ±0.1%, ±0.05%, or ±0.01%. In some embodiments, "about" represents a deviation from the indicated numerical value of ±10%. In some embodiments, "about" represents a deviation from the indicated numerical value of ±5%. In some embodiments, "about" represents a deviation from the indicated numerical value of ±4%. In some embodiments, "about" represents a deviation from the indicated numerical value of ±3%. In some embodiments, "about" represents a deviation from the indicated numerical value of ±2%. In some embodiments, “about” means a deviation of ±1% from the indicated value. In some embodiments, “about” means a deviation of ±0.9% from the indicated value. In some embodiments, “about” means a deviation of ±0.8% from the indicated value. In some embodiments, “about” means a deviation of ±0.7% from the indicated value. In some embodiments, “about” means a deviation of ±0.6% from the indicated value. In some embodiments, “about” means a deviation of ±0.5% from the indicated value. In some embodiments, “about” means a deviation of ±0.4% from the indicated value. In some embodiments, “about” means a deviation of ±0.3% from the indicated value. In some embodiments, “about” means a deviation of ±0.1% from the indicated value. In some embodiments, “about” means a deviation of ±0.05% from the indicated value. In some embodiments, “about” means a deviation of ±0.01% from the indicated value.
[0095] It should be understood that wherever aspects are described herein with the language "comprising," similar aspects described as "consisting of" and / or "consisting essentially of" are also provided.
[0096] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure relates. For example, useful descriptions of certain terms in the field of hemophilia A can be found in: Blanchette et al. J Thromb Haemost. 2014; 12(11): 1935-9, the entire contents of which are incorporated herein by reference.
[0097] Units, prefixes and symbols are all expressed in the form accepted by the International System of Units (SI). Numerical ranges include numbers that limit the range. Unless otherwise indicated, amino acid sequences are written from left to right in the amino to carboxyl direction. The headings provided herein are not limitations on the various aspects of this disclosure. Therefore, the terms of the definitions immediately below are more fully defined by reference to the specification (in its entirety).
[0098] In some embodiments, polynucleotide is an isolated nucleic acid molecule or construct, such as messenger RNA (mRNA) or plasmid DNA (pDNA). Depending on the context, "polynucleotide" can be any one or more nucleic acid segments present in a larger polynucleotide (such as a genome or vector), such as DNA or RNA fragments. Mention of "isolated" nucleic acid or polynucleotide refers to a nucleic acid molecule DNA or RNA that is not in its natural environment (such as, it is not in a wild-type cell or virus). For example, for the purposes of this disclosure, the recombinant polynucleotide encoding Factor VIII protein included in the vector is considered to be isolated. Further examples of isolated polynucleotides include recombinant polynucleotides maintained in a heterologous host cell or purified (partially or substantially) from other polynucleotides in the solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the polynucleotides of this disclosure. Polynucleotides or nucleic acids according to the separation of this disclosure further include such molecules produced synthetically. In addition, polynucleotides or nucleic acids can include regulatory elements, such as promoters, enhancers, ribosome binding sites or transcription termination signals.
[0099] Certain proteins secreted by mammalian cells are associated with a secretory signal peptide that is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. As is known to those skilled in the art, a signal peptide is typically fused to the N-terminus of a polypeptide and cleaved from the intact or full-length polypeptide to produce a secreted or mature form of the polypeptide. In some embodiments, the native signal peptide or a functional derivative of that sequence retains the ability to direct the secretion of a polypeptide with which it is operably associated. It should be understood that where a polypeptide sequence having a signal peptide is disclosed, forms of the polypeptide sequence without the signal peptide are also disclosed.
[0100] As used herein, the term "polypeptide" is intended to include a single "polypeptide" as well as a plurality of "polypeptides" and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term "polypeptide" refers to any chain of two or more amino acids, but does not refer to any particular amino acid length. Thus, peptides, dipeptides, tripeptides, oligopeptides, "proteins," "amino acid chains," or any other terms used to refer to one or more chains of two or more amino acids are included in the definition of "polypeptide," and the term "polypeptide" can replace any of these terms, or be used interchangeably, depending on the context. The term "polypeptide" is also intended to refer to products of modifications after expression of the polypeptide, including but not limited to glycosylation, acetylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, or modification of non-naturally occurring amino acids. The polypeptide can be derived from a natural biological source or recombinant production technology, but is not necessarily translated from a specified nucleic acid sequence. It can be produced in any way, including by chemical synthesis.
[0101] An "isolated" polypeptide, or fragment, variant, or derivative thereof, is one that is not in its native environment. No particular level of purification is required. For example, an isolated polypeptide can be simply removed from its native or natural environment. For the purposes of this disclosure, recombinantly produced polypeptides and proteins expressed in host cells are considered isolated, as are native or recombinant polypeptides that have been separated, fractionated, or partially or substantially purified by any suitable technique.
[0102] The present disclosure also includes fragments or variants of polypeptides and any combination thereof. When referring to the polypeptide binding domains or binding molecules of the present disclosure, the term "fragment" or "variant" includes any polypeptide that retains at least some of the characteristics of the reference polypeptide (e.g., FcRn binding affinity for FcRn binding domains or Fc variants, coagulation activity for FVIII variants, or FVIII binding activity for VWF fragments). In addition to the specific antibody fragments discussed elsewhere herein, the fragments of the polypeptide also include proteolytic fragments and deletion fragments, but do not include naturally occurring full-length polypeptides (or mature polypeptides). The variants of the polypeptide binding domains or binding molecules of the present disclosure include fragments as described above, and polypeptides with amino acid sequences altered due to amino acid substitutions, deletions, or insertions. Variants can be naturally occurring or non-naturally occurring. Non-naturally occurring variants can be produced using mutagenesis techniques known in the art. Variant polypeptides can include conservative or non-conservative amino acid substitutions, deletions, or additions.
[0103] The term "VWF fragment" includes any VWF fragment that interacts with FVIII and retains at least one or more properties typically provided to FVIII by full-length VWF (e.g., preventing or reducing premature activation of FVIIIa, preventing or reducing premature proteolysis, preventing or reducing clearance, preventing or reducing association with phospholipid membranes that can cause premature clearance, preventing or reducing binding to FVIII clearance receptors that can bind to naked FVIII but not to VWF-bound FVIII, and / or stabilizing the interaction between the FVIII heavy chain and light chain). As referred to herein, a VWF fragment is a VWF polypeptide that is smaller than the full-length VWF protein, wherein the VWF fragment retains the ability to interact and / or bind to FVIII. In some embodiments, the VWF fragment is a fragment of full-length VWF (which may be mutated) that binds to a FVIII polypeptide such that the FVIII polypeptide has reduced binding to or does not bind to full-length VWF (e.g., endogenous VWF in a subject). In some embodiments, the VWF fragment is a human VWF fragment or a mutant VWF fragment.
[0104] "Conservative amino acid substitutions" are substitutions in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, if an amino acid in a polypeptide is replaced by another amino acid from the same side chain family, the replacement is considered to be conservative. In certain embodiments, an amino acid string can be conservatively replaced with a structurally similar string that differs in the order and / or composition of the side chain family members.
[0105] As known in the art, "sequence identity" between two polypeptides is determined by comparing the amino acid sequence of one polypeptide with the sequence of a second polypeptide. Similarly, "sequence identity" between two polynucleotides is determined by comparing the nucleotide sequence of one polynucleotide with the sequence of a second polynucleotide. The terms "identical %", "identity %" or similar terms are intended to refer in particular to the percentage of identical nucleotides or amino acids (if applicable) in the most preferably alignment between the sequences to be compared. The percentages are purely statistical, and the differences between the two sequences can, but are not necessarily, randomly distributed over the entire length of the sequences to be compared. The comparison of two sequences is typically performed by comparing these sequences relative to a segment or "comparison window" after optimal alignment to identify local regions of the corresponding sequences. For example, optimal alignment for comparison can be performed manually or with the help of the local homology algorithm of Smith and Waterman, 1981, Ads App. Math. 2, 482, with the help of the local homology algorithm of Neddleman and Wunsch, 1970, J. Mol. Biol. 48, 443, with the help of the similarity search algorithm of Pearson and Lipman, 1988, Proc. Natl Acad. Sci. USA 88, 2444, or with the help of computer programs that use such algorithms, for example, GAP, BESTFIT, FASTA, BLAST P, BLAST N, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis. In some embodiments, the percent identity between two sequences is determined using the BLASTN or BLASTP algorithm, which is available on the website of the National Center for Biotechnology Information (NCBI) (e.g., at http: / / blast.ncbi.nlm.nih.gov / Blast.cgi). In some embodiments, the algorithm parameters for the BLASTN algorithm on the NCBI website include: (i) the expectation threshold is set to 10; (ii) the word size is set to 28; (iii) the maximum number of matches within the query is set to 0; (iv) the match / mismatch score is set to 1, -2; (v) the gap penalty is set to linear; and (vi) a filter for low complexity regions is used.In some embodiments, the algorithm parameters for the BLASTP algorithm on the NCBI website include: (i) the expectation threshold is set to 10; (ii) the word size is set to 3; (iii) the maximum number of matches within the query range is set to 0; (iv) the matrix is set to BLOSUM62; (v) the gap penalty is set to existence: 11 extension: 1; and (vi) the condition composition score matrix is adjusted. When discussed herein, methods and computer programs / software known in the art can be used, such as, but not limited to, the BESTFIT program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711), to determine whether any particular polypeptide has, for example, at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to another polypeptide. BESTFIT uses the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981), to find the best segment of homology between two sequences. When using BESTFIT or any other sequence alignment program to determine whether a particular sequence is, for example, 95% identical to a reference sequence according to the present disclosure, the parameters are set so that the percent identity is calculated over the entire length of the reference polypeptide sequence and that gaps in homology of up to 5% of the total number of amino acids in the reference sequence are allowed.
[0106] As used herein, an "amino acid corresponding to" or "equivalent amino acid" in a VWF or FVIII sequence is identified by aligning to maximize the identity or similarity between a first VWF or FVIII sequence and a second VWF or FVIII sequence. The numbering used to identify the equivalent amino acid in the second VWF or FVIII sequence is based on the numbering used to identify the corresponding amino acid in the first VWF or FVIII sequence.
[0107] As used herein, the term "insertion site" refers to a position in a FVIII polypeptide, or a fragment, variant, or derivative thereof, immediately downstream of the position at which a half-life extending moiety or heterologous moiety may be inserted. An "insertion site" is designated as a number that is the number of the amino acid immediately C-terminal to the insertion site in mature, native (wild-type) human FVIII (SEQ ID NO: 8) to which the insertion site corresponds. For example, the phrase "comprising an ELNN polypeptide at an insertion site corresponding to amino acid 1656 of SEQ ID NO: 8" indicates that the heterologous moiety is inserted immediately after the amino acid residue corresponding to amino acid residue 1656 of SEQ ID NO: 8 (amino acid residue 1657 of SEQ ID NO: 8 need not be present).
[0108] As used herein, the terms "insertion," "inserted into," "inserted into," or grammatically related terms with respect to the insertion of an ELNN polypeptide into FVIII refer to the position of the ELNN polypeptide in the chimeric protein relative to an analogous position in native mature human FVIII (SEQ ID NO: 8). As used herein, these terms refer to the characteristics of the recombinant FVIII polypeptide relative to native mature human FVIII and do not indicate, suggest, or infer any method or process by which the chimeric protein is prepared. For example, in reference to a chimeric protein provided herein, the phrase "the ELNN polypeptide is inserted immediately downstream of residue 745 of the FVIII polypeptide" means that the chimeric protein comprises the ELNN polypeptide immediately downstream of the amino acid residue corresponding to amino acid residue 745 in native mature human FVIII (e.g., bound to amino acids corresponding to amino acid residues 745 and 746 of native mature human FVIII) (without the presence of an amino acid residue corresponding to 746 of native mature human FVIII), and does not imply an order or method for preparing the chimeric protein.
[0109] As used herein, the terms "ELNN polypeptide" and "ELNN" are synonymous and refer to polypeptides of extended length comprising a non-naturally occurring, substantially non-repetitive sequence (e.g., a polypeptide motif) composed primarily of small, hydrophilic amino acids, which has a low degree of secondary or tertiary structure or no secondary or tertiary structure under physiological conditions. Such extended-length polypeptides include unstructured hydrophilic polypeptides comprising a repeating motif of 6 natural amino acids (G, A, P, E, S and / or T). In some embodiments, the ELNN polypeptide comprises multiple motifs of 6 natural amino acids (G, A, P, E, S, T), wherein these motifs are the same or comprise a combination of different motifs. When linked to the VWF fragment or FVIII sequence of the present disclosure to produce a chimeric protein, the ELNN polypeptide can confer certain desired pharmacokinetic, physicochemical and pharmaceutical properties. These desired properties include, but are not limited to, enhanced pharmacokinetic parameters and solubility properties. ELNN polypeptides are known in the art and relate to a class of polypeptides referred to as A non-limiting description of ELNN polypeptides and examples thereof can be found in Schellenberger et al., (2009) Nat Biotechnol 27(12): 1186-90; Brandl et al., (2020) Journal of Controlled Release 327: 186-197; and Radon et al., (2021) Advanced Functional Materials 31, 2101633 (pp. 1-33), the entire contents of each of which are incorporated herein by reference.
[0110] A "fusion" or "chimeric" protein comprises a first amino acid sequence linked to a second amino acid sequence to which the first amino acid sequence is not naturally linked in nature. Amino acid sequences that are normally present in separate proteins can be brought together in a fusion polypeptide, or amino acid sequences that are normally present in the same protein can be placed in a fusion polypeptide (e.g., a fusion of a Factor VIII domain of the present disclosure with an immunoglobulin Fc domain) in a new arrangement. For example, a fusion protein is produced by chemical synthesis or by generating and translating a polynucleotide in which the peptide regions are encoded in a desired relationship. The chimeric protein may further comprise a second amino acid sequence that is associated with the first amino acid sequence by a covalent, non-peptide, or non-covalent bond.
[0111] About sequence, as used herein, the term "connection" refers to that a first amino acid sequence or nucleotide sequence is covalently or non-covalently joined to a second amino acid sequence or nucleotide sequence, respectively. The first amino acid or nucleotide sequence can be directly connected or juxtaposed to the second amino acid or nucleotide sequence, or alternatively, an insertion sequence can covalently connect the first sequence to the second sequence. Depending on the context, the term "connection" not only means the fusion of the first amino acid sequence at the C-terminus or N-terminus with the second amino acid sequence, but also includes inserting the entire first amino acid sequence (or the second amino acid sequence) into any insertion site of the second amino acid sequence (or respectively the first amino acid sequence). In certain embodiments, the first amino acid sequence can be connected to the second amino acid sequence by a peptide bond or a joint. In certain embodiments, the first nucleotide sequence can be connected to the second nucleotide sequence by a phosphodiester bond or a joint. The joint can be a peptide or polypeptide (for a polypeptide chain) or a nucleotide or nucleotide chain (for a nucleotide chain) or any chemical moiety (for both polypeptide and polynucleotide chains). The term "connected" can also be represented by a hyphen (-).
[0112] For two polypeptides, the term "associated" refers to one or more covalent or non-covalent bonds formed between a first polypeptide and a second polypeptide. In certain embodiments, the term "associated" refers to a covalent, non-peptide or non-covalent bond. This association can be represented by a colon, i.e. (:). In certain embodiments, it means a covalent bond other than a peptide bond. For example, the amino acid cysteine comprises a thiol group that can form a disulfide bond or a bridge with the thiol group on the second cysteine residue. In many naturally occurring IgG molecules, CH1 and CL regions are associated by disulfide bonds, and the two heavy chains are associated by two disulfide bonds at positions corresponding to 239 and 242 using the Kabat numbering system (position 226 or 229, EU numbering system). Examples of covalent bonds include, but are not limited to, peptide bonds, metal bonds, hydrogen bonds, disulfide bonds, σ bonds, π bonds, δ bonds, glycosidic bonds, agnostic bonds, bent bonds, dipole bonds, π reverse bonds, double bonds, triple bonds, quadruple bonds, five bonds, six bonds, conjugation, hyperconjugation, aromaticity, Hapto number or antibonding. Non-limiting examples of non-covalent bonds include ionic bonds (e.g., cationic π bonds or salt bonds), metallic bonds, hydrogen bonds (e.g., dihydrogen bonds, dihydrogen complexes, low-barrier hydrogen bonds, or symmetric hydrogen bonds), van der Waals forces, London dispersion forces, mechanical bonds, halogen bonds, gold affinity, intercalation, stacking, entropic forces, or chemical polarity. In some embodiments, the one or more covalent bonds between the first amino acid chain and the second amino acid chain are two disulfide bonds. In some embodiments, the one or more covalent bonds between the first amino acid chain and the second amino acid chain are two disulfide bonds between the first Fc portion on the first amino acid chain and the second Fc portion on the second amino acid chain, wherein the two disulfide bonds occur in the hinge region of the two Fc portions.
[0113] In certain embodiments, the polypeptide has an enzyme cleavage site that is cut by an activated enzyme during the coagulation cascade, so that the cutting of such sites occurs at the site of clot formation. Exemplary such sites include, for example, those identified by thrombin, factor XIa or factor Xa. Other enzyme cleavage sites are known in the art and described elsewhere herein. In constructs comprising more than one processing site or cleavage site, it should be understood that these sites can be the same or different.
[0114] In some embodiments, half-life can be represented by the time required for half of the amount administered to a subject to be cleared from the circulation and / or other tissues in an animal. In some embodiments, when a clearance curve for a given polypeptide is constructed as a function of time, the curve is typically biphasic with a rapid α phase and a longer β phase. The α phase typically represents the equilibrium between the intravascular and extravascular spaces of the administered Fc polypeptide and is determined in part by the size of the polypeptide. The β phase typically represents the catabolism of the polypeptide in the intravascular space. In some embodiments, FVIII and chimeric proteins comprising FVIII are monophasic and therefore do not have an α phase, but only a single β phase. Therefore, in some embodiments, the term half-life as used herein refers to the half-life of the polypeptide in the β phase. In some embodiments, half-life is expressed as the half-life of the terminal phase.
[0115] The composition, e.g., chimeric protein, can be administered to a subject using methods known in the art. In some embodiments, administration is performed intravenously. In some embodiments, administration is performed subcutaneously. In some embodiments, administration is self-administered. In some embodiments, a parent administers the chimeric protein to a child. In some embodiments, the chimeric protein is administered to a subject by a healthcare practitioner, e.g., a physician, doctor, or nurse.
[0116] In some embodiments, a single dose is administered to a subject. In some embodiments, multiple doses are administered to a subject. A single dose can be administered all at once, e.g., as a bolus, or over a period of time, e.g., by intravenous infusion.
[0117] In some embodiments, the composition, such as a chimeric protein, is delivered by a slow push IV injection over 8 ± 2 minutes. In some embodiments, the composition is delivered at an administration rate determined by the subject's comfort level. In some embodiments, the composition is delivered via slow push IV injection at an administration rate determined by the subject's comfort level and according to the following vial injection rate recommendations: for subjects weighing ≤ 55 kg, the minimum injection time per vial is 2 minutes per vial; for subjects weighing > 55 kg, the minimum injection time per vial is 1 minute per vial.
[0118] When referring to co-administration of more than one composition, a dose of composition A may be administered simultaneously with a dose of composition B. Alternatively, a dose of composition A may be administered before or after a dose of composition B. In some embodiments, composition A and composition B are combined into a single formulation.
[0119] As used herein, the term "interval" or "dosing interval" refers to the amount of time that elapses between a first dose of Composition A and a subsequent dose of the same composition administered to a subject. A dosing interval can refer to the time that elapses between multiple administrations.
[0120] The term "dosing frequency" as used herein refers to the number of doses administered per a specific dosing interval. For example, the dosing frequency can be written as once a week, once every two weeks, etc.
[0121] As used herein in the context of hemophilia A, the term "prophylactic treatment" refers to the administration of a therapy for the treatment of hemophilia A, wherein such treatment is intended to prevent or lessen the severity of one or more symptoms of hemophilia A (e.g., bleeding episodes (such as one or more spontaneous bleeding episodes) and / or joint damage). To prevent or lessen the severity of such symptoms (e.g., bleeding episodes and progression of joint disease), patients with hemophilia A may receive regular infusions of clotting factors as part of a prophylactic treatment regimen.
[0122] "Prophylactic" treatment can also refer to preemptive administration of a composition described herein (e.g., a protein (such as a chimeric protein)) to a subject in order to control, manage, prevent, reduce the occurrence of, or lessen the severity of one or more symptoms of hemophilia A (e.g., bleeding episodes). In some embodiments, prophylactic treatment with a coagulation factor (e.g., FVIII) is used to treat a subject with severe hemophilia A. In some embodiments, prophylactic treatment refers to administering a composition disclosed herein to a subject in need thereof to reduce the occurrence of one or more symptoms of hemophilia A.
[0123] The terms "on-demand treatment" or "on-demand treatment" refer to the administration of a FVIII replacement therapy (such as a chimeric protein) "as needed" in response to symptoms of hemophilia A (e.g., a bleeding episode (such as a spontaneous bleeding episode or a traumatic bleeding episode)) or prior to activities that may cause bleeding. In some embodiments, on-demand treatment can be administered to a subject when bleeding begins, such as after an injury, or when bleeding is expected, such as before surgery. In some embodiments, on-demand treatment can be administered before activities that increase the risk of bleeding (e.g., contact sports). In some embodiments, on-demand treatment can be administered to a subject who is receiving prophylactic treatment, for example, if a supplemental FVIII replacement protein dose is administered to treat a bleeding episode or before strenuous activity. In some embodiments, on-demand treatment is administered as a single dose. In some embodiments, on-demand treatment is administered as a first dose, followed by one or more additional doses. In some embodiments, when a chimeric protein disclosed herein is administered on demand, the one or more additional doses can be administered at least about 12 hours, at least about 24 hours, at least about 36 hours, at least about 48 hours, at least about 60 hours, at least about 72 hours, at least about 84 hours, at least about 96 hours, at least about 108 hours, or at least about 120 hours after the first dose. However, it should be noted that the dosing interval associated with on-demand treatment is different from the dosing interval used for prophylactic treatment.
[0124] As used herein, "treating" in the context of hemophilia A includes, for example, reducing the severity of hemophilia A; improving one or more symptoms associated with hemophilia A; providing a beneficial effect to a subject with hemophilia A, but not necessarily curing hemophilia A; and / or preventing one or more symptoms associated with hemophilia A.
[0125] A "treated bleeding episode" is defined as a bleeding episode that requires administration of an on-demand dose of FVIII replacement therapy and begins with the first sign of bleeding and ends no more than 72 hours after the last dose of the treated bleeding episode. Any subsequent bleeding that occurs at the same location and is ≤72 hours from the last dose is considered to be the same bleeding episode. Multiple bleeding locations treated with a given dose are considered to be part of the same bleeding episode. Any dose of a treatment bleeding episode administered to a given location or locations>72 hours after the previous dose for a bleeding episode is considered to be the first dose (if applicable) for treating a new bleeding episode in the same location or locations. Any dose for treating a new bleeding episode at a different location (or group of locations) is considered to be the dose for treating an independent bleeding episode, regardless of the time from the last dose for treating an existing bleeding episode.
[0126] If a bleeding episode occurs on the same day as a scheduled prophylactic dose, then: (1) for the purpose of evaluating the number and / or duration of treated bleeding episodes, the dose that would have been considered a prophylactic dose is instead considered an on-demand dose for the bleeding episode (as are any additional doses given on the same day), provided that FVIII replacement therapy would have been required to stop the bleeding if the bleeding episode had occurred; and (2) if the bleeding episode did not require FVIII replacement therapy to stop the bleeding, the bleeding episode is considered an untreated bleeding episode. In this case, the scheduled prophylactic dose is not considered an on-demand dose.
[0127] Bleeding episodes, or bleeds, are classified as either spontaneous or traumatic. A "spontaneous bleeding episode" is a bleeding episode that occurs without a known precipitating factor, such as clear trauma or prior strenuous activity. A "traumatic bleeding episode" is a bleeding episode that occurs when there is a known or suspected cause of bleeding. For example, if a participant exercises vigorously and then has a bleeding episode without any apparent injury, the bleeding episode is still recorded as a traumatic bleeding episode. If a known behavior causes bleeding into a joint, the target joint bleed may be traumatic.
[0128] A "spontaneous treated bleeding episode" is a bleeding episode that is both a spontaneous bleeding episode and a treated bleeding episode. A "traumatic treated bleeding episode" is a bleeding episode that is both a traumatic bleeding episode and a treated bleeding episode.
[0129] An "untreated spontaneous bleeding episode" is a bleeding episode that does not require on-demand dosing and occurs in the absence of a known precipitating factor, such as clear trauma or preceding strenuous activity. An "untreated traumatic bleeding episode" is an untreated bleeding episode that occurs when there is a known or suspected cause of bleeding.
[0130] As used herein, both "spontaneous" and "traumatic" bleeding exclude bleeding during or resulting from surgery.
[0131] "Normal bleeding" refers to bleeding that is expected to occur as a result of an injury in a subject who does not have a bleeding disorder. Non-limiting examples of typical causes of bleeding include wounds, cuts, and lacerations.
[0132] In the context of treating hemophilia A, a "therapeutically effective amount" is an amount sufficient to achieve the desired therapeutic effect when administered to a subject for the treatment of hemophilia A.
[0133] "Drug labeling" is "the presentation of written matter on a container or printed medium that contains statements concerning the administration, efficacy, and / or safety of a therapeutic agent, such as a chimeric protein or a pharmaceutical composition comprising a chimeric protein." II. Chimeric Proteins
[0134] In one aspect, the present disclosure relates to a method for treating hemophilia A with a chimeric protein comprising: a first polypeptide comprising a factor VIII ("FVIII") protein or a portion thereof and a first immunoglobulin ("Ig") constant region or a portion thereof, and a second polypeptide comprising a von Willebrand Factor ("VWF") fragment and a second Ig constant region or a portion thereof. In some embodiments, the chimeric protein comprises (i) a first polypeptide comprising a FVIII polypeptide, an ELNN polypeptide inserted into the B domain of the FVIII protein (e.g., replacing a portion of the B domain, such as a majority of the B domain), and a first Fc region; and (ii) a second polypeptide comprising a VWF fragment, a second ELNN polypeptide sequence, an a2 linker, and a second Fc region. In some embodiments, the chimeric protein disclosed herein is a FVIII-ELNN-Fc / D'D3-ELNN-Fc heterodimer.
[0135] In some embodiments, the chimeric protein is enolectin alpha. Aenolectin alpha, also known as "BIVV001," "enolectin alpha," "efa," and "rFVIIIFc-VWF-XTEN," is described in: Chhabra et al. Blood 2020; 135(17): 1484-1496, Konkle et al., N Engl J Med 2020; 383: 1018-1027, and International Nonproprietary Names for Pharmaceutical Substances (INN) WHO Drug Information, 2019, Vol. 33, No. 4, pp. 828-30, the entire contents of each of which are hereby incorporated herein by reference in their entirety. Aenolectin alpha is an exemplary FVIII-ELNN-Fc / D'D3-ELNN-Fc heterodimer. Aenogram alfa temporarily replaces the missing FVIII required for effective hemostasis in patients with FVIII deficiency. Aenogram alfa is the first FVIII therapy engineered to circulate independently of VWF, thereby coupling FVIII clearance to VWF and extending its half-life.
[0136] In some embodiments, the chimeric protein is a FVIII-ELNN-Fc / D'D3-ELNN-Fc heterodimer comprising (i) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and (ii) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 2. In some embodiments, the chimeric protein comprises (i) the first polypeptide and (ii) the second polypeptide covalently linked via one or more disulfide bonds (e.g., two disulfide bonds). In some embodiments, the chimeric protein comprises a FVIII polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 4. In some embodiments, the chimeric protein comprises a VWF fragment encoded by the nucleic acid sequence of SEQ ID NO: 6.
[0137] In some embodiments, the chimeric protein is enogram alpha. In some embodiments, enogram alpha has a FVIII activity of at least 1600 IU / mg. In some embodiments, enogram alpha has an activity of at least 1700 IU / mg. In some embodiments, enogram alpha has an activity of at least 1800 IU / mg. In some embodiments, enogram alpha has an activity of at least 1900 IU / mg. In some embodiments, enogram alpha has an activity of 1600 IU / mg to 2000 IU / mg.
[0138] In some embodiments, the chimeric protein comprises a FVIII polypeptide comprising the amino acid sequence of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises a FVIII polypeptide comprising one or more disulfide bridges at one or more of the following positions: residues 153-179, 248-329, 528-554, 630-711, 1220-1246, 1287-1291, 1409-1557, 1562-1714, 1761-1821, and / or 1867-1925 of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises a FVIII polypeptide comprising one or more disulfide bridges at each of the following positions: residues 153-179, 248-329, 528-554, 630-711, 1220-1246, 1287-1291, 1409-1557, 1562-1714, 1761-1821, and 1867-1925 of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises a FVIII polypeptide comprising one or more Cys-SH residues at residues 310, 692, and / or 1388 of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises a FVIII polypeptide comprising a Cys-SH residue at each of residues 310, 692, and / or 1388 of SEQ ID NO: 1.
[0139] In some embodiments, the chimeric protein comprises a FVIII polypeptide comprising one or more N-glycosylation sites at residues N41, N239, N1198, N1506, and / or N1797 of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises a FVIII polypeptide comprising one or more O-glycosylation sites at residues 746 to 1036 of SEQ ID NO: 1 and / or Ser and Thr residues in the linker peptide. In some embodiments, the chimeric protein comprises a FVIII polypeptide comprising one or more Tyr sulfation sites at residues 346, 718, 719, 723, 729, 1052, and / or 1068 of SEQ ID NO: 1.
[0140] In some embodiments, the chimeric protein comprises a VWF fragment comprising the amino acid sequence of the D'D3 sequence within the amino acid sequence of SEQ ID NO:2. In some embodiments, the chimeric protein comprises a VWF fragment comprising one or more disulfide bridges at one or more of the following positions: residues 4-45, 13-41, 25-36, 29-64, 47-58, 66-88, 83-100, 86-95, 104-233, 126-268, 135-230, 151-158, 283-326, 297-321, 308-348, 328-334, 338-363, 367-410, 386-406, 390-402, 394-433, 414-427, 436-464, 459-474, 462-471, 698-758, and / or 804-862 of SEQ ID NO: 2. In some embodiments, the chimeric protein comprises a VWF fragment comprising one or more disulfide bridges at each of the following positions: residues 4-45, 13-41, 25-36, 29-64, 47-58, 66-88, 83-100, 86-95, 104-233, 126-268, 135-230, 151-158, 283-326, 297-321, 308-348, 328-334, 338-363, 367-410, 386-406, 390-402, 394-433, 414-427, 436-464, 459-474, 462-471, 698-758, and / or 804-862 of SEQ ID NO: 2.
[0141] In some embodiments, the chimeric protein comprises a VWF fragment comprising one or more N-glycosylation sites at residues N94, N384, N734 of SEQ ID NO: 2. In some embodiments, the chimeric protein comprises a VWF fragment comprising one or more O-glycosylation sites at residues 478 to 625 of SEQ ID NO: 2 and / or Ser and Thr residues in the linker peptide. In some embodiments, the chimeric protein comprises a VWF fragment comprising one or more Tyr-sulfation sites at residues 632, 633, 637, and / or 643 of SEQ ID NO: 2.
[0142] In some embodiments, the chimeric protein comprises a polypeptide chain comprising: the D' domain of VWF, the D3 domain of VWF, an ELNN polypeptide sequence comprising the amino acid sequence of SEQ ID NO: 21, the D3 domain of VWF comprising the amino acid sequence of SEQ ID NO: 22, the ELNN polypeptide sequence comprising the amino acid sequence of SEQ ID NO: 14 (AE144_5A), an a2 linker comprising the amino acid sequence of SEQ ID NO: 15, and / or an Fc region comprising the amino acid sequence of SEQ ID NO: 23.
[0143] Polynucleotides encoding chimeric proteins and portions thereof are also encompassed herein. In some embodiments, the polynucleotide sequence encodes a VWF fragment comprising the D1, D2, D', and / or D3 domains of VWF. In some embodiments, the polynucleotide encodes a VWF fragment comprising the D1D2 region of VWF, the VWF fragment comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, the polynucleotide encodes a VWF fragment further comprising a VWF signal peptide sequence. In some embodiments, the VWF signal peptide comprises the amino acid sequence of SEQ ID NO: 19. In some embodiments, the polynucleotide encodes a VWF fragment comprising: a VWF signal peptide comprising the amino acid sequence of SEQ ID NO: 19, a D1D2 region of VWF comprising the amino acid sequence of SEQ ID NO: 20, a D' domain of VWF comprising the amino acid sequence of SEQ ID NO: 21, a D3 domain of VWF comprising the amino acid sequence of SEQ ID NO: 22; an ELNN polypeptide sequence comprising the amino acid sequence of SEQ ID NO: 14 (AE144_5A); an a2 linker comprising the amino acid sequence of SEQ ID NO: 15; and / or an Fc region comprising the amino acid sequence of SEQ ID NO: 23.
[0144] In some embodiments, the chimeric protein of the present disclosure comprises: (i) a first polypeptide comprising a FVIII polypeptide having a first ELNN polypeptide sequence inserted therein and a first Fc region; and (ii) a second polypeptide comprising: a VWF fragment comprising the D' domain of VWF and the D3 domain of VWF, a second ELNN polypeptide sequence, an a2 linker of FVIII, and a second Fc region; wherein: the FVIII polypeptide has a deletion corresponding to amino acids 746 to 1648 of mature FVIII; the first ELNN polypeptide sequence is inserted into the FVIII polypeptide immediately downstream of amino acids 745 corresponding to mature FVIII (SEQ ID NO: 8); the first ELNN polypeptide sequence comprises an amino acid sequence identical to AE288 (SEQ ID NO: 9). NO:9) having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity; the first Fc region is fused to the C-terminus of the FVIII polypeptide; the second ELNN polypeptide sequence is fused to the C-terminus of the VWF fragment; the second ELNN polypeptide sequence comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to the amino acid sequence of AE144_5A (SEQ ID NO:14); the a2 linker is fused to the C-terminus of the ELNN polypeptide; the a2 linker comprises an amino acid sequence identical to SEQ ID NO:15 NO:15 has an amino acid sequence with at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity; the second Fc region is fused to the C-terminus of the a2 linker; and the first Fc region is covalently linked to the second Fc region via a disulfide bond (e.g., two disulfide bonds).
[0145] In some embodiments, the chimeric proteins of the present disclosure comprise two polypeptide sequences: a first polypeptide sequence comprising an amino acid sequence that is at least about 80%, 90%, 95%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 1; and a second polypeptide sequence comprising a VWF fragment comprising the D' domain and the D3 domain of VWF and an Fc region. In some embodiments, the chimeric proteins of the present disclosure comprise two polypeptide sequences: a first polypeptide sequence comprising a FVIII polypeptide and an Fc region; and a second polypeptide sequence comprising an amino acid sequence that is at least about 80%, 90%, 95%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the chimeric protein of the present disclosure comprises two polypeptide sequences: a first polypeptide sequence comprising an amino acid sequence that is at least about 80%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 1, and a second polypeptide sequence comprising an amino acid sequence that is at least about 80%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the chimeric protein of the present disclosure comprises two polypeptide sequences: a first polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 1, and a second polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the chimeric protein of the present disclosure comprises two polypeptide sequences: a first polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 1, and a second polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 2, wherein the first polypeptide sequence and the second polypeptide sequence are linked to each other by a disulfide bond. In some embodiments, the chimeric protein of the present disclosure comprises two polypeptide sequences: a first polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 1 and a second polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 2, wherein the first polypeptide sequence and the second polypeptide sequence are linked to each other by two disulfide bonds. In some embodiments, the chimeric protein of the present disclosure comprises two polypeptide sequences: a first polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 1 and a second polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 2, wherein the first polypeptide sequence comprises a first Fc portion, wherein the second polypeptide sequence comprises a second Fc portion, wherein the first Fc portion and the second Fc portion are linked to each other by two disulfide bonds in the hinge region.
[0146] In some embodiments, provided herein is a combination of polynucleotides encoding a first and a second polypeptide, the combination comprising: a polynucleotide encoding an amino acid sequence at least about 80%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 7; and wherein the polypeptide encodes an amino acid sequence at least about 80%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 2 or SEQ ID NO: 5.
[0147] In some embodiments, a chimeric protein of the disclosure comprises: (i) a first polypeptide comprising a FVIII polypeptide comprising a first FVIII polypeptide fragment comprising the amino acid sequence of SEQ ID NO: 17; a first ELNN polypeptide sequence comprising the amino acid sequence of SEQ ID NO: 9 (AE288); a second FVIII polypeptide fragment comprising the amino acid sequence of SEQ ID NO: 18; and a first Fc region comprising the amino acid sequence of SEQ ID NO: 23; and (ii) a second polypeptide comprising a VWF fragment comprising: the D' domain of VWF comprising the amino acid sequence of SEQ ID NO: 21; the D3 domain of VWF comprising the amino acid sequence of SEQ ID NO: 22; a second ELNN polypeptide sequence comprising the amino acid sequence of SEQ ID NO: 14 (AE144_5A); an a2 linker comprising the amino acid sequence of SEQ ID NO: 15; and a second Fc region comprising the amino acid sequence of SEQ ID NO: 23, and wherein the first Fc region is covalently linked to the second Fc region via a disulfide bond (e.g., two disulfide bonds).
[0148] In some embodiments, the chimeric protein of the present disclosure comprises a FVIII polypeptide comprising: a first ELNN polypeptide sequence, a first Fc region, and a VWF fragment comprising the D' domain of VWF, the D3 domain of VWF; a second ELNN polypeptide sequence, an a2 linker of FVIII, and a second Fc region, wherein the FVIII polypeptide comprises the amino acid sequence of SEQ ID NO: 17, the first ELNN polypeptide sequence comprises the amino acid sequence of AE288 (SEQ ID NO: 9) and is fused to the C-terminus of SEQ ID NO: 17, the FVIII polypeptide further comprises the amino acid sequence of SEQ ID NO: 18, the first Fc region comprises the amino acid sequence of SEQ ID NO: 23 and is fused to the C-terminus of SEQ ID NO: 18; the D' domain of VWF comprises the amino acid sequence of SEQ ID NO: 21; the D3 domain of VWF comprises the amino acid sequence of SEQ ID NO: 214, and the second ELNN polypeptide sequence comprises AE144_5A (SEQ ID NO: NO:14) and is fused to the C-terminus of the D3 domain of VWF; the a2 linker comprises the amino acid sequence of SEQ ID NO:15 and is fused to the C-terminus of the second ELNN polypeptide sequence; the second Fc region comprises the amino acid sequence of SEQ ID NO:23 and is fused to the C-terminus of the a2 linker; and wherein the first Fc region is covalently linked to the second Fc region via a disulfide bond.
[0149] In some embodiments, the chimeric protein comprises a first polypeptide and a second polypeptide. Included herein are polynucleotides (e.g., sets of polynucleotides) encoding the first and second polypeptides of a chimeric protein. In some embodiments, the polynucleotide encodes a polypeptide of a chimeric protein comprising a FVIII polypeptide comprising a FVIII signal peptide comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, the polynucleotide encodes a polypeptide of a chimeric protein comprising a VWF fragment comprising a VWF signal peptide comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, the polynucleotide encodes a polypeptide of a chimeric protein comprising a VWF fragment comprising a VWF signal peptide comprising the amino acid sequence of SEQ ID NO: 20.
[0150] In some embodiments, provided herein are combinations of polynucleotides encoding first and second polypeptides, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:3; and wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:2. In some embodiments, provided herein are combinations of polynucleotides encoding first and second polypeptides, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:5; and wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:2. In some embodiments, provided herein are combinations of polynucleotides encoding first and second polypeptides, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:3; and wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:7. In some embodiments, provided herein are combinations of polynucleotides encoding first and second polypeptides, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:5; and wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:2.
[0151] In some embodiments, the chimeric protein comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and a second polypeptide comprising the amino acid sequence of SEQ ID NO: 2. In some embodiments, the chimeric protein consists essentially of a first polypeptide having the amino acid sequence of SEQ ID NO: 1 and a second polypeptide having the amino acid sequence of SEQ ID NO: 2.
[0152] In some embodiments, the chimeric protein comprises one or more disulfide bonds between the first polypeptide and the second polypeptide. In some embodiments, the chimeric protein comprises two disulfide bonds between the first polypeptide and the second polypeptide. In some embodiments, the chimeric protein comprises: a first polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and a second polypeptide comprising the amino acid sequence of SEQ ID NO: 2, wherein the chimeric protein comprises a disulfide bridge between residue 1726 of SEQ ID NO: 1 and residue 663 of SEQ ID NO: 2, and a disulfide bridge between residue 1729 of SEQ ID NO: 1 and residue 666 of SEQ ID NO: 2. III. Methods of Treating Hemophilia A
[0153] Certain aspects of the present disclosure relate to a method for treating hemophilia A in a subject in need thereof, the method comprising: administering a chimeric protein comprising a FVIII polypeptide and a VWF fragment to the subject at a dosing interval. In some embodiments, the method comprises: administering multiple doses of a chimeric protein, for example, enogram alpha, to the subject at a dosing interval, comprising (i) a FVIII polypeptide and (ii) a VWF fragment, the VWF fragment comprising the D' domain of VWF and the D3 domain of VWF. In some aspects, the present disclosure relates to a method for treating hemophilia A in a subject in need thereof, the method comprising: administering multiple doses of a FVIII polypeptide and multiple doses of a VWF fragment to the subject at a dosing interval. In some embodiments, hemophilia A is severe hemophilia A.
[0154] In some embodiments, disclosed herein are methods for treating hemophilia A with chimeric proteins for routine prophylaxis to reduce the frequency of bleeding episodes. In some embodiments, disclosed herein are methods for treating hemophilia A with chimeric proteins for on-demand treatment and control of bleeding episodes. In some embodiments, disclosed herein are methods for treating hemophilia A with chimeric proteins for perioperative management of bleeding.
[0155] Also disclosed herein are uses of the chimeric protein according to the methods of treatment disclosed herein. Also disclosed herein are uses of the chimeric protein for treating hemophilia A in a subject. In some embodiments, the chimeric protein is anogram alfa.
[0156] The chimeric proteins described herein can be administered by any means known in the art. In some embodiments, the chimeric protein is administered by intravenous injection, intravenous infusion, or subcutaneous administration. In some embodiments, the chimeric protein is administered intravenously. In some embodiments, the chimeric protein is administered subcutaneously.
[0157] In some embodiments, the subject is less than 12 years old and is administered 50 IU / kg intravenously once weekly. A. Improvement in bleeding episode outcomes
[0158] In some embodiments, treatment of hemophilia A comprises preventing bleeding episodes or reducing the number of bleeding episodes in a human subject in need thereof. In some embodiments, treatment of hemophilia A comprises treating bleeding episodes in a human subject in need thereof. In some embodiments, treatment of hemophilia A comprises controlling the incidence or frequency of bleeding episodes in a human subject in need thereof. In some embodiments, treatment of hemophilia A comprises reducing the incidence or frequency of bleeding episodes in a human subject in need thereof.
[0159] In certain embodiments, disclosed herein are preventive treatment methods for preventing, reducing or controlling spontaneous bleeding, traumatic bleeding and normal bleeding. On the one hand, disclosed herein are methods for reducing the annualized bleeding rate (ABR) caused by hemophilia A in a subject in need. In certain embodiments, ABR is the ABR ("spontaneous ABR") of spontaneous bleeding episodes. In certain embodiments, ABR is the ABR ("traumatic ABR") of traumatic bleeding episodes. In certain embodiments, ABR is the ABR ("total ABR") of spontaneous and traumatic bleeding episodes. In certain embodiments, ABR is the ABR ("total hemophilia ABR") of spontaneous and traumatic bleeding episodes except normal bleeding. In certain embodiments, ABR is the ABR ("spontaneous ABR") of spontaneous bleeding episodes treated. In certain embodiments, ABR is the ABR ("traumatic ABR") of traumatic bleeding episodes treated. In certain embodiments, ABR is the ABR ("total ABR") of spontaneous bleeding episodes treated and traumatic bleeding episodes treated. In some embodiments, the method reduces the subject's ABR to less than 1. In some embodiments, the subject's ABR is 0 to about 0.25. In some embodiments, the subject's ABR is 0.25 to about 0.50. In some embodiments, the subject's ABR is 0.50 to about 0.75. In some embodiments, the subject's ABR is 0.75 to about 1. In some embodiments, the method reduces the subject's ABR to near zero. In some embodiments, the method reduces the subject's ABR to zero. In some embodiments, the ABR is a spontaneous ABR. In some embodiments, the ABR is a traumatic ABR. In some embodiments, the ABR is a total ABR. In some embodiments, the ABR is a total hemophilia ABR. In some embodiments, the ABR is a spontaneous treated ABR. In some embodiments, the ABR is a traumatic treated ABR. In some embodiments, the ABR is a total treated ABR.
[0160] In some embodiments, the ABR is measured by the number of spontaneous bleeding episodes in a subject. In some embodiments, disclosed herein are methods for reducing spontaneous bleeding episodes in a subject in need thereof. In some embodiments, the ABR is measured by the number of spontaneous bleeding episodes and traumatic bleeding episodes in a subject. In some embodiments, disclosed herein are methods for reducing the number of spontaneous bleeding episodes and traumatic bleeding episodes in a subject.
[0161] Also disclosed herein are methods for reducing the ABR due to hemophilia A in a subject, wherein the subject is administered a chimeric protein at a dose of less than 3500 IU / kg / year to a subject in need thereof. In some embodiments, the method comprises administering a chimeric protein at a dose of less than 3500 IU / kg / year to reduce the subject's ABR to less than 3, less than 2, less than 1, or zero. In some embodiments, the method comprises administering a chimeric protein at a dose of less than 3400 IU / kg / year, less than 3300 IU / kg / year, less than 3200 IU / kg / year, less than 3100 IU / kg / year, less than 3000 IU / kg / year, less than 2900 IU / kg / year, less than 2800 IU / kg / year, less than 2700 IU / kg / year, or less than 2600 IU / kg / year. In some embodiments, the method comprises administering a chimeric protein at a dose of less than 3000 IU / kg / year. In some embodiments, the method comprises administering a chimeric protein at a dose of less than 2900 IU / kg / year. In some embodiments, the method comprises administering less than 2800 IU / kg / year. In some embodiments, the method comprises administering less than 2700 IU / kg / year. In some embodiments, the method comprises administering about 2600 IU / kg / year. In some embodiments, the ABR is less than 3 and the method comprises administering less than 3000 IU / kg / year. In some embodiments, the ABR is less than 3 and the method comprises administering less than 2900 IU / kg / year. In some embodiments, the ABR is less than 3 and the method comprises administering less than 2800 IU / kg / year. In some embodiments, the ABR is less than 3 and the method comprises administering less than 2700 IU / kg / year. In some embodiments, the ABR is less than 3 and the method comprises administering about 2600 IU / kg / year. In some embodiments, the ABR is less than 2 and the method comprises administering less than 3000 IU / kg / year. In some embodiments, the ABR is less than 2 and the method comprises administering less than 2900 IU / kg / year. In some embodiments, the ABR is less than 2 and the method comprises administering less than 2800 IU / kg / year. In some embodiments, the ABR is less than 2 and the method comprises administering less than 2700 IU / kg / year. In some embodiments, the ABR is less than 2 and the method comprises administering about 2600 IU / kg / year. In some embodiments, the ABR is less than 1 and the method comprises administering less than 3000 IU / kg / year. In some embodiments, the ABR is less than 1 and the method comprises administering less than 2900 IU / kg / year. In some embodiments, the ABR is less than 1 and the method comprises administering less than 2800 IU / kg / year. In some embodiments, the ABR is less than 1 and the method comprises administering less than 2700 IU / kg / year. In some embodiments, the ABR is less than 1 and the method comprises administering about 2600 IU / kg / year.In some embodiments, the ABR is between 1 and 0.5 and the method comprises administering less than 2700 IU / kg / year. In some embodiments, the ABR is between 1 and 0.5 and the method comprises administering about 2600 IU / kg / year. In some embodiments, the ABR is less than 1 and the method comprises administering about 2600 IU / kg / year. In some embodiments, the ABR is between 0.5 and 0 and the method comprises administering less than 2700 IU / kg / year. In some embodiments, the ABR is between 0.5 and 0 and the method comprises administering about 2600 IU / kg / year. In some embodiments, the ABR is less than 0.5 and the method comprises administering less than 2700 IU / kg / year. In some embodiments, the ABR is less than 0.5 and the method comprises administering about 2600 IU / kg / year. In some embodiments, the ABR is 0 and the method comprises administering about 2600 IU / kg / year. In some embodiments, the chimeric protein is eloquent alpha.
[0162] In some embodiments, disclosed herein are methods for reducing or controlling a traumatic bleeding episode in a subject in need thereof. In some embodiments, the methods for reducing or controlling a traumatic bleeding episode are prophylactic treatment methods. In some embodiments, the prophylactic treatment methods are capable of reducing or controlling a traumatic bleeding episode without the need for administering supplemental, on-demand FVIII replacement therapy.
[0163] Also disclosed herein is a preventive treatment method for reducing the number of bleeding episodes, which requires two or more administrations of supplemental on-demand FVIII treatment to control bleeding in a subject. In some embodiments, at least about 50%, at least about 70%, at least about 75%, at least about 77%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or at least about 100% of bleeding episodes in a subject are controlled by a single supplemental on-demand FVIII replacement therapy dose. In some embodiments, at least 99% of bleeding episodes in a subject are controlled by one or two supplemental on-demand FVIII replacement therapy doses. In some embodiments, about 70% to about 99%, about 70% to about 80%, about 75% to about 80%, about 75% to about 85%, about 70% to about 90%, or about 80% to about 95% of bleeding episodes in a subject are controlled by a single supplemental on-demand FVIII replacement therapy dose. In some embodiments, the bleeding episode is a traumatic bleeding episode. In some embodiments, the bleeding episode is a spontaneous bleeding episode.
[0164] In some embodiments, disclosed herein are methods for reducing the ABR caused by hemophilia A in a specific body part of a subject in need thereof. In some embodiments, the method reduces the ABR in the subject's joints. In some embodiments, the method reduces the ABR in the subject's joints to less than 3, less than 2, less than 1, or zero. In some embodiments, the method reduces the ABR in the subject's muscles. In some embodiments, the method reduces the ABR in the subject's muscles to less than 3, less than 2, less than 1, or zero. In some embodiments, the method reduces the ABR in the subject's skin or mucous membranes. In some embodiments, the method reduces the ABR in the subject's skin or mucous membranes to less than 3, less than 2, less than 1, or zero. In some embodiments, the ABR is an ABR for spontaneous bleeding. In some embodiments, the ABR is an ABR for traumatic bleeding other than normal bleeding.
[0165] In certain embodiments, the methods disclosed herein result in a reduction in the utilization of medical resources (HRU) for the medical treatment of a subject due to hemophilia A. In certain embodiments, the number of medical care encounters (e.g., outpatient clinics, emergency care, emergency rooms) of the subject is reduced. In certain embodiments, the duration of hospitalization of the subject (e.g., total hospital days or duration, including the duration of stay in a ward (e.g., intensive care unit)) is reduced. In certain embodiments, the reduction in the length of a given time period is experienced during the treatment with the chimeric protein compared to the same amount of time immediately before the start of treatment with the chimeric protein. In certain embodiments, the length of time is at least 1, 3, 6, 9, or 12 months. In certain embodiments, the length of time is about 1, 3, 6, 9, or 12 months.
[0166] In some embodiments, the methods disclosed herein produce a greater reduction in the ABR in a subject with hemophilia A than treatment with another coagulation factor replacement product. Non-limiting examples of other coagulation factor replacement products include and Provided herein is a method for reducing the ABR compared to lonoctocog alfa, octocog alfa, rurioctocog alfapegol, damoctocog alfa pegol, efmoroctocog alfa, simoctocog alfa, moroctocog alfa, plasma-derived FVIII, beroctocog alfa, FVIII / VWF complex, and / or turoctocog alfa, the method comprising administering a chimeric protein disclosed herein (such as lonoctocog alfa) to a subject in need thereof once weekly at a dose of about 50 IU / kg. In some embodiments, the method comprises: reducing the ABR compared to ronocog alfa, sinocog alfa, pergo-lulicog alfa, pergo-dancog alfa, eimocog alfa, sermocog alfa, murocog alfa, plasma-derived FVIII, berocog alfa, FVIII / VWF complex and / or turocog alfa when administered according to labeling approved by the U.S. Food and Drug Administration or the European Medicines Agency, the method comprising: administering a chimeric protein disclosed herein (such as ienocog alfa) to a subject in need thereof once weekly at a dose of about 50 IU / kg. In some embodiments, the method comprises a method of reducing the ABR compared to lonoctocog alfa, octocog alfa, rurioctocog alfa pegol, damoctocog alfa pegol, efmoroctocog alfa, simoctocogalfa, moroctocog alfa, plasma-derived FVIII, beroctocogalfa, FVIII / VWF complex, and / or turoctocog alfa when administered 2 to 3 times per week, the method comprising administering a chimeric protein disclosed herein (such as lonoctocog alfa) to a subject in need thereof once weekly at a dose of about 50 IU / kg. In some embodiments, the ABR is reduced by at least 50%. In some embodiments, the ABR is reduced by at least 60%. In some embodiments, the ABR is reduced by at least 70%. In some embodiments, the ABR is reduced by at least 75%. In some embodiments, the ABR is reduced by at least 77%. In some embodiments, the ABR is reduced by at least 80%.In some embodiments, the ABR is reduced by at least 85%. In some embodiments, the ABR is reduced by at least 90%. In some embodiments, the ABR is reduced by at least 95%. In some embodiments, the ABR is reduced by 100%. In some embodiments, the ABR is reduced by at least 50% to 75%. In some embodiments, the ABR is reduced by at least 70% to 90%. In some embodiments, the ABR is reduced by at least 75% to 80%. In some embodiments, the ABR is reduced by at least 75% to 85%. In some embodiments, the ABR is reduced by at least 75% to 90 ... ABR decrease compared to a previous administration of ronocoag alfa at a dose of 20 IU / kg to 50 IU / kg 2 to 3 times per week. This compares to a decrease in the ABR where ronocoag alfa was previously administered at a dose of 30 IU / kg to 50 IU / kg 2 to 3 times per week in children under 12 years of age.
[0167] In some embodiments, octocog alpha Compared to a decrease in ABR, wherein octocog alpha was previously administered at a dose of 20 IU / kg to 40 IU / kg every other day or 3 to 4 times per week. In some embodiments, octocog alpha is administered at a dose of 20 IU / kg to 40 IU / kg. ABR was reduced compared to that of patients who had previously been treated with octocog alpha at a dose of 25 IU / kg three times a week. The ABR was decreased in comparison with that in patients with octocognin alfa previously administered at a dose of 25 IU / kg every other day.
[0168] In some embodiments, the Compared to a decrease in ABR, wherein the previous administration of 40 IU / kg to 50 IU / kg of benign proteoglycans alpha twice a week. In some embodiments, the administration of 40 IU / kg to 50 IU / kg of benign proteoglycans alpha is compared to a decrease in ABR, wherein the previous administration of 40 IU / kg to 50 IU / kg of benign proteoglycans alpha twice a week is compared to a decrease ABR reduction compared to that previously administered twice weekly at a dose of 55 IU / kg in children less than 12 years of age. This is compared to a decrease in the ABR in which pergolazone alfa was previously administered twice weekly in a dose not exceeding 70 IU / kg in children younger than 12 years of age.
[0169] In some embodiments, the Compared to the ABR reduction, wherein the previous administration of beco-dancog alfa at a dose of 30 IU / kg to 40 IU / kg twice a week. In some embodiments, the This was compared to a decrease in ABR in which bego-dancog alfa was previously administered at a dose of 45 IU / kg to 60 IU / kg every 5 days.
[0170] In some embodiments, ABR was reduced compared to that of patients who had previously been treated with emoticon alpha at a dose of 50 IU / kg every 4 days. A decrease in ABR compared to a decrease in ABR, wherein emoticin alfa was previously administered at a dose of 25 IU / kg to 65 IU / kg every 3 to 5 days. Compared to the ABR reduction, where the previous dose of 50 IU / kg twice weekly was administered to children under 6 years old, emoticon alfa. In some embodiments, the This compares to a decrease in the ABR where emogram alfa was previously administered at a dose of 80 IU / kg twice weekly in children under 6 years of age.
[0171] In some embodiments, the This was compared to a decrease in ABR in which sermocog alfa was previously administered at a dose of 30 IU / kg to 40 IU / kg every other day.
[0172] In some embodiments, the ABR is reduced compared to Murocog alfa, wherein Murocog alfa was previously administered at a dose of 30 IU / kg three times per week.
[0173] In some embodiments, the FVIII / VWF complex The ABR was reduced in comparison to the control group in which the FVIII / VWF complex was previously administered at a dose of 30 IU / kg 3 times per week.
[0174] In some embodiments, the ABR is reduced compared to a bispecific antibody that binds FIX or FIXa and FX. In some embodiments, the bispecific antibody is emicizumab. In some embodiments, the use of chimeric proteins achieves better bleeding protection than that typically achieved by administering emicizumab Q1W. In some embodiments, the use of chimeric proteins achieves better bleeding protection than that typically achieved by administering emicizumab Q4W. In some embodiments, the use of chimeric proteins achieves better hemostatic effect than that typically achieved by administering emicizumab Q1W. In some embodiments, the use of chimeric proteins achieves better hemostatic effect than that typically achieved by administering emicizumab Q4W.
[0175] In some embodiments, the ABR is a spontaneous ABR. In some embodiments, the ABR is a traumatic ABR. In some embodiments, the ABR is a total ABR. In some embodiments, the ABR is a total hemophilia ABR. In some embodiments, the ABR is a spontaneous treated ABR. In some embodiments, the ABR is a traumatic treated ABR. In some embodiments, the ABR is a total treated ABR.
[0176] In some embodiments, disclosed herein are methods for reducing the annualized joint bleed rate (AJBR) caused by hemophilia A in subjects in need thereof. In some embodiments, the AJBR is measured and assessed in the same manner as the ABR described above. In some embodiments, the AJBR or joint bleed episodes requiring or suggesting treatment are less than 2 or 1. In some embodiments, the AJBR or joint bleed episodes requiring or suggesting treatment are less than 1. In some embodiments, the AJBR or joint bleed episodes requiring or suggesting treatment are between 1 and 0.5. In some embodiments, the AJBR or joint bleed episodes requiring or suggesting treatment are between 0.5 and 0. In some embodiments, the AJBR or joint bleed episodes requiring or suggesting treatment are 0. In some embodiments, treatment with the chimeric protein results in an annualized joint bleed rate (AjBR) of less than about 1. In some embodiments, treatment with the chimeric protein results in an annualized joint bleed rate (AjBR) of about 0. In some embodiments, treatment with the chimeric protein results in an annualized joint bleed rate (AjBR) of about 0. In some embodiments, treatment with the chimeric protein results in an annualized joint bleed rate (AjBR) of about 0.75 to about 1.
[0177] Joints that bleed multiple times in a row over a 6-month period are often referred to as "target joints," and these joints often progress to hemophilic arthropathy. Target joint regression is categorized as two or fewer spontaneous bleeding episodes occurring within 12 consecutive months. Disclosed herein, in some embodiments, are methods for resolving target joints in a subject. In some embodiments, administration of a chimeric protein results in complete regression of the target joint. In some embodiments, the subject has at least one target joint. In some embodiments, the subject has at least two target joints. In some embodiments, the subject has at least three target joints. In some embodiments, the subject has at least four target joints. In some embodiments, the subject has at least five target joints. In some embodiments, the subject has at least six target joints. In some embodiments, the subject has at least 1-6 target joints. In some embodiments, the subject has at least 1-3 target joints. In some embodiments, the subject has at least 3-6 target joints. In some embodiments, the subject has at least one, at least two, at least three, at least four, at least five, or at least six target joints. In some embodiments, treatment with the chimeric protein resolves all of the subject's target joints. In some embodiments, when the chimeric protein is first administered to the subject, the subject has more than one target joint, and all target joints resolve within 12 months of treatment with the chimeric protein.
[0178] In some embodiments, the FVIII activity level (e.g., about 2%, about 5%, about 10%, about 15%, or about 20%) is maintained for the entire duration of the method wherein a therapeutically effective amount (a dosage of about 45 IU / kg to about 70 IU / kg of the chimeric protein at a dosing interval of about 6 to about 14 days) of the chimeric protein is administered. In some embodiments, at least 10% of the FVIII activity level is maintained for the entire duration of the method wherein a dosage of about 50 IU / kg of the chimeric protein is administered approximately every 7 days. In some embodiments, at least 12.5% of the FVIII activity level is maintained for the entire duration of the method wherein a dosage of about 50 IU / kg of the chimeric protein is administered approximately every 7 days. In some embodiments, at least 15% of the FVIII activity level is maintained for the entire duration of the method wherein a dosage of about 50 IU / kg of the chimeric protein is administered approximately every 7 days. In some embodiments, the FVIII activity level of about 10% to about 15% is maintained for the entire duration of the following method: wherein a dose of about 50 IU / kg of the chimeric protein is administered approximately every 7 days. In some embodiments, the FVIII activity level of about 10% to about 15% is maintained for the entire duration of the following method: wherein a dose of about 50 IU / kg of the chimeric protein is administered approximately every 7 days. In some embodiments, the FVIII activity level is assessed by a one-stage activated partial thromboplastin time (aPTT) assay. In some embodiments, the aPTT assay uses actin FSL as a reagent. In some embodiments, the aPTT assay does not use actin FS as a reagent.
[0179] Also provided herein are methods for prophylactically treating hemophilia A, the method comprising administering to a human subject in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other by at least one disulfide bond, wherein the subject is not receiving any on-demand treatment for hemophilia A prior to engaging in strenuous activity.
[0180] In some embodiments, vigorous activity is an activity that increases the subject's heart rate. In some embodiments, vigorous activity is an activity that increases the subject's heart rate to at least 115 beats per minute. In some embodiments, vigorous activity is an activity that increases the subject's heart rate to at least about 115 beats per minute, at least about 120 beats per minute, or at least about 125 beats per minute. In some embodiments, vigorous activity is an activity that increases the subject's heart rate to at least about 115 beats per minute. In some embodiments, vigorous activity is an activity that increases the subject's heart rate to at least about 120 beats per minute. In some embodiments, vigorous activity is an activity that increases the subject's heart rate to at least about 125 beats per minute. In some embodiments, vigorous activity is an activity that increases the subject's heart rate to at least about 115 to about 120 beats per minute, to at least about 115 to about 125 beats per minute, to at least about 115 to about 130 beats per minute, or to at least about 120 to about 130 beats per minute. In some embodiments, vigorous activity is an activity that increases the subject's heart rate to at least about 115 to about 120 beats per minute. In some embodiments, vigorous activity is activity that increases a subject's heart rate to at least about 115 to about 125 beats per minute. In some embodiments, vigorous activity is activity that increases a subject's heart rate to at least about 115 to about 130 beats per minute. In some embodiments, vigorous activity is activity that increases a subject's heart rate to at least about 120 to about 130 beats per minute.
[0181] In certain embodiments, the subject increases confidence when participating in physical activity such as strenuous activity. In certain embodiments, the subject increases confidence that bleeding will not occur when participating in physical activity such as strenuous activity. In certain embodiments, the increase is compared with the following situation: the subject has accepted the FVIII replacement therapy (for example, currently approved by the European Medicines Agency, Japan Pharmaceuticals and Medical Devices Administration, the State Drug Administration of the People's Republic of China, the Ministry of Food and Drug Safety of the Republic of Korea and / or the U.S. Food and Drug Administration) for treatment or other treatments (such as emicizumab) for hemophilia A. In certain embodiments, the subject reduces the anxiety that bleeding may occur when participating in physical activity. In certain embodiments, the subject reduces the anxiety that injury may occur when participating in physical activity. In certain embodiments, the reduction is compared with the following situation: the subject has accepted the FVIII replacement therapy (for example, currently approved by the European Medicines Agency, Japan Pharmaceuticals and Medical Devices Administration, the State Drug Administration of the People's Republic of China, the Ministry of Food and Drug Safety of the Republic of Korea and / or the U.S. Food and Drug Administration) for treatment or other treatments (such as emicizumab) for hemophilia A.
[0182] In some embodiments, compared to before treatment with the chimeric protein, when treated with the chimeric protein, the subject's ability to participate in physical activity increases. For example, compared to before treatment with the chimeric protein, when being treated with the chimeric protein, the subject can engage in more intense activities without increasing the risk of bleeding episodes. In some embodiments, compared to before treatment with the chimeric protein, when the chimeric protein is used to treat the subject, the subject's physical fitness level is improved. Physical activity measurements include, for example, raw acceleration, activity counts, number of steps taken, physical activity intensity, number of activities, number of sedentary times, body position and / or other biometric measurements. In some embodiments, a three-axis medical grade accelerometer (e.g., ActiGraph activity monitor) is used to perform an assessment of physical activity. In some embodiments, when a subject is treated with the chimeric protein, the subject's body mass index improves compared to before treatment begins. In some embodiments, the subject's body mass index is reduced to 18.5 to 24.9 from more than 25 (e.g., 25-29.9 or 30 or more). In some embodiments, the subject's body mass index increases to 18.5 to 24.9 from less than 18.5.
[0183] In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by at least about 70%, at least about 75%, at least about 77%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or 100%. In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by at least about 70%. In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by at least about 75%. In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by at least about 80%. In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by at least about 85%. In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by at least about 90%. In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by at least about 95%. In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by 100%. In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by at least about 70% to 99%. In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by at least about 70% to 80%. In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by at least about 75% to 80%.In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by at least about 75% to 85%. In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by at least about 70% to 90%. In some embodiments, administration of the chimeric protein reduces the risk of bleeding episodes requiring more than one supplemental, on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the risk is reduced by at least about 80% to 95%. B. Improve joint health outcomes
[0184] In one aspect, disclosed herein are methods for improving one or more joint health outcomes in subjects with hemophilia A. An example of a joint health outcome is the International Society on Thrombosis and Haemostasis (ISTH) 4-point assessment scale disclosed in Blanchette et al. J Thromb Haemost [Journal of Thrombosis and Haemostasis]. 2014;12(11):1935-9. The ISTH 4-point scale is shown in Table 1. In some embodiments, the methods disclosed herein produce excellent ISTH 4-point assessment results for at least 75%, 80%, 90%, 95%, 99% or 100% of bleeding. In some embodiments, the methods disclosed herein produce excellent ISTH 4-point assessment results for at least 95% of bleeding. In some embodiments, the methods disclosed herein produce good or excellent ISTH 4-point assessment results for at least 75%, 80%, 90%, 95%, 99% or 100% of bleeding. In some embodiments, the bleeding is spontaneous bleeding. In some embodiments, the bleeding is traumatic bleeding. In some embodiments, the bleeding is spontaneous bleeding and traumatic bleeding.
[0185] Another example of a joint health outcome in a subject is based on the Physician's Global Assessment (PGA), which is an assessment by the physician of the subject's response to treatment using a 4-point response scale (see Table 2). In some embodiments, the methods disclosed herein produce excellent PGA results. In some embodiments, the methods disclosed herein result in excellent results for at least 95% of joint bleeds as assessed using the PGA scale. In some embodiments, the methods disclosed herein produce PGA results that are effective for at least 75%, 80%, 90%, 95%, 99% or 100% of bleeds. In some embodiments, the bleed is spontaneous. In some embodiments, the bleed is traumatic. In some embodiments, the methods disclosed herein produce excellent or effective PGA results for at least 75%, 80%, 90%, 95%, 99% or 100% of bleeds. In some embodiments, the bleed is spontaneous. In some embodiments, the bleed is traumatic.
[0186] Another example of a subject's joint health outcome is based on the Hemophilia Joint Health Score (HJHS) (Hilliard et al. (2006) Haemophilia 12(5):518-25; Feldman et al. (2011) Arthritis Care Res. 63(2):223-30; both incorporated herein by reference). Joint function, assessed by a physical examination of the joints performed by an experienced healthcare professional, is commonly used as the primary outcome for hemophilic arthropathy. The HJHS is a validated 11-item scoring tool developed specifically for assessing joint health in subjects with hemophilia. The following domains were assessed for the elbow, knee, and ankle joints: swelling (scored 0 = no swelling to 3 = severe), duration of swelling (scored 0 = no swelling and 1 = >= 6 months), muscle atrophy (scored 0 = no to 2 = severe), crepitus during movement (scored 0 = no to 2 = severe), loss of flexion (scored 0 = <5" to 3 = >20"), loss of extension (scored 0 = <5" to 3 = >20"), joint pain (scored 0 = no pain through active range of motion to 2 = pain through active range of motion), and strength (scored 0 = holding the test position with maximum resistance to 4 = trace / no muscle contraction), with 0 = no and higher scores = severe impairment in each item. The overall gait score is an assessment of walking, stair climbing, running, and jumping on one leg, with a score range of 0-4. This assessment was performed by a healthcare professional trained in the use of anthropometric measurements.
[0187] In some embodiments, disclosed herein are methods for improving a subject's overall HJHS score. In some embodiments, disclosed herein are methods for improving one or more HJHS domain scores in a subject. In some embodiments, disclosed herein are methods for improving a subject's swelling and / or strength HJHS domain scores. In some embodiments, the subject's HJHS score is improved by at least 1 compared to the subject's HJHS score before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the subject's HJHS score is improved by at least 2 compared to the subject's HJHS score before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the subject's HJHS score is improved by at least 3 compared to the subject's HJHS score before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the subject's HJHS score is improved by at least 4 compared to the subject's HJHS score before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the subject's HJHS score is improved by at least 5 compared to the subject's HJHS score before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the subject's HJHS score is improved by at least 1 to 3 compared to the subject's HJHS score before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the subject's HJHS score is improved by at least 1 to 4 compared to the subject's HJHS score before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the subject's HJHS score is improved by at least 1 to 5 compared to the subject's HJHS score before the subject first received prophylactic treatment with a chimeric protein described herein.
[0188] In some embodiments, improving one or more joint outcomes comprises increased joint flexion ability, increased joint extension, increased range of motion, increased muscle strength, reduced swelling, reduced duration of swelling, reduced crepitus, reduced pain, or reduced muscle atrophy of one or more joints. In some embodiments, improving one or more joint outcomes comprises improved walking, improved ability to use stairs, improved running ability, or improved ability to hop on one leg.
[0189] In some embodiments, the HJHS score of the subject is improved by at least 5% compared to the HJHS score of the subject before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the HJHS score of the subject is improved by at least 10% compared to the HJHS score of the subject before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the HJHS score of the subject is improved by at least 12.5% compared to the HJHS score of the subject before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the HJHS score of the subject is improved by at least 15% compared to the HJHS score of the subject before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the HJHS score of the subject is improved by at least 20% compared to the HJHS score of the subject before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the HJHS score of the subject is improved by at least 10% to 12.5% compared to the HJHS score of the subject before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the HJHS score of the subject is improved by at least 5% to 10% compared to the HJHS score of the subject before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the HJHS score of the subject is improved by at least 12.5% to 15% compared to the HJHS score of the subject before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the HJHS score of the subject is improved by at least 10% to 15% compared to the HJHS score of the subject before the subject first received prophylactic treatment with a chimeric protein described herein. In some embodiments, the HJHS score of the subject is improved by at least 15% to 20% compared to the HJHS score of the subject before the subject first received prophylactic treatment with a chimeric protein described herein.
[0190] In certain embodiments, the subject treated with the chimeric protein described herein shows an improvement in joint health as assessed by ultrasound. In certain embodiments, the improvement in joint health is assessed using US joint images from the joint tissue activity and injury examination (JADE) scheme and / or hemophilia early arthropathy ultrasound detection (HEAD-US) in musculoskeletal ultrasound (MSKUS). In certain embodiments, joint health is assessed using HEAD-US. The HEAD-US scoring system (alternatively, the HEAD-US scheme) is based on 3 parameters for 6 joints (left and right knee, elbow, and ankle) (synovitis [score, 0 to 2], cartilage [0 to 4], and subchondral bone [0 to 2]). A reduction in score indicates improved joint health. In certain embodiments, the subject shows an improvement in synovial hypertrophy. In certain embodiments, the subject shows an improvement in cartilage thickness. In certain embodiments, as observed by power Doppler (JADE) or power Doppler ultrasound (PDUS), the subject shows an improvement in synovial congestion. C. Improvement in quality of life
[0191] In one aspect, disclosed herein are methods for improving one or more quality of life (QoL) outcomes in a subject with hemophilia A.
[0192] An example of a QoL outcome is based on the Hemophilia Quality of Life Questionnaire (Haem-A-QoL), which measures health-related QoL in hemophilia subjects. (See, e.g., Wyrwich et al., Haemophilia 2015; 21(5):578-84; von Mackensen et al., Haemophilia 2017; 23(3):383-391). Disclosed herein, in some embodiments, are methods for improving the total Haem-A-QoL score in a subject. Disclosed herein, in some embodiments, are methods for improving one or more Haem-A-QoL domain scores in a subject. Disclosed herein, in some embodiments, are methods for improving the Haem-A-QoL self-perception domain score in a subject. Disclosed herein, in some embodiments, are methods for improving the Haem-A-QoL work and school domain score in a subject. Disclosed herein, in some embodiments, are methods for improving the Haem-A-QoL sports and leisure domain score in a subject. Disclosed herein, in some embodiments, are methods for improving the Haem-A-QoL therapy domain score in a subject. In some embodiments, disclosed herein are methods for improving a Haem-A-QoL sensory domain score in a subject. In some embodiments, disclosed herein are methods for improving a Haem-A-QoL partnership and sexual domain score in a subject. In some embodiments, disclosed herein are methods for improving a Haem-A-QoL physical well-being score in a subject. In some embodiments, the subject's Haem-A-QoL score improves by at least 5% compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 10% compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 12.5% compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 15% compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 20% compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein.In some embodiments, the subject's Haem-A-QoL score improves by at least 5% to 10% compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 10% to 12.5% compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 12.5% to 15% compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 10% to 15% compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 15% to 20% compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein.
[0193] In some embodiments, the subject's Haem-A-QoL score improves by at least 5 compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 6 compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 7 compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 8 compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 9 compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 10 compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 5 to 7 compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 5 to 8 compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 5 to 9 compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein. In some embodiments, the subject's Haem-A-QoL score improves by at least 5 to 10 compared to the subject's Haem-A-QoL score before the subject first received prophylactic treatment with the chimeric protein.
[0194] Another example of a QoL outcome is based on the Hemophilia Activity List (HAL) and Pediatric HAL (pedHAL) questionnaires. These questionnaires assess the functional ability of participants to perform activities of daily living. Generally, HAL is assessed in patients aged >18 years and pedHAL is assessed in patients aged <18 years. More detailed information about HAL / pedHAL can be found in: Van Genderen FR, et al. Haemophilia 2006 Jan;12(1):36-46. In some embodiments, the subject is at least 18 years old and the subject's HAL score increases by at least 5% after treatment with the chimeric protein. In some embodiments, the subject is at least 18 years old and the subject's HAL score increases by at least 10%. In some embodiments, the subject is less than 18 years old and the subject's pedHAL score increases by at least 5%. In some embodiments, the subject is less than 18 years old and the subject's pedHAL score increases by at least 10%.
[0195] Another example of QoL results is based on EuroQoL 5 dimensions 5 levels (EQ-5D-5L), which assesses 5 dimensions (activity, self-care, daily activities, pain / discomfort, anxiety / depression) of the health outcomes produced by various interventions with a general scale, with the purpose of being converted into a single summary score for health status. EQ-5D is a universal quality of life measurement standard, which is not specific to hemophilia, and is therefore not sensitive to the change (improvement) in quality of life as the measurement standard specific to hemophilia. EQ-5D-5L includes a descriptive system and a visual analog system (VAS). EQ-5D index scores can also be measured, which are values attached to the EQ-5D spectrum according to a set of weights, which averagely reflect people's preferences for the good or bad of a situation. For more details on EQ-5D-5L, see Janssen et al. Qual Life Res [Quality of Life Research] 2013; 22(7): 1717-27 and Devlin et al. Appl Health Econ Health Policy [Applied Health Economics Health Policy] 2017; 15: 127-137. In some embodiments, after treatment with the chimeric protein, the subject's EQ-5D-5L score increases by at least 5%. In some embodiments, the subject's EQ-5D-5L score increases by at least 10%.
[0196] In some embodiments, treatment with the chimeric proteins disclosed herein reduces pain associated with hemophilia A (e.g., pain caused by bleeding or inflammation or tissue damage caused by bleeding). In some embodiments, the pain is chronic pain. In some embodiments, the pain is joint pain. In some embodiments, the pain is chronic joint pain.
[0197] Another example of QoL results is based on the Patient Reported Outcomes Measurement Information System (PROMIS). PROMIS is a system that reliably and accurately measures participant-reported health status (Cella et al. Medical Care. [Healthcare] 2007; 45(5 Suppl 1): S3-11). The PROMIS program is part of the National Institutes of Health (NIH) goal to develop a system to support research across all NIH-funded institutes and centers. PROMIS measures cover physical, mental, and social health and can be used for many chronic conditions. These questionnaires use a 5-point Likert response scale. The PROMIS-SF (abbreviated) v 1.0 pain intensity 3a tool consists of 3 questions about the patient's pain in the past 7 days, asking the patient to answer: "no pain," "mild," "moderate," "severe," and "very severe." (Cook et al. J Clin Epidemiol [Clinical Epidemiology] 2016; 73: 89-102, the entire contents of which are incorporated herein by reference).
[0198] The PROMIS-SF v2.0 Physical Function 6b tool consists of two items from the modified Health Assessment Questionnaire (HAQ) and four items from the modified Physical Function 10 (PF-10) tool. Both tools assess the subject's current abilities and have five response options: HAQ: 1 = no difficulty, 2 = very little difficulty, 3 = some difficulty, 4 = a lot of difficulty, 5 = not able to do. PF-10: 1 = not at all, 2 = very little, 3 = a little, 4 = quite a bit, 5 = not able to do. The total score can be determined based on the average score of the component items, which ranges from 0 (no disability) to 100 (maximum disability). In some embodiments, a T score is calculated by rescaling the raw scale score (the sum of the scores from all answered questions) to a standardized score with a mean of 50 and a standard deviation of 10 (lower score = better outcome) based on the scoring table provided in the PROMIS scoring manual. In some embodiments, the subject's T score improves when the subject is treated with the chimeric protein compared to before treatment with the chimeric protein.
[0199] In some embodiments, disclosed herein are methods for improving a subject's PROMIS pain intensity score. In some embodiments, disclosed herein are methods for improving a subject's PROMIS physical function score. In some embodiments, treatment with the chimeric protein disclosed herein reduces chronic pain. In some embodiments, improving a subject's quality of life comprises reducing the subject's self-reported pain intensity over a period of time, such as over the previous 7 days. In some embodiments, treatment with the chimeric protein disclosed herein reduces joint pain. In some embodiments, the subject's self-reported pain intensity improves (i.e., decreases or reduces) by at least 10%.
[0200] In some embodiments, the subject's self-reported pain intensity is selected from the options of "very severe", "severe", "moderate", "mild" or "no pain", and wherein the intensity improves from "very severe" to "severe", "moderate", "mild" or "no pain". In some embodiments, the subject's self-reported pain intensity is selected from the options of "very severe", "severe", "moderate", "mild" or "no pain", and wherein the intensity improves from "severe" to "moderate", "mild" or "no pain". In some embodiments, the subject's self-reported pain intensity is selected from the options of "very severe", "severe", "moderate", "mild" or "no pain", and wherein the intensity improves from "moderate" to "mild" or "no pain". In some embodiments, the subject's self-reported pain intensity is selected from the options of "very severe", "severe", "moderate", "mild" or "no pain", and wherein the intensity improves from "mild" to "no pain".
[0201] In some embodiments, improving the subject's quality of life comprises reducing the subject's self-reported pain intensity, wherein the subject's self-reported pain intensity changes from severe to moderate, mild, or no pain.
[0202] In some embodiments, the subject's self-reported pain intensity is scored on a scale of 1 to 5. In some embodiments, the subject's self-reported pain intensity is scored on a scale of 1 to 5, where 1 = no pain, 2 = mild pain, 3 = moderate pain, 4 = severe pain, and 5 = very severe pain. In some embodiments, the score improves from 5 to 4. In some embodiments, the score improves from 5 to less than 4. In some embodiments, the score improves from 5 to less than 3. In some embodiments, the score improves from 5 to 2 or less. In some embodiments, the score improves from 4 to 3. In some embodiments, the score improves from 4 to less than 3. In some embodiments, the score improves from 4 to 2 or less. In some embodiments, the score improves from 3 to 2 or 1. In some embodiments, the score improves from 2 to 1.
[0203] In some embodiments, the subject self-reports pain intensity on a scale of 1 to 10.
[0204] In some embodiments, treatment with the chimeric proteins disclosed herein reduces the amount of analgesic required to reduce or manage pain associated with hemophilia A. In some embodiments, the amount of analgesic is reduced compared to the amount required when treating a subject for hemophilia A with: (i) a FVIII replacement protein capable of being bound by endogenous von Willebrand Factor (VWF); (ii) a complex, wherein the complex comprises a FVIII protein and a wild-type VWF protein, or a portion thereof, wherein the FVIII protein and the VWF protein, or a portion thereof, are not covalently attached, directly or indirectly, to each other; or (iii) emicizumab. In some embodiments, the amount of analgesic is reduced in the following circumstances: (i) compared to the amount required when treating a subject for hemophilia A with prophylactic treatment with emicizumab, (ii) compared to the amount required when treating a subject for hemophilia A with a FVIII replacement protein other than the chimeric protein, wherein the FVIII replacement protein is capable of being bound by endogenous VWF, (iii) compared to the amount required for a corresponding subject receiving prophylactic treatment with emicizumab, or (iv) compared to the amount required for a corresponding subject receiving prophylactic treatment for hemophilia A that includes administering a FVIII replacement protein other than the chimeric protein, wherein the FVIII replacement protein is capable of being bound by endogenous VWF. In some embodiments, the number of doses of the analgesic is reduced. In some embodiments, the number of doses of the analgesic is reduced in a day or week. In some embodiments, the chimeric protein disclosed herein is administered to the subject, followed by administration of a reduced dose of the analgesic. In certain embodiments, analgesics include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids or non-opioid analgesics. In certain embodiments, analgesics include non-opioid analgesics. In certain embodiments, analgesics include NSAIDs. In certain embodiments, analgesics include fentanyl, hydromorphone, morphine, oxycodone, oxymorphone, tramadol, oxycodone, oxycodone, acetaminophen (also known as acetaminophen), ibuprofen, naproxen sodium, analgin, celecoxib, ketorolac, diclofenac, diclofenac potassium, diclofenac epolamide, lidocaine or aspirin. In certain embodiments, analgesics are acetaminophen. In certain embodiments, analgesics are celecoxib.
[0205] In some embodiments, treatment with a chimeric protein disclosed herein reduces the amount of analgesic required to reduce or manage pain associated with hemophilia A within 1, 3, or 6 hours before, during, or after strenuous activity: (i) as compared to the amount required when the subject is treated for hemophilia A with prophylactic treatment with emicizumab, (ii) as compared to the amount required when the subject is treated for hemophilia A with prophylactic treatment with a FVIII replacement protein other than the chimeric protein, wherein the FVIII replacement protein is capable of being bound by endogenous VWF, (iii) as compared to the amount required for a corresponding subject receiving prophylactic treatment with emicizumab, or (iv) as compared to the amount required for a corresponding subject receiving prophylactic treatment for hemophilia A that includes administration of a FVIII replacement protein other than the chimeric protein, wherein the FVIII replacement protein is capable of being bound by endogenous VWF. In some embodiments, the subject does not require analgesic to reduce or manage pain associated with hemophilia A within 1 hour, 3 hours, or 6 hours before, during, or after strenuous activity.
[0206] In some embodiments, strenuous activity is an activity that increases the subject's heart rate to at least 115 beats per minute. In some embodiments, strenuous activity is an activity that increases the subject's heart rate to at least 115 beats per minute. Non-limiting examples of strenuous activity include parkour, running, swimming, cycling, rock climbing, mountain climbing, other climbing, and hiking. In some embodiments, strenuous activity is sports. In some embodiments, strenuous activity is contact sports. Non-limiting examples of strenuous activity include football, tennis, skiing, snowboarding, skateboarding, basketball, rugby, hockey, football, boxing, wrestling, or martial arts.
[0207] The methods of the present disclosure may also relate to treating a bleeding episode or symptom caused by hemophilia A in a subject in need thereof. Examples of bleeding episodes and symptoms include hemarthrosis, muscle bleed, oral bleed, blood loss, blood loss into muscle, oral blood loss, bleeding due to trauma, head trauma, gastrointestinal bleeding, intracranial blood loss, intraabdominal blood loss, intrathoracic blood loss, bleeding due to fracture, central nervous system bleeding, bleeding in the retropharyngeal space, bleeding in the retroperitoneal space, bleeding in the iliopsoas sheath, or any combination thereof.
[0208] In some embodiments, the methods of the disclosure are directed to improving the quality of life of a subject, where the quality of life of the subject is improved compared to: (i) prophylactic treatment with emicizumab (e.g., a previous prophylactic treatment), (ii) prophylactic treatment with a FVIII replacement protein other than a chimeric protein (e.g., a previous prophylactic treatment), wherein the FVIII replacement protein is capable of being bound by endogenous VWF, (iii) the quality of life of a corresponding subject receiving prophylactic treatment with emicizumab, or (iv) the quality of life of a corresponding subject receiving prophylactic treatment for hemophilia A comprising administration of a FVIII replacement protein other than a chimeric protein, wherein the FVIII replacement protein is capable of being bound by endogenous VWF.
[0209] In some embodiments, the subject's quality of life is improved compared to prophylactic treatment with emicizumab (e.g., a previous prophylactic treatment). In some embodiments, the subject's quality of life is improved compared to prophylactic treatment with a FVIII replacement protein other than a chimeric protein (e.g., a previous prophylactic treatment), wherein the FVIII replacement protein is capable of being bound by endogenous VWF. In some embodiments, the subject's quality of life is improved compared to the quality of life of a corresponding subject receiving prophylactic treatment with emicizumab. In some embodiments, the subject's quality of life is improved compared to the quality of life of a corresponding subject receiving prophylactic treatment for hemophilia A comprising administering a FVIII replacement protein other than a chimeric protein, wherein the FVIII replacement protein is capable of being bound by endogenous VWF.
[0210] In some embodiments, when treated with the chimeric protein, the subject experiences a reduction in the number of bleeding episodes and bleeding-related complications compared to the previous treatment. In some embodiments, when treated with the chimeric protein, the subject experiences reduced pain compared to the previous treatment. In some embodiments, when treated with the chimeric protein, the subject has improved joint mobility compared to the previous treatment. In some embodiments, the administration time of the chimeric protein is shorter compared to the previous treatment. In some embodiments, when treated with the chimeric protein, the subject feels better protected compared to the previous treatment. In some embodiments, when treated with the chimeric protein, the subject has greater confidence that bleeding episodes will not occur (e.g., when engaging in physical activity such as strenuous activity) compared to the previous treatment. In some embodiments, when treated with the chimeric protein, the subject's fatigue is reduced compared to before starting treatment with the chimeric protein. In some embodiments, when treated with the chimeric protein, the subject's fatigue is reduced compared to the previous treatment. In some embodiments, when treated with the chimeric protein, the subject's sense of well-being increases compared to the previous treatment. In some embodiments, the subject has improved mobility. In some embodiments, the subject has improved ability to use fine hand movements. In some embodiments, the subject has improved buttoning, knitting, and / or typing abilities.
[0211] In some embodiments, the subject's quality of life is improved as compared to the quality of life that would be expected for a corresponding subject who has not received treatment with the chimeric protein. In some embodiments, the corresponding subject is a subject with hemophilia A of similar health, weight, body mass index, and age. In some embodiments, the corresponding subject is a hypothetical subject who is identical to the subject in every respect except for the type of hemophilia A treatment he or she receives. D. Perioperative management
[0212] Also disclosed herein are methods for the perioperative management of bleeding, comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (c) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond.
[0213] In some embodiments, the subject is expected to undergo surgery within 72 hours. In some embodiments, the subject is currently undergoing surgery. In some embodiments, the subject underwent surgery within the past week. In some embodiments, the surgery is major surgery. In some embodiments, the surgery is minor surgery. In some embodiments, the surgery is a hip, knee, or ankle replacement. In some embodiments, the surgery is an organ transplant. In some embodiments, the organ transplant is a lung, liver, stem cell, cornea, heart, kidney, or pancreas transplant.
[0214] In some embodiments, the therapeutically effective amount achieves a superior hemostatic response as assessed by a surgeon.
[0215] In some embodiments, the therapeutically acceptable amount is a dose of about 30 IU / kg to 50 IU / kg. In some embodiments, the therapeutically effective amount is a dose of 30 IU / kg. In some embodiments, the therapeutically effective amount is a dose of 50 IU / kg.
[0216] In some embodiments, a total of about 30 IU / kg to about 50 IU / kg of the chimeric protein is administered on the day of surgery or within 24 hours prior to surgery. In some embodiments, a total of about 30 to about 50 IU / kg of the chimeric protein is administered within 72 hours after surgery. In some embodiments, a total of about 75 to about 125 IU / kg of the chimeric protein is administered from day 4 to day 14 after surgery. In some embodiments, a total of about 150 to about 200 IU / kg of the chimeric protein is administered from 24 hours prior to surgery to two weeks after surgery.
[0217] In some embodiments, the dose is administered before the start of surgery. In some embodiments, the dose is administered before and after surgery. In some embodiments, the dose is administered once. In some embodiments, the dose is administered every 2 or 3 days after surgery until the surgical bleeding ends. In some embodiments, a dose of 30 IU / kg to 50 IU / kg is administered less than 24 hours before surgery. In some embodiments, a dose of 30 IU / kg to 50 IU / kg is administered less than 24 hours before surgery, and then at least one additional dose of 30 IU / kg to 50 IU / kg is administered after surgery until the bleeding stops due to surgery. In some embodiments, a dose of 30 IU / kg to 50 IU / kg is administered within 24 hours before the start of surgery, and then an additional dose of 30 IU / kg to 50 IU / kg is administered about 2 days to about 3 days after the surgery has ended. In some embodiments, the dose is administered 2 to 3 days or less after the prophylactic dose.
[0218] In some embodiments, the therapeutically effective amount includes a preoperative loading dose of 50 IU / kg, followed by one or more 30 IU / kg or 50 IU / kg doses every 2 to 3 days. In some embodiments, the therapeutically effective amount includes a preoperative loading dose of 50 IU / kg, followed by one or more 30 IU / kg or 50 IU / kg doses every 2 to 3 days as needed to reduce or control bleeding associated with surgery. In some embodiments, the therapeutically effective amount includes a preoperative loading dose of 50 IU / kg, followed by one or more 30 IU / kg or 50 IU / kg doses every 2 to 3 days for up to a week. In some embodiments, the therapeutically effective amount includes a preoperative loading dose of 50 IU / kg, followed by one or more 30 IU / kg or 50 IU / kg doses every 2 to 3 days for at least a week. In some embodiments, the preoperative loading dose is administered within 3 days of surgery. In some embodiments, the preoperative loading dose is administered within 2 days of surgery.
[0219] In some embodiments, when the subject is treated with the chimeric protein, the risk that the subject will require a blood transfusion due to surgery (e.g., during or after surgery) is reduced compared to when the subject or a corresponding subject is administered a FVIII replacement protein capable of being bound by endogenous VWF. E. Medication
[0220] In some embodiments, the chimeric protein, such as Aynog alpha, is administered as a single dose or multiple doses. In some embodiments, the amount of each of the multiple doses is the same. In some embodiments, one or more of the multiple doses is different from one or more of the other multiple doses. In some embodiments, at least one of the multiple doses of chimeric protein is about 45 IU / kg to about 70 IU / kg. In some embodiments, each of the multiple doses of the chimeric protein is about 45 IU / kg to about 70 IU / kg. In some embodiments, the chimeric protein is administered once a week at a dose of 50 IU / kg.
[0221] In some embodiments, each dose in the plurality of doses is about 45 IU / kg. In some embodiments, each dose in the plurality of doses is about 50 IU / kg. In some embodiments, each dose in the plurality of doses is about 55 IU / kg.
[0222] In some embodiments, the chimeric protein, such as agnog alfa, is administered prophylactically. In some embodiments, at least one of the multiple doses is about 45 IU / kg to about 70 IU / kg. In some embodiments, at least one of the multiple doses administered prophylactically is about 50 IU / kg. In some embodiments, each of the multiple doses administered prophylactically is about 50 IU / kg.
[0223] In some embodiments, the chimeric protein, such as ainogram alfa, is administered on demand. When administered on demand, the chimeric protein can be administered as a single dose or multiple doses. In some embodiments, the chimeric protein is administered at one or more doses of about 45 IU / kg to about 70 IU / kg. In some embodiments, at least one of the multiple doses administered prophylactically is about 50 IU / kg. In some embodiments, each of the multiple doses administered prophylactically is about 50 IU / kg. In some embodiments, a single on-demand dose is about 50 IU / kg.
[0224] In certain aspects, the present disclosure relates to methods for resolving a withdrawal bleeding episode. In some embodiments, the method for resolving a withdrawal bleeding episode comprises administering to a human subject in need thereof a single, on-demand dose of a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond.
[0225] In some embodiments, each dose of the chimeric protein administered to a subject is approximately the same for at least 1 month. In some embodiments, each prophylactic dose of the chimeric protein administered to a subject is approximately the same for at least 1 month. In some embodiments, each dose of the chimeric protein administered to a subject is approximately the same for at least 3 months. In some embodiments, each prophylactic dose of the chimeric protein administered to a subject is approximately the same for at least 3 months. In some embodiments, each dose of the chimeric protein administered to a subject is approximately the same for at least 6 months. In some embodiments, each prophylactic dose of the chimeric protein administered to a subject is approximately the same for at least 6 months. In some embodiments, each dose of the chimeric protein administered to a subject is approximately the same for at least 9 months. In some embodiments, each prophylactic dose of the chimeric protein administered to a subject is approximately the same for at least 9 months. In some embodiments, each dose of the chimeric protein administered to a subject is approximately the same for at least 12 months. In some embodiments, each prophylactic dose of the chimeric protein administered to a subject is approximately the same for at least 12 months.
[0226] In some embodiments, the subject was previously treated for hemophilia A with a FVIII replacement protein other than a chimeric protein disclosed herein (such as enogram alfa), and the subject was more compliant with the chimeric protein's dosing regimen (e.g., adhered to a dosing regimen such as a once-weekly dose of 50 IU / kg) than the subject was with the previous treatment. In some embodiments, the subject missed fewer doses of the chimeric protein than were missed with the previous treatment.
[0227] In some embodiments, the subject was previously treated for hemophilia A with a FVIII replacement protein other than the chimeric protein disclosed herein (such as enogram alfa) administered intravenously prior to switching to treatment with the chimeric protein administered intravenously. In some embodiments, the health of one or more injection sites for intravenous injection improves after the subject is switched. In some embodiments, the improvement in health at one or more injection sites includes reduced swelling, reduced redness, or reduced itching.
[0228] In some embodiments, the subject has received on-demand treatment for at least 1 to 7 bleeding episodes within the past year (e.g., prior to the first administration of the chimeric protein or within the year prior to the start of prophylactic treatment with the chimeric protein). In some embodiments, the subject has received on-demand treatment for at least 2 to 5 bleeding episodes within the past year. In some embodiments, the subject has received on-demand treatment for at least 3 to 5 bleeding episodes within the past year. In some embodiments, the subject has received on-demand treatment for at least 3 to 6 bleeding episodes within the past year. In some embodiments, the subject has received on-demand treatment for at least 4 to 7 bleeding episodes within the past year. In some embodiments, the subject has received on-demand treatment for at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, or at least 7 bleeding episodes within the past year. In some embodiments, the subject has received on-demand treatment for at least 1 bleeding episode within the past year. In some embodiments, the subject has received on-demand treatment for at least 2 bleeding episodes within the past year. In some embodiments, the subject has received on-demand treatment for at least 3 bleeding episodes within the past year. In some embodiments, the subject has received on-demand treatment for at least 4 bleeding episodes within the past year. In some embodiments, the subject has received on-demand treatment for at least 5 bleeding episodes in the past year. In some embodiments, the subject has received on-demand treatment for at least 6 bleeding episodes in the past year. In some embodiments, the subject has received on-demand treatment for at least 7 bleeding episodes in the past year. F. Dosing Interval
[0229] In certain embodiments, particularly for prophylactic treatment, a chimeric protein, such as Anogram α, is administered as multiple doses at dosing intervals. In some embodiments, the dosing interval is about 7 days. In some embodiments, the dosing interval is about 8 days. In some embodiments, the dosing interval is about 9 days. In some embodiments, the dosing interval is about 10 days. In some embodiments, the dosing interval is about 11 days. In some embodiments, the dosing interval is about 12 days. In some embodiments, the dosing interval is about 13 days. In some embodiments, the dosing interval is about 14 days. In some embodiments, the dosing interval is about 6 days to about 8 days. In some embodiments, the dosing interval is 7 to 14 days. In some embodiments, 50 IU / kg of a chimeric protein (e.g., Anogram α) is administered once a week.
[0230] In some embodiments, the dosing frequency, e.g., for prophylactic treatment of hemophilia A, is at least once a week or at least once every 2 weeks. In some embodiments, the dosing interval, e.g., for prophylactic treatment of hemophilia A, is once a week. In some embodiments, the dosing interval, e.g., for prophylactic treatment of hemophilia A, is once every 2 weeks.
[0231] In some embodiments, the chimeric protein is administered for prophylactic treatment of hemophilia A. Prophylactic treatment of hemophilia A includes alleviating or reducing the severity of symptoms of hemophilia A on a continuous or near-continuous basis. In some embodiments, the prophylactic treatment is administered before the onset of symptoms of hemophilia A, e.g., before a bleeding episode. In some embodiments, the prophylactic treatment is administered on a regular basis (e.g., at the dosing intervals described herein) to prevent the onset of symptoms or reduce the severity of symptoms before the onset of symptoms.
[0232] In some embodiments, the chimeric protein is administered prior to an activity that may cause one or more symptoms of hemophilia A, for example as an on-demand treatment. For example, a chimeric protein of the present disclosure may be administered to a subject with hemophilia A before the subject engages in an activity that would otherwise increase the risk of physical trauma and / or bleeding accidents. When administered on-demand, the chimeric protein may be administered as a single dose or multiple doses. In some embodiments, on-demand treatment comprises administering multiple doses of the chimeric protein at a dosing interval of at least about 12 hours, at least about 24 hours, at least about 36 hours, at least about 48 hours, at least about 60 hours, at least about 72 hours, at least about 84 hours, at least about 96 hours, at least about 108 hours, or at least about 120 hours. In certain embodiments, on-demand treatment comprises administering at least 2 doses, at least 3 doses, at least 4 doses, or at least 5 doses of the chimeric protein.
[0233] In some embodiments, the subject has been previously treated with one or more FVIII replacement therapies. In some embodiments, the subject has not responded to a previous FVIII replacement therapy. In some embodiments, the FVIII replacement therapy is or
[0234] In some embodiments, the subject is an adult. In some embodiments, the subject is an adult male. In some embodiments, the subject is an adult female. In some embodiments, the subject is a child, e.g., less than or equal to about 12 years old, less than or equal to about 11 years old, less than or equal to about 10 years old, less than or equal to about 9 years old, less than or equal to about 8 years old, less than or equal to about 7 years old, less than or equal to about 6 years old, less than or equal to about 5 years old, less than or equal to about 4 years old, less than or equal to about 3 years old, less than or equal to about 2 years old, or less than or equal to about 1 year old. In some embodiments, the subject is a female. In some embodiments, the subject is a male. In some embodiments, the subject is a female less than or equal to about 12 years old. In some embodiments, the subject is a female less than or equal to about 11 years old. In some embodiments, the subject is a female less than or equal to about 10 years old. In some embodiments, the subject is a male less than or equal to about 12 years old. In some embodiments, the subject is a male less than or equal to about 11 years old. In some embodiments, the subject is a male less than or equal to about 10 years old. In some embodiments, the subject is at least 12 years old. In some embodiments, the subject is at least 18 years old. In some embodiments, the subject has previously received treatment (prophylaxis or on demand) for hemophilia A with recombinant and / or plasma-derived FVIII or cryoprecipitate for at least 150 exposure days (ED). In some embodiments, the subject has previously received treatment (prophylaxis or on demand) for hemophilia A with recombinant and / or plasma-derived FVIII or cryoprecipitate for less than 150 ED. In some embodiments, the subject has not previously received treatment (prophylaxis or on demand) for hemophilia A with recombinant and / or plasma-derived FVIII or cryoprecipitate.
[0235] The chimeric proteins described herein can be administered by any means known in the art. In some embodiments, the chimeric protein is administered by intravenous injection, intravenous infusion, or subcutaneous administration. In some embodiments, the chimeric protein is administered intravenously. In some embodiments, the chimeric protein is administered subcutaneously.
[0236] In some embodiments, weekly administration of a chimeric protein (e.g., ainogram α) results in a minimum (trough) FVIII plasma activity level of at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, or at least about 15% between doses. In some embodiments, the minimum FVIII plasma activity level is at least about 5%. In some embodiments, the minimum FVIII plasma activity level is at least about 4%. In some embodiments, the minimum FVIII plasma activity level is at least about 5%. In some embodiments, the minimum FVIII plasma activity level is at least about 5.6%. In some embodiments, the minimum FVIII plasma activity level is at least about 7%. In some embodiments, the minimum FVIII plasma activity level is at least about 10%. In some embodiments, the minimum FVIII plasma activity level is at least about 12%. In some embodiments, the minimum FVIII plasma activity level is at least about 15%. In some embodiments, the minimum FVIII plasma activity level is at least about 20%. As used herein, plasma activity levels are expressed as a percentage (%). Alternatively, plasma activity can be expressed in IU / dL units, where 1% is equal to 1 IU / dL. In some embodiments, the FVIII activity level is assessed by an aPTT assay. In some embodiments, the aPTT assay uses actin FSL as a reagent. In some embodiments, the aPTT assay does not use actin FS as a reagent.
[0237] In some embodiments, once-weekly administration of the chimeric protein (e.g., enocog alfa) results in high, sustained FVIII activity within the normal to near-normal range for a duration longer than currently marketed coagulation factor replacement therapies for hemophilia A (e.g., ronocog alfa, sinocog alfa, pergo-lulycog alfa, pergo-dancog alfa, eimocog alfa, sermocog alfa, murocog alfa, plasma-derived FVIII, berocog alfa, FVIII / VWF complex, and / or turocog alfa). In some embodiments, once weekly administration of a chimeric protein (e.g., enocog alpha) results in a high sustained FVIII activity of at least> 40% for a duration longer than that of currently available hemophilia A coagulation factor replacement therapy (e.g., ronocog alpha, sincog alpha, pergo-lulicog alpha, pergo-dancog alpha, eimocog alpha, sermocog alpha, moroccog alpha, plasma-derived FVIII, berocog alpha, FVIII / VWF complex and / or torocog alpha). In some embodiments, administration of a chimeric protein (e.g., enocog alpha) to a subject with hemophilia A achieves health equity with a corresponding subject who does not suffer from hemophilia A. In some embodiments, administration of a chimeric protein (e.g., enocog alpha) to a subject with hemophilia A achieves a functional cure for hemophilia A in the subject. In some embodiments, the FVIII activity level is as assessed by aPTT assay. In some embodiments, the aPTT assay uses actin FSL as a reagent. In some embodiments, the aPTT assay does not use actin FS as a reagent.
[0238] In some embodiments, the FVIII plasma activity level is at least about 40% at least about 4 days after administration of the chimeric protein, for example, at a dose of 50 IU / kg. In some embodiments, the FVIII plasma activity level is at least about 25% at least about 5 days after administration of the chimeric protein, for example, at a dose of 50 IU / kg. In some embodiments, the FVIII plasma activity level is at least about 30% at least about 5 days after administration of the chimeric protein, for example, at a dose of 50 IU / kg. In some embodiments, the FVIII plasma activity level is at least about 35% at least about 5 days after administration of the chimeric protein, for example, at a dose of 50 IU / kg. In some embodiments, the FVIII plasma activity level is at least about 5% at least about 7 days after administration of the chimeric protein, for example, at a dose of 50 IU / kg. In some embodiments, the FVIII plasma activity level is at least about 7.5% at least about 7 days after administration of the chimeric protein, for example, at a dose of 50 IU / kg. In some embodiments, the FVIII plasma activity level is at least about 10% at least about 7 days after administration of the chimeric protein, for example, at a dose of 50 IU / kg. In some embodiments, the FVIII plasma activity level is at least about 15% at least about 7 days after administration of the chimeric protein, e.g., at a dose of 50 IU / kg. In some embodiments, the FVIII plasma activity level is at least about 2% at least about 14 days after administration of the chimeric protein, e.g., at a dose of 50 IU / kg. In some embodiments, the FVIII plasma activity level is at least about 1% at least about 14 days after administration of the chimeric protein, e.g., at a dose of 50 IU / kg. In some embodiments, the FVIII activity level is assessed by an aPTT assay. IV. Pharmaceutical Compositions
[0239] In one aspect, the disclosure relates to pharmaceutical compositions of chimeric proteins, such as enogram alfa.
[0240] In some embodiments, the present disclosure relates to a pharmaceutical composition comprising: enolectin alpha, L-histidine, L-arginine hydrochloride, sucrose, calcium chloride, and polysorbate 80. In some embodiments, the pharmaceutical composition comprises 250, 500, 1000, 2000, 3000, or 4000 IU of enolectin alpha. In some embodiments, the pharmaceutical composition comprises 1000 IU of enolectin alpha. In some embodiments, the pharmaceutical composition comprises enolectin alpha and a buffer comprising 10 mM L-histidine, 250 mM arginine-HCl, 5 mM CaCl2, 5% (w / v) sucrose, 0.05% (w / v) polysorbate 80. In some embodiments, the pH of the pharmaceutical composition is about 7.0. In some embodiments, the pH of the pharmaceutical composition is 6.8 to 7.2. In some embodiments, the pH of the pharmaceutical composition is 6.8. In some embodiments, the pH of the pharmaceutical composition is 7.0.
[0241] In some embodiments, the chimeric protein is in a pharmaceutical composition comprising about 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU, or 4,000 IU of the chimeric protein. In some embodiments, the chimeric protein is enogram alfa. In some embodiments, enogram alfa is in a pharmaceutical composition comprising: (a) 45 mg / mL to 60 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 40 mg / mL to 60 mg / mL L-arginine; (d) 0.5 mg / mL to 0.9 mg / mL calcium chloride; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80. In some embodiments, enogram alfa is in a pharmaceutical composition comprising: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, enogram alfa is in a pharmaceutical composition comprising: (a) 5% (w / v) to 7.5% (w / v) sucrose; (b) 7.5 mM to 12.5 mM histidine; (c) 225 mM to about 300 mM arginine; (d) 5 mM to 6 mM calcium chloride; and (e) 0.01% (w / v) to about 0.075% (w / v) polysorbate 80.
[0242] In some embodiments, the lyophilized pharmaceutical composition is in a lyophilized cake. In some embodiments, the lyophilized cake is white. In some embodiments, the lyophilized cake is less than Y4 on the European Pharmacopoeia color scale. See Liquid Color (Method 2.2.2), European Pharmacopoeia, 10th Edition (2021).
[0243] In some embodiments, the pharmaceutical compositions disclosed herein are lyophilized pharmaceutical compositions (eg, powders). In some embodiments, the pharmaceutical compositions are provided in sterile vials that require reconstitution with sterile water.
[0244] In some embodiments, the lyophilized pharmaceutical composition and sterile water are combined to produce an injectable solution. In some embodiments, the lyophilized pharmaceutical composition is mixed with about 2 mL to about 5 mL of sterile water. In some embodiments, the lyophilized pharmaceutical composition is mixed with about 3 mL of sterile water. In some embodiments, the lyophilized pharmaceutical composition is mixed with 3 mL of sterile water. In some embodiments, the sterile water is USP grade sterile water. In some embodiments, the sterile water is USP grade sterile water for injection. In some embodiments, the sterile water is pyrogen-free or non-pyrogenic. In some embodiments, the sterile water does not contain a bacteriostatic or antimicrobial agent. In some embodiments, the sterile water contains a bacteriostatic or antimicrobial agent. In some embodiments, the sterile water is sterilized using a filter. In some embodiments, the sterile water is sterilized using a 0.1 μm filter. In some embodiments, the sterile water is distilled water. In some embodiments, the sterile water is sterile, non-pyrogenic, hypotonic distilled water with an osmotic pressure of zero mOsmol / L and does not contain a bacteriostatic or antimicrobial agent.
[0245] Also disclosed herein are pharmaceutical kits for treating hemophilia A, comprising a label and a chimeric protein. In some embodiments, the label comprises instructions for administering the chimeric protein. In some embodiments, the label comprises instructions for administering the chimeric protein once weekly at a dose of 50 IU / kg. In some embodiments, the pharmaceutical label comprises instructions or recommendations for practicing the methods disclosed herein.
[0246] In some embodiments, the chimeric protein in the pharmaceutical kit is in a lyophilized pharmaceutical composition. In some embodiments, the kit further comprises a diluent for reconstitution of the lyophilized pharmaceutical composition. In some embodiments, the diluent is sterile water. In some embodiments, the diluent is in a prefilled syringe.
[0247] In some embodiments, for a dose of 50 IU / kg, the following formula is used to estimate the expected in vivo peak increase in Factor VIII levels expressed as IU / dL (or % of normal): Estimated increase in Factor VIII (IU / dL or % of normal) = 50 IU / kg x 2 (IU / dL / IU / kg). In some embodiments, efficacy is determined using an aPTT-based one-stage coagulation assay. In some embodiments, the aPTT assay uses actin FSL as a reagent. In some embodiments, the aPTT assay does not use actin FS as a reagent.
[0248] In some embodiments, the chimeric protein (eg, Anogram alfa) is administered at a conventional prophylactic dosage regimen. In some embodiments, the recommended dosage for conventional prophylaxis is 50 IU / kg every 7 days.
[0249] In some embodiments, the chimeric protein is provided as part of a kit with a pharmaceutical label, wherein the pharmaceutical label contains sufficient information to enable a human subject, a caregiver, or a medical practitioner to practice the methods of administering the chimeric protein as described herein.
[0250] In some embodiments, chimeric protein (e.g., Ainolectin α) is administered on demand and / or for controlling bleeding episodes. In some embodiments, the dosage for treating and controlling bleeding episodes on demand is as described in Table 3. Examples of mild bleeding include, but are not limited to, early signs of mild epistaxis, joint bleeding, and mild soft tissue bleeding. Examples of moderate bleeding include, but are not limited to, epistaxis with a large blood flow, muscle bleeding, gastrointestinal / oral mucosal bleeding, post-tooth extraction gum bleeding, hematuria, and hemarthrosis. Examples of severe to life-threatening bleeding include, but are not limited to, epistaxis with a very large blood flow, postpharyngeal and pharyngeal bleeding, abdominal and retroperitoneal bleeding, postoperative bleeding, and CNS bleeding. Table 3 shows other examples of mild, moderate, and severe bleeding. Table 3: Exemplary dosages based on bleeding type.
[0251] In some embodiments, to resume prophylaxis (if applicable) after treating a bleed, it is recommended to allow at least 72 hours between the last 50 IU / kg dose for treating the bleed and the resumption of prophylaxis. In some embodiments, thereafter, prophylaxis may be continued as usual according to the subject's regular schedule.
[0252] Now having described the present disclosure in detail, the present disclosure will be more clearly understood by reference to the following examples, which are included herein for illustrative purposes only and are not intended to limit the present disclosure. All patents, publications and articles mentioned herein are expressly and specifically incorporated herein by reference. Examples Example 1: A Phase 3, Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Anocog Alpha in Previously Treated Patients ≥12 Years with Severe Hemophilia A
[0253] Aenogram alfa, also known as "BIVV001," "aenogram alfa," "Efa," and "rFVIIIFc-VWF-XTEN," is engineered to have an extended half-life independent of von Willebrand Factor (VWF). Preclinical and clinical experience demonstrates that Efa has an extended half-life, regardless of VWF levels, and maintains higher, sustained FVIII activity levels for longer periods than currently available FVIII replacement therapies.
[0254] The purpose of this study was to determine the safety, efficacy, and pharmacokinetics (PK) of enocog alfa administered as weekly (QW) prophylaxis or as needed treatment at a dose of 50 IU / kg IV. The study enrolled patients with severe hemophilia A (PTP) aged 12 years or older who had previously received treatment. The study design took into account the European Medicines Agency (EMA) guidance on clinical studies of recombinant and human plasma-derived factor VIII products (July 26, 2018).
[0255] In accordance with current treatment paradigms for hemophilia A, the current study design allowed the inclusion of patients with hemophilia who were receiving either prophylactic therapy (Group A) or on-demand therapy (Group B). A. Research Design
[0256] This is a Phase 3 open-label, multinational, multicenter study of the safety, efficacy, and PK of IV enogram alpha in previously treated patients PTP aged ≥12 years with severe hemophilia A (defined as <1 IU / dL [<1%] endogenous FVIII). Participants currently on a prophylactic treatment regimen with FVIII entered Group A and received enogram alpha at a dose of 50 IU / kg IV once a week (QW) based on a 52-week prophylactic treatment regimen. Many participants in Group A participated in the observational study 242HA201 / OBS16221 for at least 6 months before baseline.
[0257] Many participants who were currently treated on an as-needed basis were enrolled in Arm B and received enocog alfa at a dose of 50 IU / kg IV on an as-needed basis for 26 weeks, followed by enocog alfa at a dose of 50 IU / kg IV QW on a prophylactic treatment regimen for up to 26 weeks. The switch design of Arm B allowed for within-subject comparisons of as-needed treatment versus prophylactic treatment. Finally, Arm B also supported the evaluation of the efficacy of enocog alfa for as-needed treatment and surgical management of bleeding episodes.
[0258] Participants (except those in the sequential PK subgroup in Group A) underwent brief PK sampling after the first dose of enocoag alfa (baseline). Participants in the sequential PK subgroup in Group A underwent more extensive PK sampling at baseline and again at Week 26.
[0259] filter
[0260] Participants underwent a washout period of at least 48 hours before screening inhibitor testing to obtain interpretable test results. If the participant is receiving a traditional FVIII product, the washout before the first day dose of Aynogamma α (baseline visit) is at least 96 hours (4 days), and if the current treatment is with an extended half-life (EHL) FVIII product, the washout is at least 120 hours (5 days). The washout period before the baseline visit of the subject in the brief PK sampling can be modified according to individual PK data and clinical phenotype.
[0261] Enrollment and Baseline (Day 1)
[0262] After successfully completing all screening assessments and determining eligibility for the study (see Inclusion / Exclusion Criteria), participants will be enrolled. Many participants will be enrolled in Arm A: the preventive treatment regimen. Many participants will be enrolled in Arm B: the switch-to-preventive treatment regimen as needed. Some participants will be enrolled in the sequential PK subgroup of Arm A.
[0263] Participants in Group A received weekly prophylactic treatment with Aynog α for 52 weeks. Additional doses were given as needed to treat breakthrough bleeding episodes. Doses were given clinically according to the schedule of activity (SoA) (Table 4). Other doses were administered by participants or caregivers at home or in the clinic.
[0264] Participants in Group B received elocurative alpha to treat bleeding during the 26-week on-demand treatment period. At week 26, participants in Group B switched to preventive dosing, with elocurative alpha at a dose of 50 IU / kg once a week until week 52. During the 26-week prevention period, additional doses were given as needed to treat breakthrough bleeding episodes. Clinically, doses were given according to SoA (Table 4). Other doses were administered by participants or caregivers at home or in the clinic.
[0265] Participants were provided with an electronic patient diary (ePD) at the baseline visit to record all bleeding episodes and the dose of Aynog alfa administered after the baseline visit. Dosage details were entered promptly, preferably immediately or within 7 days of administration. Participants were prompted to enter the location and type of bleeding (spontaneous or traumatic) and the reason for administration (prevention or treatment of a bleeding episode). ePD training was completed at the study site at the baseline visit.
[0266] Participants undergoing preplanned surgery who were enrolled in the sequential PK subgroup were not entered into the surgery subgroup until repeat PK sampling had been completed 26 weeks after the day 1 PK analysis of eloquent α.
[0267] Participants in either group who underwent major surgery during the study period were included in the surgical subgroup.
[0268] All participants received an initial dose of Aynococcus alfa on day 1 and underwent subsequent PK assessments.
[0269] Study Clinic Visits
[0270] All enrolled participants had scheduled visits at the following time points: baseline (day 1), week 4, week 13, week 26, week 39, and week 52. Details of each visit are shown in Table 4.
[0271] For participants in Group A: Each scheduled study visit after Anocog alfa Day 1 will be 7 days (± 1 day) after the previous prophylactic dose. Participants should withhold their weekly prophylactic dose on the day of the study visit so that it can be administered at the time of the study visit.
[0272] A subgroup of participants in Group A (Sequential PK Subgroup) underwent baseline Anogram alfa PK sampling and repeated Anogram alfa PK sampling at the Week 26 visit (occurring 7 (+2) days after the previous prophylactic dose).
[0273] For participants in Arm B: Each scheduled study visit after Week 26 should be scheduled when the scheduled dose is due 7 days (± 1 day) after the previous prophylactic dose. Participants should withhold their weekly prophylactic dose to be administered at the study visit.
[0274] Participants underwent efficacy and safety assessments throughout their study participation. Safety assessments included testing for inhibitor development against FVIII. A follow-up safety visit or telephone call was conducted 2 to 3 weeks after the last dose of Anocog alfa, unless the participant participated in an open-label extension study. Participants completed an end-of-study (EOS) visit 52 weeks (±7 days) after baseline, or earlier if an EOS was declared.
[0275] Statistical analysis
[0276] Data on bleeding episodes were collected from each participant via an electronic diary or, if a bleeding episode occurred and / or was treated at the study site, on an electronic case report form and included the type of bleeding, location of bleeding, and date of treatment (if applicable). This information was used to derive the primary and related secondary efficacy endpoints.
[0277] All analyses of bleeding end points were based on treated bleeding episodes, with the exception of the ABR summary of all bleeding episodes, which included both treated and untreated bleeding episodes.
[0278] All primary analyses of bleeding endpoints were based on treated bleeding episodes using standardized definitions that met ISTH criteria (Blanchette 2014). A bleeding episode began with the first sign of bleeding and ended no more than 72 hours after the last injection to treat the bleeding episode. Any subsequent bleeding in the same location and injections administered within 72 hours or less after the last injection will be considered the same bleeding episode. Multiple bleeding sites treated with a single injection will also be considered a single bleeding episode. Any injection to treat a bleeding episode administered more than 72 hours after the previous injection will be considered the first injection to treat a new bleeding episode in the same location. Any injection used to treat a subsequent bleeding episode in a different location will be considered a separate bleeding episode, regardless of the time interval since the last injection to treat the bleeding episode. If a bleeding episode occurred on the same day as a regularly scheduled prophylactic dose, participants were instructed to record the treated and untreated bleeding, as well as the time of prophylactic treatment and bleeding treatment, in their diary.
[0279] In addition, all bleeding episodes, including untreated bleeds, were analyzed. All bleeds were defined according to ISTH criteria, but untreated bleeds were counted based on the date and time of the bleed itself.
[0280] The following hemophilia history variables were summarized by study group and treatment regimen (including surgical subgroups) and descriptive statistics were used overall: age at diagnosis of severe hemophilia (years); family history of inhibitors (yes, no); blood type (A, B, AB, O); Rh factor (positive, negative); lowest recorded FVIII level in history (<1%, ≥1%); FVIII genotype; human immunodeficiency virus (HIV) status; hepatitis C (HCV) status; hepatitis B (HBV) status; vaccination history in the past year (yes, no); type of FVIII product previously administered at study entry; age at initiation of the first prophylaxis regimen (years; <6 years, 6 to <10 years, 10 to <18 years, and ≥18 years); number of days of previous exposure to FVIII (<150, ≥150); number of bleeds in the past 12 months; number of joint bleeds in the past 12 months; and target joints at baseline.
[0281] In addition, information on the most recent prestudy FVIII regimen and other FVIII regimens used within the past 12 months was collected and summarized, including: category of most recent prestudy FVIII regimen (prophylaxis, as needed); duration of the prestudy regimen (>12 months, 6-12 months, <6 months); and injection frequency for those participants who indicated prophylaxis as the most recent prestudy regimen. B. Research Group
[0282] Inclusion criteria
[0283] Participants were eligible for inclusion in the study only if they met all of the following criteria: I-01. Participants must be 12 years of age or older (inclusive) at the time of signing the informed consent form. I-02. Patients had severe hemophilia A, defined as <1 IU / dL (<1%) endogenous FVIII activity (as documented at screening by central laboratory testing or in historical medical records from a clinical laboratory demonstrating <1% FVIII clotting activity (FVIII:C)) or a documented genotype known to produce severe hemophilia A. I-03. Previous hemophilia A treatment (prophylaxis or as needed) with any recombinant and / or plasma-derived FVIII or cryoprecipitate for at least 150 EDs. I-04. Current treatment regimen included one of the following: (1) Prophylactic treatment with a FVIII product or prophylactic emicizumab for at least 6 months in the previous 12 months. (2) On-demand regimen with FVIII products with a history of at least 12 bleeding episodes in the past 12 months or at least 6 bleeding episodes in the past 6 months prior to study enrollment (on-demand participants will receive a prophylactic regimen that is transferred to the 26-week on-demand period). I-05. Platelet count ≥ 100,000 cells / μL at screening. I-06. Participants known to be positive for human immunodeficiency virus (HIV) antibodies (either previously documented or determined by screening assessment) must have the following results prior to enrollment: a) CD4 lymphocyte count > 200 cells / mm 3, and b) viral load <400 copies / mL. Documented CD4 lymphocyte count and viral load results are accepted if the sample was collected within 26 weeks prior to screening, or if the sample was collected during the screening period and evaluated by the central laboratory. Participants with a previously negative HIV test must have a repeat test by the central laboratory during the I-07 screening period. Participant or surrogate (caregiver or family member ≥18 years of age) completes training in the use of the study electronic patient diary (ePD) and demonstrates willingness and ability to use the ePD throughout the study. I-08. Male or female; use contraception that complies with local regulations regarding contraception for those participating in clinical research. a) Male participants - Contraception is not required for this study. b) Female participants - Female participants are eligible to participate if they are not pregnant or breastfeeding, are not a woman of childbearing potential (WOCBP), or are WOCBP and use an acceptable method of contraception during the intervention period (at least until the safety follow-up call or visit). A high-sensitivity pregnancy test result for the WOCBP must be negative before the first dose of the study intervention. I-09. The participant must be able to provide signed informed consent, including compliance with the requirements and limitations outlined in the Informed Consent Form (ICF) and this protocol. I-10. The participant or his or her legally authorized representative (e.g., parent or legal guardian) must understand the purpose and risks of the research and provide a signed and dated informed consent or permission (if applicable) authorizing the use of protected health information in accordance with state and local participant privacy regulations.
[0284] Exclusion criteria
[0285] Participants were excluded from the study if any of the following conditions (medical conditions, previous / concurrent therapy, previous / concurrent clinical research experience, and other exclusions) existed:
[0286] Medical Conditions:E-01. Any concurrent clinically significant liver disease that, in the opinion of the investigator, would make the participant ineligible for enrollment. This may include, but is not limited to, cirrhosis, portal hypertension, and acute hepatitis. E-02. Serious active bacterial or viral infection within 30 days of screening (excluding chronic hepatitis or HIV). E-03. One or more known coagulation disorders other than hemophilia A. E-04. History of hypersensitivity or anaphylactic reaction to any FVIII product. E-05. History of a positive inhibitor test, defined as ≥0.6 BU / mL, or any value greater than or equal to the lower sensitivity cutoff for the laboratory with a cutoff value for inhibitor detection between 0.7 BU / mL and 1.0 BU / mL, or clinical signs or symptoms of reduced response to FVIII administration. A family history of inhibitors will not exclude participants. E-06. A positive inhibitor result is defined as ≥0.6 BU / mL at screening. E-07. Abnormal renal function, defined as serum creatinine >2.0 mg / dL at screening. E-08. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5x upper limit of normal (ULN) when collected at screening. E-09. Serum total bilirubin > 3x ULN when collected at screening.
[0287] Prior / concomitant therapy : E-10. Vaccinations within 30 days of screening. E-11. Treatment with acetylsalicylic acid (ASA) or non-NSAID antiplatelet therapy within 2 weeks prior to screening. E-12. Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) exceeding the maximum dose specified in the regional prescribing information within 2 weeks prior to screening. E-13. Systemic treatment with chemotherapy and / or other immunosuppressive drugs (excluding hepatitis C virus [HCV] or HIV treatment) within 12 weeks prior to screening. Corticosteroids are permitted, except for daily or alternate-day systemic corticosteroids for >14 days. Topical, external, and / or inhaled steroids are permitted.
[0288] Previous / concurrent clinical research experience E-14. Use of emicizumab within 20 weeks prior to screening. E-15. Previous enrollment in this study; participants who fail screening may be rescreened. E-16. Treatment with an investigational product within 30 days or 5.5 half-lives prior to screening, whichever is longer. For investigational products with a duration of effect exceeding a half-life, the maximum effect must have returned to baseline before screening.
[0289] Other exclusions:E-17. Major surgery within 8 weeks prior to screening. Major surgery is defined as any surgical procedure (elective or emergency), usually but not always involving general anesthesia and / or respiratory assistance, in which a major body cavity is penetrated and exposed, or produces a serious impairment to physical or physiological function (e.g., laparotomy, thoracotomy, craniotomy, joint replacement, or limb amputation). E-18. Individuals institutionalized by regulation or legal order; prisoners or participants legally committed. E-19. Any country-specific regulations that would prevent the participant from participating in the study. E-20. The participant is unsuitable for participation for any reason, including medical or clinical conditions, in the investigator's judgment, or the participant may be at risk of noncompliance with study procedures. E-21. The participant is dependent on the sponsor or investigator. E-22. The participant is an employee of the clinical research center or other individual directly involved in the conduct of the study, or an immediate family member of such an individual. E-23. The participant is deemed unsuitable for study participation by the investigator due to sensitivity to any study intervention or component, or to medication or other allergies.
[0290] Any medications or vaccines (including over-the-counter or prescription medications, vitamins, and / or herbal supplements) that participants are receiving at enrollment or during the study must be recorded along with the reason for use, dates of administration (including start and end dates), and dosing information, including dose and frequency. Participants must stop taking prescription or over-the-counter medications (including vitamins and dietary or herbal supplements) within 7 days (or 14 days if the medication is a potential enzyme inducer) or 5 half-lives (whichever is longer) before the start of the study intervention until the completion of follow-up, unless the medication will not interfere with the study.
[0291] Participants who routinely take additional doses of FVIII before physical activity or increased physical activity were not allowed to do so in this study. However, the dosing date (prophylaxis period) for Efa in Groups A and B could be chosen to precede the weekly repetition of physical activity. Study Interventions and Administration
[0292] For this study, a study intervention was defined as any study intervention administered to study participants according to the study protocol. Table 5 shows an overview of the study interventions administered.
[0293] Preventive treatment
[0294] The preventive treatment regimen is to give 50IU / kg Aynol alpha once a week (every 7 days). The goal of the 50IU / kg IV QW treatment regimen is to provide a sustained FVIII activity level within the normal to mild hemophilia range (FVIII trough levels are maintained at approximately 10% to 20% on the 7th day) and to alleviate the treatment burden of once-a-week dosing. During the planned study visits, Aynol alpha is delivered by a slow push IV injection of 8±2 minutes, and the rate of administration is determined by the participant's comfort level. For all Aynol alpha injections performed at home, Aynol alpha is delivered via a slow push IV injection at a rate of administration determined by the participant's comfort level according to the vial injection rate recommendation.
[0295] Any missed dose should be taken as soon as possible or as directed by the Investigator, taking into account that 2 consecutive prophylactic doses of 50 IU / kg should be separated by a period of at least 72 hours.
[0296] During clinic visits and monthly phone calls, study site staff will verify whether a bleeding episode has occurred and whether the bleeding is “spontaneous” or “traumatic.” During the monthly phone calls, participants or their parents / caregivers will be reminded of the requirement to enter ePD data as soon as possible (up to 7 days) after the injection and to verify adherence to the treatment regimen.
[0297] Bleeding episodes that require treatment during prophylaxis with Aynol α can be treated with a single dose of 50 IU / kg. If the bleeding does not improve, an additional 30 or 50 IU / kg dose every 2 to 3 days may be considered. For mild / moderate bleeding within 2-3 days after the most recent prophylactic dose, an initial 30 IU / kg dose is also used. Treatment of any bleeding in the same location reported within 72 hours of a previous bleed is considered a follow-up injection, and the event should not be recorded as a new bleeding episode. If a bleeding episode occurs when a regular prophylactic dose of Aynol α is due, the participant is injected with a dose of 50 IU / kg.
[0298] On-demand treatment
[0299] Bleeding episodes that occurred during the on-demand treatment regimen of Aynol α (first 26 weeks of Group B) were treated with a single dose of 50 IU / kg Aynol α. Bleeding episodes can be treated in a hospital / clinic or at home (as appropriate). Participants are instructed to consult the research site before giving follow-up injections. The administration of a second dose of Aynol α as a follow-up treatment is determined by the investigator based on the participant's clinical condition. If the bleeding episode does not improve, an additional 30 or 50 IU / kg dose every 2 to 3 days may be considered. Any treatment for bleeding in the same location reported within 72 hours of a previous bleeding should be considered a follow-up injection, and the event should not be recorded as a new bleeding episode.
[0300] Surgical medication
[0301] Minor surgery can be performed at the time of participation in this trial by administering a dose of 50 IU / kg of Aynol alpha. Participants in any group who have undergone major surgery during the study will be included in the surgical subset. Major surgery is defined as any invasive surgical procedure that requires any of the following: opening into a major body cavity (e.g., abdominal cavity, thoracic cavity, cranial cavity), joint surgery, organ resection, extraction of any molar or ≥3 non-molar teeth, surgical changes to normal anatomical structures, or crossing interstitial barriers (e.g., pleura, peritoneum, dura mater). It is recommended that any elective non-dental major surgery be performed at the study site whenever possible. Minor surgery is defined as any invasive surgical procedure in which only the skin, mucosa, or superficial connective tissue is manipulated and does not meet the criteria for major surgery (e.g., extraction of <3 non-molar teeth). Minor surgical procedures can be performed at local healthcare facilities.
[0302] For all participants in the surgical subgroup, the surgical period began with the first dose of 50 IU / kg IV of Aynol α (i.e., preoperative loading dose) given to them for surgery. All patients received a preoperative loading dose before the surgical procedure. If necessary, the dose level of Aynol α should be adjusted according to the WFH guidelines during surgery to achieve at least 100% FVIII activity level and maintain this dose level.
[0303] Postoperatively, FVIII activity levels are monitored daily by local measurement of FVIII activity for as long as the patient is hospitalized. FVIII levels are maintained at the recommended levels and durations according to WFH guidelines. Depending on the target FVIII activity level, this may mean administering a second dose approximately 48-72 hours after the preoperative loading dose. Depending on the desired FVIII activity level and the severity of the surgery, additional doses of 30 or 50 IU / kg may be administered every 2 to 3 days. Due to the long half-life of enogram alfa, dosing frequency may be extended after the first postoperative week. C. Preparations - Drugs
[0304] The drug product of enogram alfa is provided in a lyophilized form in sterile vials and requires reconstitution with sterile water for injection (diluent). For this study, each vial of drug product contained 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU or 4000 IU of enogram alfa in formulation buffer (10 mM L-histidine, 250 mM arginine-HCl, 5 mM CaCl2, 5% (w / v) sucrose, 0.05% (w / v) polysorbate 80, pH approximately 7.0). D. Efficacy: Goals and Endpoints
[0305] The main efficacy target of this study is to evaluate the efficacy of Aynoglucin α as a preventive treatment. The main efficacy endpoint is the annualized bleeding rate (ABR) of preventive treatment (Group A). ABR has traditionally been used to evaluate the efficacy of FVIII products in clinical trial settings, and is considered to be an objective and measurable endpoint that meets current EMA guidelines and established regulatory precedents. The efficacy evaluation in the clinical study of novel hemophilia therapy usually compares preventive treatment with an on-demand treatment regimen. However, it is now widely recognized that prevention is considered to be the standard of care treatment for hemophilia A and is reflected in current hemophilia treatment guidelines (see, for example, World Federation of Hemophilia (WFH) Guidelines for the management of hemophilia [World Federation of Hemophilia (WFH) Hemophilia Management Guidelines], 2012, 2nd Edition). Therefore, in order to more appropriately reflect current hemophilia practice patterns and treatment guidelines, the main efficacy was evaluated for the preventive treatment in Group A. Given the reliable information available from previously marketed FVIII products and the well-characterized efficacy of prophylactic treatments, an estimation approach was used for the primary efficacy analysis.
[0306] The mean annualized bleeding rate and one-sided 97.5% confidence interval were estimated for prophylaxis in Group A using a negative binomial regression model with a predefined success threshold based on published historical data from other marketed FVIII products. Notably, recently approved hemophilia therapies also utilized estimation methods for key efficacy endpoint analyses (see, e.g., Collins et al. Blood. 2014; 124(26): 3880-3886; Mahlangu et al. NEJM. 2018; 811-822.)
[0307] The key secondary efficacy endpoint compared ABR between weekly prophylaxis with enogram alfa and historical prophylaxis using within-patient comparisons for participants in observational study 242HA201 / OBS16221 in Group A. Non-inferiority testing using margins preserving a substantial treatment effect provided meaningful data in the context of current standard of care treatment. The non-inferiority margin was estimated using a meta-analysis that included consideration of the results of studies published in: Manco-Johnson et al. J Thromb Haemost. 2013;11:1119-27, Mahlangu et al. Blood. 2014;123(3):317-25, Konkle et al. Blood. 2015;126(9):1078-85, Kavakli et al. J Thromb Haemost. 2015;13(3):360-9, Mahlangu et al. Blood. 2016;128(5):630-7, Reding et al. J Thromb Haemost. 2017;15(3):411-9, and Giangrande et al. Thromb. Haemost. [Thrombosis and Hemostasis] 2017;117:252-61. This observational study allowed for prospective data collection on bleeding episodes and treatment management in participants using a commercially available FVIII product. Data collection using ePD was similar to that in this phase 3 study, facilitating robust comparisons to support the primary endpoint results.
[0308] Other secondary efficacy endpoints for this objective included the ABR by bleed type (spontaneous, traumatic, or unknown type) and location of bleeding in each study group; the ABR for all bleeding episodes (including untreated bleeding episodes) treated with prophylaxis in each study group; a within-patient comparison of the ABR during QW prophylaxis in Group B with the ABR during as-needed treatment; and the percentage of participants in Group A who maintained FVIII activity levels above 1%, 5%, 10%, 15%, and 20%.
[0309] The study's secondary efficacy objective was to evaluate the efficacy of enocog alfa in treating bleeding episodes. Efficacy endpoints for this objective included the number and dose of enocog alfa injections used to treat bleeding episodes in each study group and treatment regimen; the percentage of bleeding episodes treated with a single enocog alfa injection in each study group and treatment regimen; the response of individual bleeding episodes to enocog alfa treatment in each study group and treatment regimen, as assessed by the International Society on Thrombosis and Haemostasis (ISTH) 4-point response scale; and the physician's global assessment (PGA) of the participant's response to enocog alfa treatment in each study group and treatment regimen, as assessed by the 4-point response scale.
[0310] Another secondary efficacy objective of the study was to evaluate the effect of enocog alfa consumption on the prevention and treatment of bleeding episodes. The efficacy endpoint for this objective included the annualized total enocog alfa consumption per participant.
[0311] Another secondary efficacy objective of the study is to evaluate the effect of enoxapro alpha prevention on joint health outcomes. Efficacy endpoints for this objective include changes from baseline to week 52 in the total score and domain scores (e.g., swelling and strength) assessed by the Hemophilia Joint Health Score (HJHS) in Group A; the annualized joint bleeding rate (AJBR) for each study group and treatment regimen; and target joint resolution at week 52 according to ISTH criteria in Group A.
[0312] Another efficacy objective of the study was to evaluate the effect of enogram alfa prophylaxis on quality of life (QoL) outcomes. Efficacy endpoints for this objective included changes in the Haem-A-QoL (≥17 years) total score and physical health score measure from baseline to week 52 in Group A; changes in PROMIS Pain Intensity 3a from baseline to week 52 in Group A; and changes in PROMIS SF physical function (≥18 years) measure from baseline to week 52 in Group A.
[0313] Another efficacy objective of the study was to evaluate the efficacy of enocog alfa in perioperative management. Efficacy endpoints for this objective included the participant's hemostatic response to enocog alfa treatment as assessed by the investigator or surgeon using the ISTH 4-point Procedural Response Scale; the number and dose of injections used to maintain hemostasis during the perioperative period of major surgery; the total amount of enocog alfa consumed during the perioperative period of major surgery; the number and type of blood component transfusions used during the perioperative period of major surgery; and the estimated blood loss during the perioperative period of major surgery. E. Efficacy Evaluation
[0314] The planned time points for all efficacy assessments are provided in the SoA (Table 4).
[0315] In this study, a standardized definition of bleeding episodes based on the International Society on Thrombosis and Haemostasis (ISTH) criteria was used (Blanchette et al. J Thromb Haemost. 2014; 12(11): 1935-9).
[0316] As used in this Example 1, a "treated bleeding episode" is defined as a treated episode that begins with the first sign of bleeding and ends no more than 72 hours after the last injection for the treatment of the bleeding episode. Any subsequent bleeding at the same location and an injection that is ≤72 hours from the last injection will be considered the same bleeding episode. Multiple bleeding locations treated with a single injection will also be considered a single bleeding episode. Any injection for the treatment of a bleeding episode administered >72 hours after the previous injection will be considered the first injection for the treatment of a new bleeding episode in the same location. Any injection for the treatment of subsequent bleeding at a different location will be considered a separate bleeding episode, regardless of the time interval since the last injection for the treatment of the bleeding episode.
[0317] If a bleeding episode occurred on the same day as a regularly scheduled prophylaxis dose, participants were asked to record in their diary: -Treatment of bleeding episodes (if a bleeding episode requires enoxaparin alfa treatment on routine prophylaxis days) -Follow-up injections (if additional injections are needed on routine prophylaxis days to treat bleeding). or -Prophylactic Dosage: If a bleeding episode does not require treatment with Aynococcus alfa on a routine prophylaxis day, the bleeding episode should be recorded and treated as an untreated bleeding episode.
[0318] Bleeding episodes or hemorrhages are classified as spontaneous or traumatic. As used in Example 1, a "spontaneous bleeding episode" is a bleeding episode that occurs in the absence of a known contributing factor (such as clear trauma or prior "vigorous" activity) determined at the investigator's discretion, and requires instructions to parents / caregivers / participants based on appropriate classification by the investigator. As used in this Example 1, a "traumatic bleeding episode" refers to a bleeding episode that occurs when the cause of the bleeding is known or believed. For example, if a participant exercises vigorously and then has a bleeding episode without any obvious injury, the bleeding episode is still recorded as a traumatic bleeding episode. If a known behavior causes bleeding into a joint, the target joint bleeding may be traumatic.
[0319] To assess the clinical response to bleeding episodes treated with Aynococcus alfa, the ISTH 4-point acute bleeding treatment scale (Blanchette 2014) will be used throughout the study. Assessments should be performed approximately 72 hours after the initial treatment of a bleeding episode.
[0320] Target Joint Resolution: Investigators will assess target joints at baseline according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. Target joints are defined as major joints (e.g., hip, elbow, wrist, shoulder, knee, or ankle) with ≥3 spontaneous bleeds within 6 consecutive months. Target joint resolution is defined as ≤2 bleeding episodes in a target joint within 12 consecutive months of exposure.
[0321] Surgery: The investigator / surgeon performing the surgery will assess the participant's response to surgery with enoxacin alfa using a 4-point scale as summarized in Table 6 (see Blanchette et al. 2014; 12(11): 1935-9). This includes observations during surgery and within 24 hours after surgery. This assessment will be performed 24 hours after surgery.
[0322] Patient-Reported Outcomes: Table 7 shows the measurement concepts used in the trial and their associated patient-reported outcome (PRO) questionnaires. Where available, PROs (excluding HRU assessments) were distributed to adult and pediatric patients as specified in the SoA (Table 4). All PROs, except HRUs, were collected via electronic tablets and transmitted over a public network to a third-party vendor data server using encrypted data. The PROMIS instrument was administered at baseline and at weeks 26 and 52. F. Safety: Goals and Endpoints
[0323] Another objective of the study was to evaluate the safety and tolerability of enocog alfa treatment. Safety endpoints for this objective included the occurrence of adverse events (AEs) and serious adverse events (SAEs); clinically significant changes from baseline in physical examination, vital signs, and laboratory tests; the development of inhibitors (neutralizing antibodies to factor VIII [FVIII]) as determined by the Nijmegen modified Bethesda assay; and the occurrence of embolic and thrombotic events. G. Safety Assessment
[0324] The planned timing for all safety assessments and drug tolerance studies is provided in the Schedule of Activities (SoA) (Table 4). Non-limiting examples of these studies include the following:
[0325] 1. Physical examination: Assessment of the cardiovascular, respiratory, gastrointestinal, neurologic, cutaneous, and musculoskeletal systems.
[0326] 2. Vital signs: blood pressure, pulse rate, respiratory rate and body temperature (℃).
[0327] 3. Laboratory tests, including:
[0328] Hematology: Platelet count; red blood cell (RBC) count; white blood cell (WBC) count and differential; hemoglobin (Hgb); hematocrit (HCT).
[0329] Clinical chemistry: alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase (ALP); gamma glutamyltransferase (GGT); bilirubin; blood urea nitrogen (BUN); creatinine; blood glucose (nonfasting); total protein; potassium; sodium; chloride.
[0330] Von Willebrand Comprehensive Panel: VWF ristocetin cofactor activity; VWF antigen
[0331] Immunogenicity: Nijmegen modified Bethesda inhibitor assay; anti-drug antibodies (ADA); ADA subtypes.
[0332] Coagulation parameters: activated partial thromboplastin time (aPTT).
[0333] Other tests and evaluations: Ultrasound evaluation using the JADE and / or HEAD US protocols (select sites only); high-sensitivity [serum or urine] human chorionic gonadotropin (hCG) pregnancy test (as needed for women of reproductive potential); HIV (HIV-1 antibody, HIV-2 antibody, and HIV-1p24 antigen), HBV (HBV surface antigen [HBsAg], anti-HBV surface antibody, and anti-HBV core antibody), and HCV (anti-HCV antibody) for previously negative patients; follicle-stimulating hormone and estradiol (as needed only for women of non-reproductive potential); CD4 count and viral load (for patients known to be HIV-positive).
[0334] Adverse events
[0335] Adverse events (AEs) were reported by participants (or, where appropriate, by caregivers, surrogates, or the participant's legally authorized representative).
[0336] In this study, an adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical study participant that is temporally associated with the use of an investigational intervention, whether or not related to the investigational intervention. Thus, an AE can be any unfavorable and unexpected sign (including abnormal laboratory findings), symptom, or disease (new or worsening) that is transiently associated with the use of an investigational intervention.
[0337] Whether abnormal laboratory values and / or vital sign results meet the definition of an AE will be determined by the investigator. Abnormal laboratory results will not be considered an AE unless they meet one or more of the following criteria: (1) are symptomatic, (2) require corrective treatment or consultation, (3) result in IMP discontinuation or modification of dosing, (4) meet severity criteria, and / or (5) are defined as adverse events of special interest (AESI).
[0338] Bleeding episodes in this patient population were not considered AEs; however, incidental events related to bleeding episodes were reported as AEs as appropriate (e.g., elbow fractures). Bleeding episodes that met serious adverse event (SAE) criteria were reported as SAEs as appropriate.
[0339] In this study, a serious adverse event (SAE) was defined as any untoward medical occurrence at any dose that resulted in death, was life-threatening, required hospitalization or prolongation of an existing hospitalization, caused persistent or significant disability / incapacity, or was a congenital anomaly / birth defect, or was a medically important event.
[0340] In this study, adverse events of special interest (AESI) are defined as adverse events (serious or non-serious) of scientific and medical interest specific to the IMP or project for which continued monitoring by the investigator and prompt communication to the sponsor may be appropriate. AESIs may require further investigation to characterize and understand them. Examples of AESIs include the development of an inhibitor (e.g., an inhibitor result of ≥0.6 BU / mL confirmed by a second test result of ≥0.6 BU / mL drawn 2 to 4 weeks after the date on which the original sample was drawn) or a Grade 3 or higher allergic reaction. H. Pharmacokinetics: Goals and Endpoints
[0341] The pharmacokinetic (PK) objectives of this study were to evaluate the PK of enocog alfa based on a one-stage activated partial thromboplastin time (aPTT) and a two-stage chromogenic FVIII activity assay. PK endpoints included maximum activity (C max ), elimination half-life (t 1 / 2 ), total clearance (CL), total clearance at steady state (CLss), accumulation index (AI), area under the activity-time curve (AUC), volume of distribution at steady state (Vss), mean residence time (MRT), incremental recovery (IR), trough activity (C 谷 ) and time above a predefined FVIII activity level. I. Pharmacokinetic Assessment
[0342] Pharmacokinetic (PK) assessments were performed on participant samples collected during the study. Abbreviated pharmacokinetic sampling or sequential pharmacokinetic sampling was used to estimate PK parameters, including but not limited to the following: maximum activity (Cmax), elimination half-life (t1 / 2), total clearance (CL), total clearance at steady state (CLss), accumulation index (AI), area under the activity-time curve (AUC), volume of distribution at steady state (Vss), mean residence time (MRT), incremental recovery (IR), trough activity (Ctrough), and time above 1% FVIII activity.
[0343] Group A: For all participants in Group A (preventive treatment regimen), all participants received the Day 1 dose, and the sampling time for blood collection was before injection, followed by 15 (± 3) minutes, 3 hours (± 15 minutes), 24 (± 2) hours, 72 (± 5) hours [Day 4], and 168 (± 5) hours [Day 8] from the start of injection. Many participants in Group A participated in the Sequential PK group to complete the PK sampling required to estimate the terminal half-life of Aynog α. For participants in the Sequential PK group, the sampling time was extended to 240 (± 5) hours [Day 11] and 336 (± 5) hours [Day 15] from the start of injection. A repeat PK profile analysis will be performed at 26 weeks.
[0344] Group B: For all participants in Group B (switch to prophylaxis as needed), all participants received the Day 1 dose, and sampling times for blood collection were pre-injection, then 15 (±3) minutes, 3 hours (±15 minutes), 24 (±2) hours, 72 (±5) hours [Day 4], and 168 (±5) hours [Day 8] from the start of the injection.
[0345] Trough measurement is carried out before injection. Peak measurement is carried out 15 (± 3) minutes after the start of injection using two different assays: FVIII activity assay based on 1 stage aPTT and Efa capture colorimetric Coatest FVIII activity assay. The first assay for measuring the FVIII activity of Efa uses a modification to aPTT, which uses Dade actin FSL activated PTT reagent (1 stage aPTT) on a BCS XP analyzer (Siemens Healthcare Diagnostics). The assay is validated using plasma standards, which have been calibrated according to WHO (World Health Organization) FVIII International Standard No. 6. 1 stage aPTT assay is able to measure native FVIII activity and Efa FVIII activity. The LLOQ of the assay is 1% of normal FVIII activity (0.010 IU / mL). The second assay for determining Efa activity in plasma is a modified colorimetric Coatest FVIII activity assay. In this assay, anti-ELNN antibodies are first used to capture the analyte (Efa). The activity of the captured Efa is then determined using a Coatest FVIII colorimetric assay, which provides a colorimetric substrate assay that quantifies the conversion of factor X (FX) to activated FX (FXa) mediated by activated FVIII (FVIIIa) in the presence of trace amounts of thrombin (for FVIII activation) and excess activated factor IX (FIXa), FX, Ca++, and phospholipids. The formation of FXa is measured by the turnover of a colorimetric FXa peptide substrate. The LLOQ of the assay is 0.4% (0.004 IU / mL or 4 mIU / mL) of normal FVIII activity. The assay is validated using Efa's own standards. J. Inhibitor production
[0346] Blood samples are collected for detecting inhibitors. Inhibitor production is assessed by the Nijmegen Modified Bethesda assay and is defined as an initial test result of ≥0.6BU / mL, which is confirmed by a second test result of an independent blood sample collected within 2 to 4 weeks of the first positive sample. Low-titer inhibitor production is defined as an inhibitor test result>0.6 and <5.00BU / mL. High-titer inhibitor production is defined as an inhibitor test result of ≥5.00BU / mL. Participants with differential inhibitor test results (initial low-titer result followed by high-titer result, or initial high-titer result followed by low-titer result) have performed repeated inhibitor tests from independent blood samples collected 2 to 4 weeks after the previous sample. If 2 of the 3 test results are <5.00BU / mL, the inhibitor is considered as low titer. If 2 of the 3 test results are ≥5.00BU / mL, the inhibitor is considered as high titer. K. Exploratory Objectives and End Points
[0347] An exploratory objective of this study was to assess structural joint health outcomes via ultrasound using the Joint Motion and Injury Examination (JADE) protocol and / or Hemophilia Early Arthropathy Ultrasound Detection (HEAD-US). Exploratory endpoints for this objective included changes from baseline to Week 52 in anatomical structural joint health outcomes via the JADE and / or HEAD-US protocols for ultrasound imaging in a subpopulation of Group A at selected sites.
[0348] Another exploratory objective of the study was to evaluate the effect of enogram alfa treatment on patient-reported outcome (PRO) measures and physical activity (measured across each study group and treatment regimen). Exploratory endpoints for this objective included changes in PRO measures and physical activity across each study group and treatment regimen, including PROMIS-SF Physical Function (≥18 years) or PROMIS Pediatric-SF Physical Activity (<18 years); Haem-A-QoL (≥17 years) or Haemo-QoL (<17 years) total and subscale scores; PROMIS-SF Pain Interference (≥18 years) or PROMIS Pediatric-SF Pain Interference (<18 years); EQ-5D-5L; Medication Satisfaction Questionnaire-9 (TSQM-9); Patient Global Impression of Severity (PGIS) (Activity Component); PGIS (Joint Component); and changes in physical activity measures (ActiGraph Activity Monitor); and the Hemophilia Activity List (HAL) (≥18 years) or pedHAL (<18 years). Other exploratory endpoints for this objective included changes in the HJHS total score and domain scores (e.g., swelling and strength) in Group B as a result of treatment regimen; patient global impression of change (PGIC) at weeks 26 and 52 for each study group and treatment regimen; patient preference at week 52 for each study group and treatment regimen; and an exit interview at week 52 (or at a subsequent follow-up visit). L. Results
[0349] Unless otherwise stated, all ABRs mentioned in the data of this Example 1 and in the associated tables and figures are for treated bleeding episodes.
[0350] Demographics and Study Participation
[0351] Key Phase 3 study demographics and disease characteristics are shown in Table 8. One female participant was enrolled in this study.
[0352] The demographics of the Phase 3 study participants are shown in Table 9. Reasons for discontinuation were withdrawal of consent in 3 participants (1.9%) and use of prohibited medications for medical reasons in 3 participants (1.9%). The remaining reasons were adverse events, protocol violations, death (assessed as unrelated to Efa treatment), and other, each affecting 1 participant (0.6%). *Participants with evaluable pharmacokinetic (PK) profiles at both baseline and Week 26
[0353] All subjects were previously treated. The types of FVIII products previously used before the study (242HA201 / OBS16221) were plasma derivatives, recombinants, and cryoprecipitates (in 138 subjects receiving prophylaxis and 19 subjects receiving on-demand treatment; see Table 10). Most subjects receiving prophylaxis before the study (242HA201 / OBS16221) had previously been treated with recombinant FVIII products (101 / 138 subjects [73.2%]), while most subjects receiving on-demand treatment had previously received plasma-derived FVIII products (14 / 19 subjects [73.7%]). Overall, most subjects (86 / 157 subjects [54.8%]) before the study (242HA201 / OBS16221) had received their respective treatment regimens for >12 months prior to the screening date. Table 10: Type of FVIII product previously administered before the study (242HA201 / OBS16221) On Demand prevention overall # of subjects 19 138 156 Cryoprecipitate 8(42.1) 20(14.5) 28(17.9) Plasma derivatives 14(73.7) 65(47.1) 78(50.0) recombinant 6(31.6) 101(73.2) 107(68.6)
[0354] For the pre-study (242HA201 / OBS16221) prophylaxis regimen, most subjects were administered 3 times per week (44 / 139 subjects [31.7%]) or 2 times per week (40 / 139 subjects [28.8%]). Additional information about participants in the pre-study (242HA201 / OBS16221) prophylaxis regimen can be found in Table 11. In Table 11, patients are included in each treatment regimen in which they participated and may appear in more than one treatment regimen. Each patient is counted only once in the overall column. Additional demographic data and treatment and bleeding history of Phase 3 study participants can be found in Tables 12 and 14, respectively. Patient FVIII genotype data can be found in Table 13. Table 11. Summary of the most recent pre-study (242HA201 / OBS16221) FVIII regimen Table 12. Summary of demographic and baseline characteristics by group and subgroup. Table 13. Patient FVIII genotype Table 14. Summary of Hemophilia Treatment and Bleeding History - Complete Analysis Set Note: 1: Percentages are based on the number of participants with nonmissing data in the full analysis set. 2: Participants were included in every study group and treatment regimen (including surgical subgroups) in which they participated and therefore may have appeared in more than one treatment regimen. Each participant is counted only once in the overall column. a Participants may be counted in more than one category.
[0355] Observational study results
[0356] Additional data related to the Phase 3 study endpoints were collected for participants in the observational study. The mean (standard deviation [SD]) duration of the observation period was 42.3 (14.1) and 46.7 (8.4) weeks for patients receiving prophylaxis and on-demand treatment, respectively. The mean (SD) number of routine prophylaxis injections per week was 2.2 (1.07). The median (quarterly [Q]1, Q3) ABR for patients receiving prophylaxis and on-demand treatment, respectively, was: overall, 2.0 (0.0, 5.7) and 29.1 (8.4, 40.0); spontaneous, 0.0 (0.0, 3.0) and 14.7 (7.7, 30.1); traumatic, 1.0 (0.0, 2.1) and 4.8 (0.0, 8.7). Table 15 summarizes additional results from the observational study. Table 15. Summary of results from observational studies
[0357] Primary endpoint of the Phase 3 study
[0358] like Figure 3As shown, once a week, prophylactic treatment with 50 IU / kg ainolectin α can effectively prevent bleeding. In the ABR statistical model analysis, the estimated mean ABR was 0.71 (95% CI 0.52; 0.97) (if the CI upper limit is ≤ 6, bleeding is adequately controlled). In Group A, the mean (SD) overall ABR was 0.71 (1.43, n = 133) throughout the 12-month study period and 0.59 (1.32, n = 128) during the last 6 months of the study. A descriptive analysis of ABR is shown in Table 16 below. Table 16. Summary of Primary Endpoints in Phase 3 Studies (Group A)
[0359] The distribution of annualized bleeding rates (Table 18) and annualized joint bleeding rates (AjBR) (Table 17) among subjects in Group A was analyzed (see also Figure 5 ). Of the subjects enrolled in Group A and analyzed for ABR (n=133), 86 patients (64.7%) had zero bleeds during the study. 45 subjects (33.8%) had 1 to 5 bleeds during the study. 1 subject (0.8%) had 6 to 10 bleeds. 1 subject (0.8%) had 11 to 20 bleeds. No subject had 21 or more bleeding episodes during the study. For AjBR, 96 subjects (72.2%) had zero joint bleeds during the study. 35 subjects (26.3%) had 1 to 5 joint bleeds. 2 subjects (1.5%) had 6 to 10 joint bleeds. No subject had 11 to 20 or more joint bleeds during the study. Historical treated joint bleed rates are from subjects enrolled in the observational study 242HA201 / OBS16221. See also Table 17.
[0360] The mean (SD) efficacy period for the 6-month prophylactic duration in Group B was 22.89 (6.00) weeks, with 77% of participants experiencing zero bleeds (see Table 18). Table 17. Annualized Joint Bleeding Rates in Subjects in Observational Study 242HA201 / OBS16221 and Phase 3 Studies
[0361] The annualized total bleeding rates for the observational and phase 3 studies are shown in Table 18. Table 18: Annualized Total Bleeding Rates for Subjects in Observational Study 242HA201 / OBS16221 and Phase 3 Studies aNegative binomial models were estimated with the total number of treated bleeding episodes during the observation period as the response variable and the log-transformed duration of the observation period (in years) as the offset variable.
[0362] The rate of bleeding episodes remained consistent in Group A throughout the study period, indicating that weekly prophylaxis with Aynococcus alfa provides immediate and sustained protection against bleeding ( Figure 6 ).
[0363] In Group A, 18 spontaneous bleeding episodes occurred 5 to 7 days after the last prophylactic dose, 13 occurred 3 to 4 days after the last dose, and 2 occurred 0 to 2 days after the last dose ( Figure 7 A). Overall, the 25 patients in Group A had a total of 33 spontaneous bleeding episodes, of which 19 patients (76%) experienced a single spontaneous bleeding episode. For traumatic bleeding episodes, 19 each occurred 3 to 4 days and 5 to 7 days after the last prophylactic dose, and 5 occurred 0 to 2 days after the last prophylactic dose ( Figure 7 B). A summary of ABR and bleeding episodes in Groups A and B is shown in Table 19. Table 19: Summary of ABR and bleeding episodes in Groups A and B.
[0364] The treatment of bleeding episodes is summarized in Table 20. Table 20: Summary of bleeding treatment in Groups A and B.
[0365] Secondary endpoints of the phase 3 study
[0366] The key secondary efficacy endpoint of the study was a comparison of weekly prophylaxis with enogram alfa versus historical prophylaxis using within-patient (also known as within-participant) comparisons of participants in Group A who participated in the observational study 242HA201 / OBS16221. Figure 4 (and Figure 24A ), the estimated mean ABR for those in the observational study prior to study (242HA201 / OBS16221) prophylaxis (i.e., prophylaxis with a drug product other than elocoag alfa) was 2.96 (2.00; 4.37) (n=78). See also Table 22. The estimated mean ABR for these patients in the study with weekly prophylactic doses of elocoag alfa was 0.69 (0.43; 1.11). The reduction in bleeding rate from historical prophylactic treatment for these patients was an estimated 77% reduction in the mean ABR (see Table 22). Figure 24A ).
[0367] The overall ABR mean difference between historical prophylaxis and Aynol alpha in the within-participant comparison was -2.30 (95% CI -3.49; -1.11).The overall ABR results are shown in Table 21 (per regimen set, n=77) and Table 22 (full analysis set, n=78).
[0368] This shows that compared with historical preventive treatment, the non-inferiority condition of enocaproic acid alpha is met (95% CI upper limit of ABR mean difference <4). The ratio of weekly preventive treatment of enocaproic acid alpha to historical prevention is 0.23 (95% CI 0.13; 0.42; p < 0.0001). This shows that compared with historical preventive treatment, the conditions for demonstrating the superiority of enocaproic acid alpha are met (95% CI upper limit of ratio <1; p value ≤ 0.05). Table 21: Comparison of Annualized Bleeding Rates Within Participant: Efa(BIVV001) Versus Historical Prophylaxis (Per Protocol Set) Table 22. Comparison of Annualized Bleeding Rates Within Participant: Efa(BIVV001) Versus Historical Prophylaxis (Full Analysis Set) NOTE: 1: Summary based on treated bleeds. 2: Percentages are based on the number of participants in each study's preventive treatment regimen who had an evaluable observation or efficacy period. 3: This analysis was based on the full analysis set and included participants in Group A who had an efficacy period of at least 6 months in Study EFC16293 and a prevention-based observation period of at least 6 months collected in Study OBS16221. 4: The efficacy period reflects the sum of all intervals during which participants were treated with BIVV001, according to study arm and treatment regimen, excluding periods of PK assessments, surgery / recovery (minor and major), and major injection intervals (>28 days). aEstimated using negative binomial regression models with treatment (BIVV001 prophylaxis vs. historical prophylaxis) as a covariate. b P-values relate to the null hypothesis: rate ratio (BIVV001 prevention / historical prevention) = 1. c was estimated using the Hodges-Lehmann method. d P values are relative to the null hypothesis: median pairwise difference (BIVV001 prevention−historical prevention) = 4 based on the Wilcoxon signed-rank test.
[0369] The annualized bleeding rate in participants who received weekly prophylactic treatment with enocoag alfa was comparable with that in those who had received The results are shown in Table 23. Compared with patients who had historically used prophylaxis with eloquent antagonists (eloquent antagonists alfa), these patients appeared to have significantly fewer bleeds with weekly eloquent antagonists. As shown in Table 23, the mean ABR for participants using eloquent antagonists alfa was 0.57, while that for participants using eloquent antagonists alfa was 0.64. The number of participants was 2.74. After switching to enoxaparin alfa, the mean difference (95% CI) was -2.19 (-3.42; -0.96) and the rate ratio (95% CI) was 0.21 (0.12; 0.37), with a p-value < 0.0001, corresponding to a 79% (63% to 88%) rate reduction (95% CI). Table 23: Comparison of Annualized Bleeding Rates Within Participants: Weekly Prophylaxis and Use of Efa (BIVV001) Historical prophylaxis comparison with (emoticon alfa) NOTE: 1: Summary based on treated bleeds. 2: Percentages are based on the number of participants in each study's preventive treatment regimen who had an evaluable observation or efficacy period. 3: This analysis included participants in Group A who had an efficacy period of at least 6 months in Study EFC16293 and a prevention-based observation period of at least 6 months collected in Study OBS16221. 4: The efficacy period reflects the sum of all time intervals during which participants were treated with Efa, according to study group and treatment regimen, excluding periods of PK assessments, surgery / recovery (minor and major), and major injection intervals (>28 days). a Negative binomial regression models were estimated with treatment (Efa prevention vs. historical prevention) as a covariate. b The P value is related to the null hypothesis: rate ratio (Efa prevention / historical prevention) = 1.
[0370] Further ABR assessments were performed within the participants for the participants treated with weekly prophylactic treatment with eloquent alpha (in the study), and compared with the historical treatment (before the study) with standard half-life (SHL) or extended half-life (EHL) FVIII products. It should be noted that before the study, SHL included SHL rFVIII and plasma-derived FVIII. In addition, internal participant ABR assessments included joint ABR, spontaneous joint ABR, and spontaneous joint ABR. The average (95% confidence interval [CI]) changes of joint, spontaneous, and spontaneous joint ABR were -1.55 (-2.46, -0.64), -1.20 (-1.84, -0.57), and -0.93 (-1.42, -0.43), respectively. A summary of the ABR results comparing historical treatment (before the study) and eloquent alpha treatment (in the study) is shown in Table 24. Overall, 42.3% of patients were free of bleeding before the study (median observation period: 50.05 weeks), compared with 64.1% during the study (median observation period: 50.09 weeks). Table 24. Pre-study ABR and On-study ABR and FVIII Prophylaxis Within Participants ABR, annualized bleeding rate; CI, confidence interval; EHL, extended half-life; FVIII, factor VIII; IQR, interquartile range; rFVIII, recombinant factor VIII; SHL, standard half-life.
[0371] Within-participant FVIII consumption and injection frequency were also analyzed for historical treatment with SHL or EHL (before the study) and compared with treatment with enoxaparin alfa (on the study). The mean (standard deviation) number of injections for bleeding therapy before the study was 1.8 (5.10) and during the study was 1.1 (0.30). The mean (95% CI) change in injection frequency per week was -1.37 (-1.59, -1.15) doses (see Table 1). Figure 8 A). The mean (95% CI) change in annualized consumption per week was -1828.22 (-2491.88, -1164.57) IU / kg (see Figure 8 B). SHL before the study included SHL rFVIII and plasma-derived FVIII. The results of FVIII consumption and injection frequency are shown in Table 25. Table 25. Comparison of Weekly Injection Frequency and FVIII Consumption Before and During the Study Within Participants (Median IQR)
[0372] On-demand treatment results
[0373] In the on-demand treatment portion of Group B of the Phase 3 study, the mean ABR observed for these 26 subjects was 21.42 (SD=7.41). The median ABR observed was 21.13 (Q1-15.12; Q3-27.13). When switched to a prophylactic dose of 50 IU / kg of Ainocoag alpha once a week, these subjects showed an observed mean ABR of 0.69 (SD=1.35). After switching to prophylactic treatment, the median ABR of these subjects was 0.00. The observed total ABR data from Group B (on-demand) and Group B (prevention) are shown in Table 26, and the annualized joint bleeding rate data from Group B are shown in Table 27. Table 26: Summary of Annualized Bleeding Rates - Group B Table 27: Summary of Annualized Joint Bleeding Rates - Group B
[0374] The distribution of the number of bleeding episodes among subjects was also examined in Arm B of the Phase 3 study. During on-demand treatment, 0 subjects had no bleeding episodes and 0 subjects had 1 to 5 bleeding episodes. One subject (3.8%) had 6 to 10 bleeding episodes. Ten subjects (38.5%) had 11 to 20 bleeding episodes. Fifteen subjects (57.7%) had 21 or more bleeding episodes. In contrast, when these 26 subjects were switched to prophylaxis, 20 subjects (76.9%) had no bleeding episodes. Six subjects (23.1%) had 1 to 5 bleeding episodes during the 26-week prophylaxis period. No subject had 6 to 10, 11 to 20, or more than 20 bleeding episodes.
[0375] Among the 14 patients with target joints at baseline and at least 12 months of on-study prophylaxis, all 45 target joints identified at baseline resolved. In addition, target joint bleeding decreased in Group B after switching from on-demand treatment to prophylaxis.
[0376] A summary of the annualized bleeding rates by bleeding location (full analysis set) is shown in Table 28.
[0377] Low bleeding rates were observed after switching from historical factor therapy to prophylaxis with enoxaparin alfa (Group A). The overall annualized bleeding rate for prophylactic therapy was 0.71 (Table 20), while the annualized bleeding rate due to spontaneous bleeding was 0.29 (Table 48). The annualized bleeding rate for traumatic bleeding was 0.36 (0.83), and the annualized bleeding rate for joint bleeding was 0.52 ( Figure 24B ).
[0378] Reduced bleeding rates were also observed when prophylaxis was administered after the as-needed portion of Group B. During the as-needed treatment portion, the mean (SD) annualized overall bleeding rate was 21.42 (7.41), the spontaneous bleeding rate was 15.87, the mean (SD) traumatic bleeding rate was 4.82 (6.31), and the mean (SD) joint bleeding rate was 17.45 (7.31). Once patients were placed on prophylaxis, these rates decreased to 0.69 (1.35), 0.45 (1.13), 0.15 (0.78), and 0.61 (1.33), respectively ( Figure 24C ). Table 28. Summary of Annualized Bleeding Rates by Bleeding Location - Full Analysis Set
[0379] Quality of life (QoL) outcomes
[0380] The secondary efficacy objectives of the study were to evaluate the effect of enogram alfa prophylaxis on joint health outcomes and quality of life (QoL) outcomes. Treatment with enogram alfa demonstrated statistically significant improvements in physical well-being, pain intensity, and joint health measures assessed as secondary endpoints compared to baseline in patients previously treated with other FVIII products for prophylaxis (see, e.g., Figure 10 A to C).
[0381] Physical health and function
[0382] Haem-A-QoL score
[0383] Physical health was measured by the Haem-A-QoL score in adult subjects (≥17 years) from baseline to week 52 (n=98) (see Von Mackensen S et al. Haemophilia 2017 23(3):383-91)( Figure 10 A). As part of the stratified testing procedure, the change in Haem-A-QoL physical health scores from baseline to week 52 was analyzed in Group A. Using a repeated measures mixed effects model (MMRM) (>=17 years), the mean change in Haem-A-QoL physical health subscale scores from baseline to week 52 is shown in Table 29. For Group A, the mean (SD) Haem-A-QoL physical health subscale scores at baseline, week 26, and week 52 were 37.02 (23.83), 30.33 (23.17), and 29.66 (23.40), respectively.
[0384] From baseline to Week 52, all participants receiving prophylaxis with enoxicillin alfa experienced an improvement in the Haem-A-QoL total score of -4.25 (LS mean 95% CI: -6.31 to -2.20, p<0.0001). Psychometric analyses based on Phase 3 data reported a meaningful within-group improvement in the Haem-A-QoL total score of -5.8 to -3.5. Statistically significant improvements were observed in 7 / 10 domains of the Haem-A-QoL: self-perception (-6.84 [-10.17; -3.50]; p < 0.0001); physical health (-6.74, LS mean 95% CI: -10.13 to -3.36; p = 0.0001; n = 98); work and school (-6.05, LS mean 95% CI: -10.09 to -2.02; p = 0.0038); sports and leisure (-5.87, LS mean 95% CI: -9.16 to -2.58; p = 0.0006); treatment (-5.71, LS mean 95% CI: -8.41 to -3.01; p < 0.0001); and feelings (-4.39, LS mean 95% CI: -4.70 to -4.91; p = 0.0001; n = 98). CI: -7.59 to -1.18; p = 0.0078); partnership and sexual behavior (-3.00, LS mean 95% CI: -5.40 to -0.60; p = 0.0148). A summary of the Haem-A-QoL total score, domain scores, and changes from baseline to week 52 is provided in Table 30 (for participants > 17 years of age), Table 31 (for participants 13 to 16 years of age), and Table 32 (for participants 12 years of age). The total scores and subscale scores of Tables 30-32 are presented in the form of transformed scale scores (TSS). The T score of Haem-A-QoL PH is calculated using the sum of the transformed raw scores of all items.
[0385] As shown in Table 29, the adjusted mean change in the Haem-A-QoL physical health score (n=98) from baseline to Week 52 was -6.74 (95% CI: -10.13 to -3.36, p-value=0.0001), indicating a statistically significant improvement in physical health. The adjusted change in the Haem-A-QoL physical health score from baseline to Week 52 was -6.74, equivalent to an average improvement of 18.2%. An extensive psychometric analysis based on Phase 3 data reported a significant improvement in the Haem-A-QoL physical health score of -6.8 to -4.8.
[0386] Most patients (71.4%; n = 98) maintained or improved numerically their PH scores from baseline to week 52 ( Figure 20Psychometric analyses supported a meaningful within-patient improvement threshold of -10 (range: -15.0 to -8.7). Nearly 42% of patients reported a clinically meaningful improvement in PH scores from baseline to Week 52. Table 29. Mean Change from Baseline to Week 52 in the Haem-A-QoL Physical Health Subscale Score Using the MMRM (>= 17 Years) - Full Analysis Set Table 30: Summary of Haem-A-QoL Total Score, Domain Scores, and Change from Baseline to Week 52 (≥17 Years) - Full Analysis Set Table 31: Summary of Haemo-QoL total score, domain scores, and change from baseline to Week 52 (13-16 years) - Full Analysis Set. Table 32: Summary of Haemo-QoL Total Score, Domain Scores, and Change from Baseline to Week 52 (12 Years) - Full Analysis Set
[0387] Prophylactic treatment with enoxicam alpha improves physical function. Physical function was measured at baseline and week 52 according to PROMIS-SF v2.0 physical function (PF) 6b. For PROMIS-SF PF 6b in group A, the least squares (LS) mean (standard error; SE) and 95% confidence interval (CI) were estimated by a repeated measures mixed effects model (MMRM) with visit as a fixed effect and baseline score as a covariate. Numerical improvement was observed in PROMIS PF 6b scores (LS mean [standard error] change relative to baseline: 0.56 [0.47]; N = 108). The proportion of patients who were unable to climb stairs at a normal speed decreased from 12% (12 / 103) at baseline to 6% (6 / 102) at week 52.
[0388] Hemophilia Activity List (HAL) score
[0389] Physical function is also measured using the Hemophilia Activity List (HAL) in Group A. For the HAL overall score in Group A, least squares (LS) means (standard error; SE) and 95% confidence interval (CI) are estimated by a repeated measurement mixed effects model (MMRM), which uses a medical visit as a fixed effect and baseline score as a covariate. During baseline, overall HAL score means [SD] was 76.11 [20.73]. During the 52nd week, a numerical improvement in overall HAL score was observed (LS mean change: 0.67 [95% CI:-2.03 to 3.38]; P=0.6229, N=96)). A summary of the overall HAL score, domain score, component score, and the change from baseline to the 52nd week for participants aged ≥18 years is provided in Table 33. A summary of the overall pediatric HAL (pedHAL) score, domain score, and the change from baseline to the 52nd week for participants aged <18 years is shown in Table 34. No participants in Group B met the age requirement for pedHAL. Table 33: Summary of Hemophilia Activity List (HAL) Overall Score, Domain Scores, Component Scores, and Change from Baseline to Week 52 (≥18 Years) - Full Analysis Set Table 34: Summary of Pediatric Hemophilia Activity List (pedHAL) Overall Score, Domain Scores, Component Scores, and Change from Baseline to Week 52 (<18 years) - Full Analysis Set
[0390] EuroQol 5-Dimension 5-Level (EQ-5D-5L) score
[0391] General health-related quality of life was assessed as an exploratory endpoint in groups A and B using the EuroQol 5-dimension 5-level (EQ-5D-5L) assessment, which consists of a descriptive system of five dimensions (mobility, daily activities, self-care, pain / discomfort, and anxiety / depression) and a visual analog scale (EQ-VAS; scores range from 0 to 100, with higher scores indicating better health-related quality of life). According to the EQ-5D-5L, at baseline, a total of 18% (22 / 122) and 9% (11 / 122) of patients reported moderate to severe problems with mobility and daily activities, respectively. A total of 23.5% (27 / 115) of patients reported an improvement in at least 1 activity category at week 52, while 67.0% (77 / 115) reported no change and 9.6% (11 / 115) reported a worsening in the activity category. A total of 19.1% (22 / 115) of patients reported improvement in at least 1 category of daily activities at Week 52, while 73.0% (84 / 115) reported no change, and 7.8% (9 / 115) reported worsening in the daily activities category. Table 35 provides a summary of the EQ-5D-5L descriptive system at baseline and Week 52. Table 36 provides a summary of the EQ visual analog scale (VAS) and the change from baseline to Week 52. Table 37 provides a summary of the EQ-5D index score and the change from baseline to Week 52. For Tables 35-37, the baseline characteristics of Group B are reported at the start of the initial on-demand treatment period. Table 35: Summary of EQ-5D-5L Descriptive Systems at Baseline and Week 52 - Full Analysis Set Table 36: Summary of EQ Visual Analog Scale (VAS) and Change from Baseline to Week 52 - Full Analysis Set Table 37: Summary of EQ-5D Index Scores and Change from Baseline to Week 52 - Full Analysis Set
[0392] These improvements in physical function were consistent with the results of the exit interview (N = 29, including 17 patients in Group A), in which most patients reported improved physical function (26 of 29). In addition, a trend toward improved physical activity was observed in the actigraphy data (mean [SD]: 5376
[3796] steps per day at baseline to 5758
[4472] steps per day at Week 52; overall patients, N = 158, including 132 patients in Group A).
[0393] These results show that weekly prophylaxis with enoxicillin alpha causes improvements in physical function in patients with hemophilia A, with a positive impact on activities of daily living in patients who previously received standard of care FVIII prophylaxis. Results from a Phase 3 trial showed that even in patients receiving conventional standard of care FVIII prophylaxis, significant and clinically meaningful improvements in health-related quality of life (associated with the prevention of bleeding) were achieved when switching to weekly enoxicillin alpha prophylaxis. Improvements in health-related quality of life may bring patients with hemophilia A closer to the goal of optimal outcomes, achieving a “hemophilia-free mentality.” See Krumb E and Hermans C. Res Pract Thromb Haemost. [Research and Practice of Thrombosis and Hemostasis] 2021; 5(5): e12567.
[0394] pain intensity
[0395] Pain intensity was measured as a secondary endpoint according to the PROMIS-Short Form (SF) v.1.0 3a 1st question (worst pain intensity in the past 7 days (PAINQU6 score)). The change in score from baseline to Week 52 was analyzed (n=119) ( Figure 10 B). A repeated measures mixed effects model (MMRM) was used to estimate the change in PROMIS Pain Intensity 3a score from baseline to Week 26 and Week 52. The results are shown in Table 38. Pain was also assessed as an exploratory endpoint using the PROMIS-SF v1.0 Pain Intensity 3a Total T score, the PROMIS-SF v1.0 Pain Interference 6a T score (in patients ≥18 years of age), and the EuroQol-5 Dimensions 5 Levels (EQ-5D-5L) pain / discomfort domain. Exit interviews and analgesic use were assessed for all patients in the trial.
[0396] At baseline, 53.6% (67 / 125) of patients in Group A reported moderate, severe, or very severe pain (at its worst in the past 7 days) based on the PROMIS-SF Pain Intensity 3a scale, while 19.7% (24 / 122) experienced moderate, severe, or extremely severe pain / discomfort based on the EQ-5D-5L. The mean (SD) PROMIS Pain Intensity 3a scores in Group A were 2.47 (1.15), 2.34 (1.15), and 2.21 (1.21) at baseline, week 26, and week 52, respectively (see Table 38). Approximately 75% of adults (75 / 103) indicated that pain interfered with their daily activities.
[0397] For the majority of patients (81.5% [97 / 119]), pain intensity (at its worst) improved or was maintained (change from baseline ≤ 0) at Week 52 ( Figure 21 On the PROMIS Pain Intensity 3a Item 1 (pain at its worst) scale, a greater proportion of patients experienced no pain at Week 52 (37% [44 / 119]) compared with baseline (29% [35 / 119]) ( Figure 22 The "average pain over the past 7 days" score improved by -0.20 (LS mean 95% CI: -0.33 to -0.63; p-value = 0.0042). The "current pain intensity" score improved by -0.14 (LS mean 95% CI: -0.25 to -0.03; p-value = 0.0128).
[0398] Prophylactic treatment with Ainocog α showed statistically significant improvement in the first item of the PROMIS pain intensity 3a score. For Group A, the least squares (LS) mean change in the PROMIS pain intensity score (n=119) from baseline to week 52 was -0.21 (95% CI: -0.41 to -0.02, p-value=0.0276). This improvement was also clinically significant because it was within the range of meaningful within-group changes (-0.5 to -0.2) determined using psychometric analysis in the context of the study. Table 38. Mean Change from Baseline to Week 52 in PROMIS Pain Intensity 3a at its Worst Score in the Past 7 Days Using the MMRM (>= 12 Years) - Full Analysis Set
[0399] These results were supported by a statistically significant improvement in overall pain intensity in the PROMIS-SF Pain Intensity 3a T score (LS mean change from baseline: -1.94 [95% CI: -3.26 to -0.63]; P = 0.0042). Numerical improvement was observed in the PROMIS-SF Pain Interference 6a T score (LS mean change from baseline to Week 52: -1.16 [95% CI: -2.45 to 0.14]; P = 0.0793). (See Table 39). Table 39. PROMIS-SF Pain Intensity 3a T-score and PROMIS-SF Interference 6a T-score
[0400] These results were also supported by patient reports on the EQ-5D-5L survey and exit interviews. For the EQ-5D-5L, at week 52, 20.9% (24 / 115) of patients reported improvement compared to baseline in at least one category of the pain / discomfort domain. During the exit interview (N=29, including 17 patients in Group A), the majority of patients reported significant improvement in pain (25 / 29). Exit interview results (n=29; 17 in Group A) showed that almost all patients (96.6%; 28 / 29) had experienced hemophilia-related pain before the study. Of these 28 patients, 25 reported improvement in joint pain, and one additional patient reported improvement in the ability to move without pain.
[0401] The percentage of patients from both Groups A and B who had not taken any hemophilia-related analgesics in the 14 days prior to visit increased from baseline (73.6%; [n=117]) to Week 52 (81.9% [n=127]), reflecting a trend toward a relative decrease in hemophilia-related analgesic use at Week 52. Figure 23 The most commonly used concomitant medications during the study period were paracetamol (40.9%; 65 patients) and celecoxib (15.7%; 25 patients).
[0402] Joint health
[0403] Joint health was measured by the Hemophilia Joint Health Score (HJHS) v2.1 from baseline to week 52 (n=106) ( Figure 10C). The changes in the total HJHS scores for the two study groups from baseline to week 52 are shown in Table 40. The mean total HJHS score in Group A decreased from baseline to week 52 (-1.54 [95% CI -2.70 to -0.37]; P = 0.01) (Table 40). The changes in the HJHS domain scores relative to baseline at week 52 for the prophylaxis and on-demand treatment groups are shown in Table 41. In Group A, the HJHS domains with the greatest mean improvement from baseline to week 52 were swelling, muscle atrophy, crepitus with movement, and loss of flexion (Table 41, Figure 27A The mean (SD) change from baseline to Week 52 in the HJHS total joint score (calculated if all 48 individual scores were present, 8 domains x 6 joints) was -1.4 (6.2); n = 108. The mean (SD) change from baseline to Week 52 in the HJHS gait score was -0.1 (0.8); n = 120 (assessed on a scale of 0-4).
[0404] In Group B, the HJHS domains with the greatest mean improvement from baseline to Week 52 were swelling, duration of swelling, crepitus with movement, loss of flexion, joint pain, and strength (Table 41, Figure 27B The mean (SD) change from baseline to Week 52 in the HJHS total joint score (calculated as if all 48 individual item scores were present, 8 domains x 6 joints) was -3.9 (8.6); n = 22. The mean (SD) change from baseline to Week 52 in the HJHS gait score was -0.2 (0.5); n = 23 (assessed on a scale of 0-4).
[0405] In group A, including participants who received stable standard of care FVIII replacement prevention before enrollment, the mean (SD) HJHS total score at baseline was 18.1 (18.4). The adjusted mean change from baseline to week 52 in the HJHS total score in group A (n=107) was -1.54 (95% CI:-2.70 to -0.37) (p value=0.0101), and in group B (n=22) was -4.1 (95% CI:-7.94 to -0.25) (p value=0.0382; n=22), thus demonstrating statistically significant improvement in the functional measurement results of joint health. See Table 40.
[0406] The HJHS scores were further analyzed by demographic data in both Group A and Group B (Table 42; Figure 26), and the demographic data of the participants in Group A were also analyzed by HJHS score (Table 43). Participants were grouped according to the decrease in HJHS total score of ≥4 points, <4 points, ≥2 points, or <2 points (Table 44). Participants whose HJHS total score decreased by ≥4 points tended to be older and have a higher BMI than those whose HJHS total score decreased by less than 4 points.
[0407] The improvements reported for participants receiving enocog alfa prophylaxis after only 52 weeks represent clinically meaningful improvements, especially considering that the majority of patients (80.5%) had no target joints at baseline and all received standard of care pre-study prophylaxis.
[0408] In addition, post hoc analysis indicated that There was a numerical trend toward reduction (i.e., improvement) in the Haem-A-QoL physical health score, PROMIS Pain Intensity 3a Item 1, and Hemophilia Joint Health Score (HJHS) total score after 52 weeks of prophylaxis with Aynog alfa in patients treated with Aynog alfa. However, the 95% CI for the mean reduction did not exclude zero. Table 40. Mean Change from Baseline to Week 52 in the Hemophilia Joint Health Score (HJHS) Total Score Using the MMRM - Full Analysis Set Table 41. Change from Baseline in Hemophilia Joint Health Score (HJHS) Domain Scores at Week 52: Group A and Group B Table 42. Demographics of participants by HJHS total score assessed at week 52 Table 43. Greater improvements in joint health were observed in Group A participants who were older and had higher HJHS total scores at baseline. Table 44. Patient Demographics by HJHS Total Score Reduction
[0409] Structural joint health was also assessed in a subset of patients from this phase 3, open-label, multicenter study using the Hemophilia Early Arthropathy Ultrasound Detection (HEAD-US). Power Doppler ultrasound (PDUS) in the target tissue was used semiquantitatively to evaluate synovial congestion, an indicator of neovascularization and active synovitis (score 0-3).
[0410] The results of this substudy are shown in Table 45. Thirty-one patients participated in this substudy, of whom 8 (26%) had ≥1 target joint at baseline (defined as ≥3 spontaneous bleeds in a major joint within 6 consecutive months). The median age (range) was 39 (16-72) years. The mean (standard deviation [SD]) total HEAD-US score per patient decreased from 12.2 (11.8) at baseline to 10.7 (11.6) at Week 52 (mean [SD] change -1.3 [4.5]) (Table 45). A numerically greater decrease (improvement) in the total HEAD-US score from baseline to Week 52 was observed in patients who did not have a target joint at baseline compared to those with ≥1 target joint (mean [SD] changes of -1.5 [3.93] and -0.7 [6.15], respectively). Overall, 41% (9 / 22) of participants had an improvement in their total HEAD-US score from baseline to week 52, for 27% (6 / 22) of participants, their score remained unchanged, and for 32% (7 / 22) of participants, their score worsened. At least 20% of patients had an improvement in HEAD-US scores from baseline to week 52 in the left elbow (8 / 26; 31%), right ankle (7 / 26; 27%), right knee (6 / 27; 22), and left ankle (5 / 25; 20%). A total of 46% (13 / 28) of participants had an improvement in their semiquantitative hypertrophic synovium score, and 33% (8 / 24) had an improvement in PDUS grade assessment. Improvements in semiquantitative bone and cartilage scores were observed in 29% (8 / 28) and 21% (6 / 28) of participants, respectively. Table 45. Summary of HEAD-US total score and ultrasound parameter scores
[0411] Exit interview
[0412] Exit interviews were conducted to understand symptoms and experiences of hemophilia and to obtain feedback on the PROMIS Pain Intensity 3a (specifically the item addressing the most severe pain) and Haem-A-QoL Physical Health Questionnaires included in the study. Overall, the exit interviews supported the improvements in physical health observed on these questionnaires.
[0413] Exit interviews were qualitative, semistructured interviews conducted with 29 of the 159 participants (27 adults and 2 adolescents) from six countries (Argentina, France, Italy, South Korea, the United Kingdom, and the United States) within 6 months of study withdrawal but before study closure. Seventeen participants (58.6%) were included in Group A. Questions addressed participants' pre-study experiences with hemophilia A, pain, and physical function, as well as the impact of previous treatment; participants' study experiences with pain intensity and physical function following treatment with enocog alfa; and participants' reported meaningful changes, if any, following treatment with enocog alfa.
[0414] Pre-study participant experience: Of the 17 participants (58.6%; 17 / 29) enrolled from Group A, 13 (76.5%) had reported a "wearing off" feeling from the previous prophylactic treatment, including more pain, stiffness, feeling unprotected, breakthrough bleeding, and limited physical activity.
[0415] Of the 29 interviewed participants, 28 (96.6%) reported that they had experienced hemophilia-related pain of at least "moderate intensity" before the study. Most participants (26 / 28; 92.9%) experienced varying degrees of pain intensity in more than one joint (e.g., knee, knuckle, ankle, elbow). Participants also reported that hemophilia-related pain and other symptoms had a negative impact on their daily activities, particularly their physical function. At least 25 / 29 participants (86.2%) had experienced most of the concepts assessed in the exit interview before the study. Regarding pre-study experiences with hemophilia A, 41.4% of participants experienced increased preparation time, 86.2% experienced an inability to walk the desired distance, 89.7% experienced pain with movement, 96.6% experienced pain in the joints, and 86.2% experienced painful swelling.
[0416] Study Participants' Experiences: Of the 28 participants who had hemophilia-related pain before the study, 25 / 28 (89.3%) reported meaningful improvement in joint pain after switching to Anocog alfa. Regarding the experience of study participants with hemophilia A, 75.0% of participants reported improvement in preparation time, 80.0% reported improvement in the ability to walk the desired distance, 88.5% reported improvement in the ability to exercise without pain, 89.3% reported improvement in pain in the joints, and 84% reported improvement in painful swelling. The remaining three participants who reported no change in joint pain intensity after receiving Anocog alfa stated that improvement was unlikely due to the ongoing extensive cumulative joint damage they had suffered over the years due to recurrent joint bleeds.
[0417] Participants who had mild impairments before the study reported significant improvements in overall function and quality of life after the study. Although the magnitude of change varied, all interviewees considered the improvements in physical health to be meaningful.
[0418] All 29 exit interview participants (100%) preferred weekly enoxaparin alfa prophylaxis compared to their previous hemophilia treatment.
[0419] In addition to reduced bleeding events and improvements in pain, participants also reported increased confidence in protection, less fatigue, and improved health-related quality of life compared to their previous treatment. These exit interviews indicated that participants with mild injuries before the study reported significant improvements in overall function and quality of life after switching to enoxapro. These qualitative findings are consistent with the quantitative improvements observed in the study's PROMIS Pain Intensity 3a and Haem-A-QoL PH subscale results.
[0420] Other assessments
[0421] The physicians used a 4-point Physician Global Assessment (PGA) response scale to assess the subjects' responses to Efa treatment (see Table 2). The results are shown in Table 46. Table 46. Physician's Global Assessment (PGA) of Subjects' Response to Efa Treatment
[0422] Participant assessments of response to Aynol alfa treatment for bleeding episodes in the Phase 3 study were also analyzed. The results are shown in Table 47 below. Table 47: Summary of Participant Assessments of Response to Efa Treatment for Bleeding Episodes
[0423] As part of the Phase 3 study, spontaneous bleeding rates were also analyzed and compared with the observational study 242HA201 / OBS16221. The results are shown in Table 48. Table 48: Spontaneous Bleeding Rates in Subjects in Observational Study 242HA201 / OBS16221 and Phase 3 Studies
[0424] The number of spontaneous bleeds experienced by the participants was also analyzed, and the results for both groups are shown in Table 49. The ABR by bleed type (spontaneous, traumatic, and unknown type) was also analyzed, and the results are shown in Table 49. Table 49: Number of subjects grouped according to the number of spontaneous bleeds per individual during the study period, and ABR according to type of bleed.
[0425] The percentage of participants whose FVIII activity levels remained above 1%, 5%, 10%, 15% and 20% in Group A: Prophylaxis (50 IU / kg once weekly) were also analyzed. The results are shown in Table 50. Table 50: Percentage of participants in the prevention group with Factor VIII (FVIII) activity levels above 1%, 5%, 10%, 15% and 20%. Group A: Prevention Number of subjects analyzed 131 Percentage of subjects maintaining specified FVIII activity levels >1% 100 >5% 99.0 >10% 83.5 >15% 40.8 >20% 17.5
[0426] Pharmacokinetics in Phase 3 Studies
[0427] The pharmacokinetic (PK) objective of this study was to evaluate the PK of enocog alfa based on a one-stage activated partial thromboplastin time (aPTT) assay. The time above a predetermined FVIII activity level was analyzed. Prophylactic treatment with 50 IU / kg enocog alfa once weekly resulted in a mean FVIII activity level that was normal / near normal (>40%) for up to 4 days after dosing and maintained a mean FVIII activity level >10% for up to 7 days after dosing, as assessed by aPTT at 15 IU / dL on day 7 (see Figure 15 、 Figure 19 ).
[0428] Several PK parameters at week 26 are shown in Table 51. At week 26, the geometric mean (95% CI) half-life of patients was 47.0 (42.3-52.2) hours (FVIII activity was measured by a one-stage coagulation assay based on aPTT). In fact, the PK profiles after the first dose and at week 26 were similar. The geometric mean (95% CI) half-life, steady-state clearance, maximum FVIII activity, and area under the activity-time curve from 0 hours to infinity were 47.0 (42.3 to 52.2) hours, 0.439 (0.390 to 0.493) mL / h / kg, 151 (137 to 167) IU / dL, and 11500 (10200 to 13000) h×IU / dL, respectively. This low variability in the clearance of eloquent alpha suggests that there is less need to adjust the dose and / or dosing frequency of eloquent alpha.
[0429] The maximum FVIII activity (Cmax) at baseline (Day 1) in Group A was 125.05 ± 31.72 IU / dL (mean (SD)) for prevention subjects (n = 133). The Cmax at Week 52 in Group A was 144.72 ± 36.65 IU / dL (mean (SD)) for prevention subjects (n = 125).
[0430] The maximum FVIII activity (Cmax) at baseline (Day 1) in Group B subjects who received on-demand and then prophylaxis (n=26) was 138.36±48.66 IU / dL (mean (SD)). The Cmax at Week 52 in Group B subjects who received on-demand and then prophylaxis (n=23) was 149.42±29.63 IU / dL (mean (SD)).
[0431] The median elimination half-life at baseline for the 159 subjects analyzed (t 1 / 2 ) was 46.5 hours (29.1 to 104) (median full range (min-max)). The median elimination half-life (t 1 / 2 ) was 46.7 hours (29.4 to 63.5) (median full range (minimum-maximum)).
[0432] The mean clearance (CL) at baseline (Day 1) for the 153 analyzed subjects was 0.508 ± 0.124 mL / h / kg (arithmetic mean (SD)).
[0433] The total clearance at steady state (CLss) for the 17 subjects analyzed was 0.449 ± 0.101 (arithmetic mean (SD)). CLss is defined as the rate at which a drug is cleared from the body at steady state. PK population analysis was performed. Here, number of subjects analyzed = subjects evaluable for that endpoint.
[0434] The average cumulative index (AI) of the 15 analyzed subjects at week 26 was 1.17 ± 0.160 (arithmetic mean (SD)). The AI is the cumulative ratio of the drug under steady-state conditions (ie, after repeated administration) compared to a single dose. The AI is calculated as the ratio of the area under the curve (AUC) at week 26 (day 183) divided by the AUC on day 1, where AUC is the area under the plasma concentration versus time curve from time 0 to infinity. The PK population was analyzed. Here, the number of subjects analyzed = the subjects for whom this endpoint could be assessed. This AI value indicates that the cumulative amount of Aynoglucon alpha dose administered once a week is minimal.
[0435] The mean area under the plasma FVIII activity versus time curve (AUC 0-tau) was 9600±2010 hours*IU / dL (arithmetic mean (SD)) at baseline for the 153 analyzed subjects and 11800±2720 hours*IU / dL (arithmetic mean (SD)) at week 26 for the 17 analyzed subjects.
[0436] The mean retention time at baseline for the 153 analyzed subjects was 61.9 hours (34.3 to 111) (median full range (minimum-maximum)). The mean retention time at Week 26 for the 17 analyzed subjects was 66.1 hours (46.7 to 92.3) (median full range (minimum-maximum)).
[0437] The mean incremental recovery (IR) was 2.60 ± 0.648 kg*IU / dL / IU (arithmetic mean (SD)) at baseline for the 153 analyzed subjects and 3.05 ± 0.592 (arithmetic mean (SD)) at week 25 for the 17 analyzed subjects.
[0438] For both Group A and Group B, the trough concentration of Aynol alfa at baseline (Day 1) before dosing (Ctrough) was 0.00 ± 0.00 IU / dL (arithmetic mean (SD)). Group A Ctrough at Week 52: 15.70 ± 10.72 IU / dL (arithmetic mean (SD)) for prevention in 133 analyzed subjects. Group B Trough at Week 52: 21.14 ± 29.59 IU / dL (arithmetic mean (SD)) for as-needed then prevention in 26 analyzed subjects.
[0439] The volume of distribution at steady state (Vss) was 31.7 (7.44) (arithmetic mean (SD)) at baseline in Groups A and B. The Vss at Week 26 was 29.6 (8.26) (arithmetic mean (SD)). Table 51 - Pharmacokinetic parameters of Aynol alpha: Week 26 All data are geometric means (95% confidence inte...
Claims
1. A method of reducing the amount of analgesics required to reduce or manage pain associated with hemophilia A, the method comprising administering a therapeutically effective amount of a chimeric protein to a human subject with hemophilia A in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, and wherein the amount of analgesic required when the subject is treated with the chimeric protein is reduced compared to the amount required when the subject is treated for hemophilia A with: (i) a FVIII replacement protein that is capable of being bound by endogenous von Willebrand factor (VWF); (ii) a complex, wherein the complex comprises a FVIII protein and a VWF protein, or a portion thereof, wherein the FVIII protein and the VWF protein, or a portion thereof, are not covalently attached, directly or indirectly, to each other; or (iii) emicizumab.
2. The method of claim 1, wherein the amount of analgesic required when treating the subject with the chimeric protein is reduced compared to before the first administration of the chimeric protein to the subject.
3. The method of any one of claims 1 or 2, wherein the dosage of the analgesic is reduced and / or the number of doses of the analgesic is reduced over the course of a day or a week.
4. The method of any one of claims 1 to 3, wherein the analgesic comprises lidocaine, tramadol, tramadol hydrochloride, acetaminophen, metamizole, diclofenac, diclofenac potassium, diclofenac epolamide, ibuprofen, naproxen sodium, celecoxib or ketorolac.
5. A method of improving joint health in a human subject during prophylactic treatment of hemophilia A, wherein the prophylactic treatment of hemophilia A comprises administering to a human subject in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, Wherein the improvement in joint health comprises improvement in the subject's cartilage.
6. A method for the prophylactic treatment of hemophilia A, the method comprising administering to a human subject in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, and The subject was not taking any on-demand treatment for hemophilia A prior to engaging in strenuous activity.
7. The method of claim 6, wherein the vigorous activity comprises basketball, football, hockey, rugby, boxing, wrestling, or martial arts.
8. A method of improving the quality of life with prophylactic treatment of hemophilia A, the method comprising administering to a human subject in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, and wherein the subject's quality of life is improved compared to: (i) a corresponding subject receiving prophylactic treatment with emicizumab, (ii) a corresponding subject receiving prophylactic treatment for hemophilia A with a FVIII replacement protein other than the chimeric protein, wherein the FVIII replacement protein is capable of being bound by endogenous VWF, or (iii) a corresponding subject receiving prophylactic treatment for hemophilia A with a complex, wherein the complex comprises a FVIII protein and a VWF protein or a portion thereof, wherein the FVIII protein and the VWF protein or a portion thereof are not covalently attached, directly or indirectly, to each other.
9. The method of any one of claims 1 to 8, wherein the subject's physical health improves.
10. The method of any one of claims 1 to 9, wherein the subject's physical fitness improves.
11. The method of any one of claims 1 to 10, wherein the subject has (i) less pain caused by swelling, (ii) less joint pain, (iii) improved mobility, (iv) less interference with school activities, (v) less interference with work activities, (vi) less difficulty walking, (vii) less fatigue and / or (viii) increased physical fitness when treated with the chimeric protein compared to: (i) a corresponding subject receiving prophylactic treatment with emicizumab, (ii) a corresponding subject receiving prophylactic treatment for hemophilia A with a FVIII replacement protein other than the chimeric protein, wherein the FVIII replacement protein is capable of being bound by endogenous VWF, or (iii) a corresponding subject receiving prophylactic treatment for hemophilia A with a complex, wherein the complex comprises a FVIII protein and a VWF protein or a portion thereof, wherein the FVIII protein and the VWF protein or a portion thereof are not covalently attached to each other, directly or indirectly.
12. A method of achieving an annualized bleeding rate (ABR) of 2 or less, the method comprising administering a therapeutically effective amount of a chimeric protein to a human subject with hemophilia A in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, and wherein a total of about 2600 IU / kg to about 2650 IU / kg of the chimeric protein is administered to the subject per year.
13. A method of reducing the annualized bleeding rate (ABR) compared to treatment with a factor VIII (FVIII) replacement protein, complex, or emicizumab that is capable of being bound by endogenous von Willebrand factor (VWF), the method comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a VWF fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, and wherein the FVIII surrogate protein capable of being bound by endogenous VWF is ronocognin alpha, sincognin alpha, pergo-lulicognin alpha, pergo-dancognin alpha, emmog alpha, sermog alpha, morog alpha, berog alpha or torog alpha, or wherein the complex comprises a FVIII protein and a wild-type VWF protein or a portion thereof, wherein the FVIII protein and the VWF protein or a portion thereof are not covalently attached, directly or indirectly, to each other.
14. A method of maintaining a FVIII activity level of at least 2%, the method comprising administering a therapeutically effective amount of a chimeric protein to a human subject with hemophilia A in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide sequence, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, wherein after each administration of the chimeric protein, a FVIII activity level of about 35% to about 45% is maintained for at least 4 days, and wherein a FVIII activity level of about 10% to about 15% is maintained for at least 7 days after each administration of the chimeric protein.
15. A method of reducing the risk of a bleeding episode, the method requiring more than one supplemental on-demand administration of a FVIII replacement protein during a prophylactic treatment of hemophilia A, wherein the prophylactic treatment of hemophilia A comprises administering a therapeutically effective amount of a chimeric protein to a human subject in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, wherein the risk is reduced by at least 90% compared to the risk in a corresponding subject receiving prophylactic treatment for hemophilia A comprising administration of a FVIII replacement protein other than the chimeric protein, and wherein the FVIII replacement protein other than the chimeric protein is capable of being bound by endogenous VWF, and wherein the supplemental on-demand dose is 45 IU / kg to 70 IU / kg.
16. The method of any one of claims 1 to 15, wherein the therapeutically effective amount is a dose of about 50 IU / kg of the chimeric protein about once every 7 days.
17. A method of resolving a withdrawal bleeding episode, the method comprising administering to a human subject in need thereof a single on-demand dose of a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, wherein the single on-demand dose is about 50 IU / kg, and Where the bleeding episode is in a joint.
18. A method for on-demand treatment of major bleeding comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, and The major bleeding is intracranial bleeding, retroperitoneal bleeding, iliopsoas bleeding, cervical bleeding, muscle bleeding with compartment syndrome and / or bleeding associated with a significant decrease in hemoglobin level.
19. A method for the perioperative management of bleeding comprising administering to a human subject with hemophilia A in need thereof a therapeutically effective amount of a chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond.
20. The method of claim 19, wherein the subject is expected to undergo surgery within 72 hours, is currently undergoing surgery, or has undergone surgery within the last week.
21. The method of any one of claims 19 or 20, wherein the therapeutically effective amount comprises a preoperative loading dose of 50 IU / kg, followed by one or more doses of 30 IU / kg or 50 IU / kg every 2 to 3 days.
22. A chimeric protein for use in reducing the amount of analgesics required to reduce or manage pain associated with hemophilia A, comprising administering a therapeutically effective amount of the chimeric protein to a human subject with hemophilia A in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, and wherein the amount of analgesic required when the subject is treated with the chimeric protein is reduced compared to the amount required when the subject is treated for hemophilia A with: (i) a FVIII replacement protein capable of being bound by endogenous von Willebrand factor (VWF); (ii) a complex, wherein the complex comprises a FVIII protein and a VWF protein, or a portion thereof, wherein the FVIII protein and the VWF protein, or a portion thereof, are not covalently attached, directly or indirectly, to each other; or (iii) emicizumab.
23. The chimeric protein of claim 22, wherein the amount of analgesic required when treating the subject with the chimeric protein is reduced compared to before the first administration of the chimeric protein to the subject.
24. The chimeric protein of any one of claims 22 or 23, wherein the dosage of the analgesic is reduced and / or the number of doses of the analgesic is reduced over the course of a day or a week.
25. The chimeric protein of any one of claims 21 to 24, wherein the analgesic comprises lidocaine, tramadol, tramadol hydrochloride, acetaminophen, metamizole, diclofenac, diclofenac potassium, diclofenac epolamide, ibuprofen, naproxen sodium, celecoxib, or ketorolac.
26. A chimeric protein for use in improving joint health in a human subject during prophylactic treatment of hemophilia A, wherein the prophylactic treatment of hemophilia A comprises administering a therapeutically effective amount of the chimeric protein to a human subject in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, Wherein the improvement in joint health comprises improvement in the subject's cartilage.
27. A chimeric protein for use in the prophylactic treatment of hemophilia A, comprising administering a therapeutically effective amount of the chimeric protein to a human subject in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, and The subject was not taking any on-demand treatment for hemophilia A prior to engaging in strenuous activity.
28. The chimeric protein of claim 27, wherein the vigorous activity comprises basketball, soccer, hockey, rugby, boxing, wrestling, or martial arts.
29. A chimeric protein for use in improving the quality of life with prophylactic treatment of hemophilia A, comprising administering a therapeutically effective amount of the chimeric protein to a human subject in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, and wherein the subject's quality of life is improved compared to: (i) a corresponding subject receiving prophylactic treatment with emicizumab, (ii) a corresponding subject receiving prophylactic treatment for hemophilia A with a FVIII replacement protein other than the chimeric protein, wherein the FVIII replacement protein is capable of being bound by endogenous VWF, or (iii) a corresponding subject receiving prophylactic treatment for hemophilia A with a complex, wherein the complex comprises a FVIII protein and a VWF protein or a portion thereof, wherein the FVIII protein and the VWF protein or a portion thereof are not covalently attached, directly or indirectly, to each other.
30. The chimeric protein of any one of claims 22-29, wherein the subject's physical health is improved.
31. The chimeric protein of any one of claims 22 to 30, wherein the subject's physical fitness is improved.
32. The chimeric protein of any one of claims 22 to 31, wherein the subject has (i) less pain caused by swelling, (ii) less joint pain, (iii) improved mobility, (iv) less interference with school activities, (v) less interference with work activities, (vi) less difficulty walking, (vii) less fatigue and / or (viii) increased physical fitness when treated with the chimeric protein compared to: (i) a corresponding subject receiving prophylactic treatment with emicizumab, (ii) a corresponding subject receiving prophylactic treatment for hemophilia A with a FVIII replacement protein other than the chimeric protein, wherein the FVIII replacement protein is capable of being bound by endogenous VWF, or (iii) a corresponding subject receiving prophylactic treatment for hemophilia A with a complex, wherein the complex comprises a FVIII protein and a VWF protein or a portion thereof, wherein the FVIII protein and the VWF protein or a portion thereof are not covalently attached to each other, directly or indirectly.
33. A chimeric protein for achieving an annualized bleeding rate (ABR) of 2 or less, comprising administering a therapeutically effective amount of the chimeric protein to a human subject with hemophilia A in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, and wherein a total of about 2600 IU / kg to about 2650 IU / kg of the chimeric protein is administered to the subject per year.
34. A chimeric protein for use in reducing the annualized bleeding rate (ABR) compared to treatment with a factor VIII (FVIII) replacement protein, complex, or emicizumab that is capable of being bound by endogenous von Willebrand factor (VWF), comprising administering a therapeutically effective amount of the chimeric protein to a human subject with hemophilia A in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a VWF fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, and wherein the FVIII surrogate protein capable of being bound by endogenous VWF is ronocognin alpha, sincognin alpha, pergo-lulicognin alpha, pergo-dancognin alpha, emmog alpha, sermog alpha, morog alpha, berog alpha or torog alpha, or wherein the complex comprises a FVIII protein and a wild-type VWF protein or a portion thereof, wherein the FVIII protein and the VWF protein or a portion thereof are not covalently attached, directly or indirectly, to each other.
35. A chimeric protein for use in maintaining a FVIII activity level of at least 2%, comprising administering a therapeutically effective amount of the chimeric protein to a human subject with hemophilia A in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide sequence, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, wherein after each administration of the chimeric protein, a FVIII activity level of about 35% to about 45% is maintained for at least 4 days, and wherein a FVIII activity level of about 10% to about 15% is maintained for at least 7 days after each administration of the chimeric protein.
36. A chimeric protein for use in reducing the risk of bleeding episodes requiring more than one supplemental on-demand administration of a FVIII replacement protein during prophylactic treatment of hemophilia A, wherein the prophylactic treatment of hemophilia A comprises administering a therapeutically effective amount of the chimeric protein to a human subject in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, wherein the risk is reduced by at least 90% compared to the risk in a corresponding subject receiving prophylactic treatment for hemophilia A comprising administration of a FVIII replacement protein other than the chimeric protein, and wherein the FVIII replacement protein other than the chimeric protein is capable of being bound by endogenous VWF, and wherein the supplemental on-demand dose is 45 IU / kg to 70 IU / kg.
37. The chimeric protein of any one of claims 22-36, wherein the therapeutically effective amount is a dose of about 50 IU / kg of the chimeric protein about once every 7 days.
38. A chimeric protein for use in resolving a withdrawal bleeding episode, comprising administering to a human subject in need thereof a single on-demand dose of a therapeutically effective amount of the chimeric protein, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, wherein the single on-demand dose is about 50 IU / kg, and Where the bleeding episode is in a joint.
39. A chimeric protein for use in the on-demand treatment of major bleeding comprising administering a therapeutically effective amount of the chimeric protein to a human subject with hemophilia A in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond, and The major bleeding is intracranial bleeding, retroperitoneal bleeding, iliopsoas bleeding, cervical bleeding, muscle bleeding with compartment syndrome and / or bleeding associated with a significant decrease in hemoglobin level.
40. A chimeric protein for use in the perioperative management of bleeding comprising administering a therapeutically effective amount of the chimeric protein to a human subject with hemophilia A in need thereof, wherein the chimeric protein comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises (a) a FVIII polypeptide with a complete or partial B domain deletion, wherein a first ELNN polypeptide is inserted within the FVIII polypeptide, and (b) a first Fc region; and the second polypeptide comprises (a) a von Willebrand Factor (VWF) fragment, (b) a second ELNN polypeptide, (c) a thrombin-cleavable linker comprising at least a portion of the a2 region of FVIII, and (d) a second Fc region, and wherein the first Fc region and the second Fc region are covalently attached to each other via at least one disulfide bond.
41. The chimeric protein of claim 40, wherein the subject is expected to undergo surgery within 72 hours, is currently undergoing surgery, or has undergone surgery within the last week.
42. The chimeric protein of any one of claims 40 to 41, wherein the therapeutically effective amount comprises a preoperative loading dose of 50 IU / kg, followed by one or more doses of 30 IU / kg or 50 IU / kg every 2 to 3 days.
43. The method of any one of claims 1 to 21 or the chimeric protein for use of any one of claims 22 to 42, wherein the first polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 1, and the second polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 2, wherein the first polypeptide and the second polypeptide are covalently linked via two disulfide bonds between the first Fc region and the second Fc region.
44. The method of any one of claims 1 to 21 or the chimeric protein for use of any one of claims 22 to 42, wherein the chimeric protein is Anolectin alfa.
45. The method of any one of claims 1 to 21 or the chimeric protein for use of any one of claims 22 to 42, wherein the subject has severe hemophilia A.
46. The method of any one of claims 1 to 21 or the chimeric protein for use of any one of claims 22 to 42, wherein the chimeric protein is administered intravenously.
